

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



Overview for Request opi_ahr_wp002_nsdp_v01

Request ID: opi_ahr_wp002_nsdp_v01

<u>Report Description</u>: This report provides the number and proportion of "opioid-tolerant-only" episodes of transdermal fentanyl that were prescribed to patients with evidence of prior-established "opioid tolerance" by dose of transdermal fentanyl. This analysis only assesses the first eligible transdermal fentanyl episode per user, by dose.

Sentinel Modular Program Tool Used: Ad Hoc Programming

Data Source: Data from January 1, 2009 to December 31, 2013 from 15 Data Partners contributing to the Mini-Sentinel Distributed Database (MSDD) were included in this report. This is the period during which new opioid-tolerant-only dose product treatment episodes started. The request was distributed to two Data Partners in March 2016 and to the remaining 13 participating Data Partners in April 2016. Please see Appendix A for the latest date of available data for each Data Partner.

<u>Study Design</u>: The first eligible transdermal fentanyl episode per user, by dose, was identified and assessed for evidence of prior opioid tolerance, by each of the four tolerance definitions. Two washout periods were used to define new use: [1] No use of transdermal fentanyl in 183 days prior (primary analysis) and [2] No use of transdermal fentanyl in 91 days prior (sensitivity analysis).

<u>Cohort Eligibility Criteria</u>: Individuals included in the cohort were required to be continuously enrolled in plans with both medical and drug coverage for at least 183 days (for primary analysis) or 91 days (sensitivity analysis) prior to their first eligible transdermal fentanyl episode, during which gaps in coverage of up to 45 days were allowed. Individuals ages 0 through 64 years were included in the analysis. Age groupings are as follows: 0-11, 12-17, 18-24, 25-34, 35-44, 45-54, and 55-64 years. Patients were excluded if they were diagnosed with opioid poisoning in the 183 days (or 91 days for sensitivity analysis) prior to their first eligible transdermal fentanyl episode or if they were hospitalized (inpatient stay) in the 30 days prior to cohort entry. Opioid poisoning was defined using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Please see Appendix C for a list of codes.

Exposures of Interest: The exposure of interest was new use of opioid-tolerant-only transdermal fentanyl. The exposure was defined using National Drug Codes (NDCs). Please see Appendix B for a list of drugs.

Definition of opioid-tolerance-only doses: All dose formulations are opioid-tolerant-only doses, but results are stratified by dose: 12, 25, 50, 75, and 100mcg/hr, as well as any outlier doses.

Definitions of opioid tolerance:

Primary: ≥30 mg oxycodone equivalents per day for seven days consecutively in the seven days prior to new opioid-tolerant-only dose index date

Secondary: ≥30 mg oxycodone equivalents per day for seven days in the 30 days prior to new opioid-tolerant-only dose index date (seven days not required to be consecutive)

Tertiary: >0 mg (i.e., any dose of oxycodone equivalent) for seven days in the seven consecutive days prior to new opioid-tolerant-only dose index date

Quaternary: >0 mg (i.e., any dose of oxycodone equivalent) for seven days in the 30 days prior to new opioid-tolerant-only dose index date (seven days not required to be consecutive). All dose formulations are opioid-tolerant-only doses, but results are stratified by dose: 12, 25, 50, 75, and 100mcg/hr, as well as any outlier doses.

Limitations: Algorithms to define exposures and events are imperfect and, therefore, may be misclassified.

<u>Notes</u>: Please contact the Sentinel Operations Center Query Fulfillment Team (qf@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document.



	Table of Contents
Glossary	List of Terms Used in this Request and their Definitions
Table 1a	Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior
	Tolerance with a 183-day Washout Period and a Primary Definition in the Mini-Sentinel Distributed
	Database (MSDD) from January 1, 2009 to December 31, 2013
Table 1b	Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior
	Tolerance with a 183-day Washout Period and a Secondary Definition in the Mini-Sentinel Distributed
	Database (MSDD) from January 1, 2009 to December 31, 2013
Table 1c	Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior
	Tolerance with a 183-day Washout Period and a Tertiary Definition in the Mini-Sentinel Distributed
	Database (MSDD) from January 1, 2009 to December 31, 2013
Table 1d	Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior
	Tolerance with a 183-day Washout Period and a Quaternary Definition in the Mini-Sentinel Distributed
	Database (MSDD) from January 1, 2009 to December 31, 2013
Table 2a	Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior
	Tolerance with a 91-day Washout Period and a Primary Definition in the Mini-Sentinel Distributed
	Database (MSDD) from January 1, 2009 to December 31, 2013
Table 2b	Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior
	Tolerance with a 91-day Washout Period and a Secondary Definition in the Mini-Sentinel Distributed
	Database (MSDD) from January 1, 2009 to December 31, 2013
Table 2c	Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior
	Tolerance with a 91-day Washout Period and a Tertiary Definition in the Mini-Sentinel Distributed
Table 2d	Database (MSDD) from January 1, 2009 to December 31, 2013
Table 2d	Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior
	Tolerance with a 91-day Washout Period and a Quaternary Definition in the Mini-Sentinel Distributed
Appendix A	Database (MSDD) from January 1, 2009 to December 31, 2013 Latest Date of Available Data for Each Data Partner up to Request Send Date (April 20, 2016)
<u>Appendix B</u>	List of Drugs Used to Define Exposures in this Request
<u>Appendix C</u>	List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) Codes Used
	to Define Exclusion Criteria in this Request



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Tool*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt" **Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency department (E), Home (H), Inpatient (I), Outpatient (O). or Unknown or Missing (U). Along with the Principal Diagnosis Indicator. forms the Care Setting/PDX parameter. **Cohort Definition (drug/exposure)-** indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid incident treatment episode during the query period; (2) 02: Cohort includes all valid incident treatment episodes during the query period; (3) 03: Cohort includes all valid incident treatment episodes during the treatment episodes during the query period; (4) 03: Cohort includes all valid incident treatment episodes during the treatment episo

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" **Episodes** - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by **Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the **Event Deduplication** - specifies how events are counted by the MP algorithm: (0) 0: Counts all occurrences of an HOI during an exposure episode; (1) 1: de-duplicates occurrences of the same HOI code and code type on the same day; (2) 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. **Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."

Lookback Period (pre-existing condition) - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the **Query Period** - period in which the modular program looks for exposures and outcomes of interest.

Treatment Episode Truncation Indicator - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident auery code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the incident auery code. **Users** - number of members with exposure during the query period. Member must have no evidence of exposure(s) of interest (defined

by incidence criteria) in the prior washout period. A user may only be counted once in a query period.

Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug

dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event



Table 1a: Counts o Period and a Prima												aay wasn	ιουτ			
		1		Р	rimary Tolerar	nce Definitio	n (≥30 mg p	er day in the p	orior 7 conse	cutive days)			1		
		Dos	e 12 mcg/h	ır	Dos	ie 24 mcg/l	٦r	Dos	ie 25 mcg/l	٦r	Dos	e 36 mcg/	'hr	Dos	e 37 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	16,379	4,699	28.7%	3	1	33%	44,450	16,623	37.4%	1	C		298	160	549
Age (years)	0 - 11 years 12 - 17 years	32	-	0.0%	-		0% 0%	23 79	2 15	8.7% 19.0%	0	C			-	09
	18 - 24 years	375	96	25.6%			0%	827	314	38.0%	0	C			3	385
	25 - 34 years	1,464	539	36.8%	-	-	0%	3,731	1,688	45.2%	1	C			16	675
	35 - 44 years 45 - 54 years	2,841 5,214	955 1,532	33.6% 29.4%	2	1	50% 0%	7,954 14,785	3,325 5,707	41.8% 38.6%	0	C			33 47	529 549
	55 - 64 years	6,378	1,571	24.6%	1	-	0%	17,051	5,572	32.7%	0	C		113	61	549
Gender	Male	5,124	1,537	30.0%	1	1	100%	18,327	7,100	38.7%	0	C			73	555
	Female	11,255	3,162	28.1%	2	-	0%	26,123	9,523	36.5%	1	C			87	535
	Ambiguous Unknown	- 0	- 0	0.0%	- 0		0% 0%	-	- 0	0.0%	0	C				05
	Jan 2009	220	66	30.0%		-	0%	953	316	33.2%	0	C			3	755
Month and Year of	Feb 2009	206	51	24.8%	-	-	0%	890	312	35.1%		C			3	385
Episode Start Date	Mar 2009	267	72	27.0%	-		0%	982	334	34.0%	0	C			3	605
	Apr 2009 May 2009	220 248	52 61	23.6% 24.6%	-		0% 0%	969 875	334 330	34.5% 37.7%	1	C			1 5	255
	Jun 2009	258	65	25.2%			0%	909	312	34.3%	0	C			4	805
	Jul 2009	249	67	26.9%	-		0%	870		34.6%	0	C			2	335
	Aug 2009 Sep 2009	268 295	71 86	26.5% 29.2%	-		0% 0%	881 943	289 331	32.8% 35.1%	0	C			1	509 759
	Sep 2009 Oct 2009	295	69	29.2%		-	0%	943	292	35.1%	0	0			1	1009
	Nov 2009	231	67	29.0%	-	-	0%	818	274	33.5%	0	C	0%	8	4	505
	Dec 2009	244	74	30.3%	-	-	0%	900	337	37.4%		C			3	435
	Jan 2010 Feb 2010	226 238	55 79	24.3% 33.2%	-	-	0% 0%	827 753	271 270	32.8% 35.9%	0	C			- 6	09 759
	Mar 2010	258	76	28.4%			0%	791	294	37.2%	0	c			3	385
	Apr 2010	257	71	27.6%	-	-	0%	833	277	33.3%	0	C	0%	3	2	675
	May 2010	227	73	32.2%	-	-	0%	738		40.5%	0	C			1	205
	Jun 2010 Jul 2010	246 223	68 62	27.6% 27.8%			0% 0%	746 764	281 305	37.7% 39.9%	0	C			1	259
	Aug 2010	260	73	28.1%	-	-	0%	810		34.7%	0	C			2	675
	Sep 2010	301	91	30.2%	-	-	0%	833	323	38.8%	0	C			2	1005
	Oct 2010	288	70	24.3%	-	-	0%	777	292	37.6%	0	C			3	605
	Nov 2010 Dec 2010	290 291	87 87	30.0% 29.9%	-	-	0% 0%	824 731	306 294	37.1% 40.2%	0	C			4	449
	Jan 2011	252	67	26.6%	-	-	0%	724	272	37.6%	0	C			1	1005
	Feb 2011	264	61	23.1%	-	-	0%	639		36.8%	0	C			2	675
	Mar 2011	279	73	26.2%	-	-	0%	802	309	38.5%	0	C			5	565
	Apr 2011 May 2011	269 261	80 73	29.7% 28.0%			0% 0%	710 700		39.6% 36.6%	0	0			9	909 679
	Jun 2011	276	76	27.5%	-	-	0%	678		40.1%		C			2	505
	Jul 2011	282	81	28.7%	-	-	0%	679	249	36.7%	0	C			2	675
	Aug 2011	314	106	33.8%	-	-	0%	758	265	35.0%	0	C	0%	4	2	509 439
	Sep 2011 Oct 2011	291 263	85 79	29.2%			0%	730	280	38.4% 39.8%	0	c		3	2	675
	Nov 2011	288	96	33.3%	-	-	0%	659	275	41.7%	0	C	0%	8	2	255
	Dec 2011	307	93	30.3%	-		0%	689	261	37.9%	0	C	0%	5	3	605
	Jan 2012	279	80	28.7%	-		0%	720		38.6%		C			2	1005
	Feb 2012 Mar 2012	255 294	67 83	26.3% 28.2%	-		0% 0%	638 683		34.8% 36.9%		C			3 4	439
	Mar 2012 Apr 2012	294	83	28.2%	-		0%	683		36.9%	0	0			4	675
	May 2012	324	88	27.2%	-		0%	631	249	39.5%		C			5	635
	Jun 2012	242	68	28.1%	-	-	0%	564		38.8%		C			2	675
	Jul 2012 Aug 2012	295 304	90 111	30.5% 36.5%	-	-	0% 0%	617 787	244 306	39.5% 38.9%		C			2	409
	Aug 2012 Sep 2012	279	75	26.9%	-		0%	645		38.9%		C			4	805
	Oct 2012	304	91	29.9%	-		0%	699	304	43.5%	0	C	0%	3	1	335
	Nov 2012	313	82	26.2%	-	-	0%	712		33.8%	0	C			3	505
	Dec 2012 Jan 2013	293 277	78 87	26.6% 31.4%	-		0% 0%	631 593	251 220	39.8% 37.1%		C			3	385
	Feb 2013	254	76	29.9%	-		0%	638		42.3%		C			2	67
	Mar 2013	253	85	33.6%	-	-	0%	585		42.1%		C			3	75
	Apr 2013	289	99	34.3%	-	-	0%	617	243	39.4%		C			4	44
	May 2013 Jun 2013	261 271	80 69	30.7% 25.5%	-		0% 0%	640 602		40.8% 40.2%		C			4	50' 50'
	Jul 2013	331	95	28.7%			0%	663	242	39.8%		c			5	63
	Aug 2013	341	97	28.4%	-	-	0%	735		40.8%		C			1	33
	Sep 2013	302	78	25.8%	-		0%	645		39.1%		C			2	675
	Oct 2013 Nov 2013	331 310	99 89	29.9% 28.7%	1	1	100% 0%	714 651	285 255	39.9% 39.2%		C			1	339
	Dec 2013	298	86	28.9%	0		0%			39.2%					4	80



									rior 7 conse							
		Dose	e 50 mcg/	hr	Dos	e 62 mcg/l	۱r	Dos	se 75 mcg/l	hr	Dose	e 87 mcg/	hr	Dos	e 100 mcg/	'hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Toleranc
	Total	18,527	8,871	48%	22	6	27%	5,118	2,756	54%	8	2	25%	3,507	1,991	57
Age (years)	0 - 11 years	7	2	29%	1	-	0%	2	-	0%	-	-	0%	4	-	0
	12 - 17 years	32	9	28%	-	-	0%	11	3	27%	-	-	0%	8	2	25
	18 - 24 years	380	161	42%	1	-	0%		52	53%	-	-	0%	77	38	49
	25 - 34 years	1,614	900	56%	2	-	0%		309	59%	1	1	100%	290	179	62
	35 - 44 years	3,502	1,846	53%	4	1	25%		553	55%	1	-	0%	686	403	59
	45 - 54 years	6,358	3,055	48%	11	3	27%		966	54%	4	1	25%	1,276	744	58
Gender	55 - 64 years Male	6,634 8,727	2,898 4,377	44% 50%	3	2	67% 45%	1,687 2,510	873 1,428	52% 57%	2	- 1	0% 25%	1,166 1,839	625 1,111	54 60
Gender	Female	9,800	4,377	46%	11	1	43%		1,428	51%	4	1	25%	1,668	880	53
	Ambiguous	-		0%		-	0%		-	0%			0%	-	-	0
	Unknown			0%			0%		-	0%			0%			0
	Jan 2009	412	185	45%	2	2	100%	145	61	42%	1	-	0%	94	42	459
Month and Year of	Feb 2009	414	199	48%		-	0%		65	55%	-	-	0%	98	55	565
Episode Start Date	Mar 2009	424	208	49%	-	-	0%		55	49%	-	-	0%	79	38	485
	Apr 2009	423	215	51%	-	-	0%	108	62	57%	-	-	0%	88	50	579
	May 2009	368	166	45%	-	-	0%	101	50	50%	-	-	0%	84	42	505
	Jun 2009	409	176	43%	-	-	0%		53	48%	-	-	0%	75	49	65
	Jul 2009	376	170	45%	2	-	0%	89	41	46%	-	-	0%	86	48	565
	Aug 2009	348	165	47%	-	-	0%	97	53	55%	-	-	0%	72	41	575
	Sep 2009	396	180	45%	-	-	0%	95	63	66%	2	-	0%	72	37	515
	Oct 2009	433	190	44%	-	-	0%	100	52	52%	-	-	0%	90	50	565
	Nov 2009	366	172	47%	1	1	100%	94	51	54%	-	-	0%	77	46	605
	Dec 2009	379	170	45%	-	-	0%	113	59	52%	-	-	0%	74	40	549
	Jan 2010	359	158	44%	-	-	0%	101	52	51%	-	-	0%	89	55	625
	Feb 2010	325	143	44%	1	-	0%	84	39	46%	1	-	0%	60	31	529
	Mar 2010	331	142	43%	-	-	0%	113	63	56%	-	-	0%	62	35	569
	Apr 2010	307	134	44%	-	-	0%	100	57	57%	-	-	0%	67	45	679
	May 2010	326	147	45%	-	-	0%	84	38	45%	-	-	0%	60	39	659
	Jun 2010	340	167	49%		-	0%	77	40	52%	-	-	0%	49	38	789
	Jul 2010	342	180	53%	-	-	0%	92	45	49%	-	-	0%	55	37	679
	Aug 2010	325	158	49%	-	-	0%	98	50	51%	-	-	0%	71	44	629
	Sep 2010	343	165	48%	1	1	100%	93	57	61%	-	-	0%	70	41	59%
	Oct 2010	340	174	51%	-	-	0%	95	54	57%	-	-	0%	58	42	729
	Nov 2010	326	163	50%		-	0%	93	56	60%	-	-	0%	63	37	599
	Dec 2010	356	156	44%	-	-	0%		44	56%	-	-	0%	64	30	479
	Jan 2011	306	130	42%	-	-	0%		54	48%	-	-	0%	90	52	585
	Feb 2011	277	148	53%	-	-	0%		59	61%	-	-	0%	66	38	585
	Mar 2011	338	174	51%	1	-	0%	94	61	65%	-	-	0%	79	43	549
	Apr 2011	322	147	46%	-	-	0%		44	51%	-	-	0%	52	24	465
	May 2011	280	126	45%	-	-	0% 0%	86 75	47	55%	- 1	-	0% 0%	52	28	545
	Jun 2011	286 309	123 146	43% 47%	-	-	0%		45	60% 69%	1	-	0%	41 48	23	569 549
	Jul 2011 Aug 2011	309	140	47%	-	-	0%	78	48 38	49%	-	-	0%	48	26 30	675
	Sep 2011	310	140	40%			0%	78	44	56%			0%	43	23	559
	Sep 2011 Oct 2011	269	155	49%	- 2	-	0%		44	62%	-	-	0%	42	32	579
					2	-				5.00/	-	-		47		
	Nov 2011	274	140	51%	-	-	0%	//	43	56%	-	-	0%	47	26	555
	Dec 2011	286	135	47%	-	-	0%		36	50%	-	-	0%	59	37	635
	Jan 2012	273	132	48%	-	-	0%		48	55%	-	-	0%	53	27	519
	Feb 2012	266	146	55%	1	-	0%		45	60%	-	-	0%	53	34	649
	Mar 2012	282	141	50%		-	0%		43	57%	-	-	0%	48	28	585
	Apr 2012	277	143	52%	1	-	0%		40	47%	-	-	0%	48	26	549
	May 2012	287	149	52%	1	-	0%		40	56%	-		0%	52	36	695
	Jun 2012	234	111	47%	1	-	0%		34	57%	-	-	0%	49	30	619
	Jul 2012	307	156	51%	-	-	0%		43	49%	-		0%	37	17	465
	Aug 2012 Sep 2012	284 254	142 131	50% 52%	1	-	0% 0%		54 49	61% 64%	- 1	- 1	0% 100%	51 38	35 20	699 539
	Sep 2012 Oct 2012	254 251	131	52% 43%	1	-	0%		49 40	64% 58%	1	1	100%	38 47	20	439
	Nov 2012	251 296	108	43%	-	-	0%		40 39	58% 43%	- 2	- 1	0% 50%	47	20 32	43
	Nov 2012 Dec 2012	296	137	46% 54%	-	-	0%		39	43% 41%	2	1	50%	46	32 19	419
	Jan 2013	251	141	52%	- 2	- 1	50%		39	41%	-	-	0%	40	25	605
	Feb 2013	254	132	52%	2	-	0%		39	45%	-	-	0%	42	25	615
	Mar 2013	236	117	50%	-	-	0%		31	53%	-	-	0%	36	19	53
	Apr 2013	236	118	48%	-	-	0%		33	49%	-	-	0%	30	23	62
	May 2013	220	100	48% 52%	1	1	100%		41	63%	-	-	0%	42	23	57
	Jun 2013	230	116	48%	-	-	0%		36	52%	-	-	0%	42	17	50
	Jul 2013	239	110	48% 50%	-		0%		45	58%	-	-	0%	43	20	47
	Aug 2013	235	130	48%	-		0%		26	43%	-	-	0%	43	14	47
	Sep 2013	2/2 245	119	48%	-		0%		38	43% 58%	-	-	0%	44	22	50
	Oct 2013	243	130	49% 54%	-		0%		41	61%	-	-	0%	44	32	685
	Nov 2013	242	115	48%		_	0%		33	57%	-	_	0%	47	24	51
	Dec 2013	241 247	115	48%	- 1	-	0%		31	54%	-	-	0%	47	24	62



		1			imary Toleran	ce Demitio	111-00 mg pt							-		
			e 112 mcg/		Dos	e 125 mcg/		Dose	e 137 mcg/			e 150 mcg/	/hr		e 162 mcg/	/hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
Ago (waars)	Total	3	3	100%	137	68	50%	2	1	50%	172	103	60%	2	1	
Age (years)	0 - 11 years 12 - 17 years	-	-	0% 0%	- 1	-	0% 0%	-	-	0% 0%	0	0	0% 0%	0	0	
	18 - 24 years	-	-	0%	2	2	100%	-	-	0%	5	4	80%	1	0	
	25 - 34 years	-	-	0%	9	7	78%	-	-	0%	12	6		0	0	
	35 - 44 years	-	-	0%	20	8	40%	-	-	0%	30	21		0	0	
	45 - 54 years 55 - 64 years	1	1	100% 100%	57 48	29 22	51% 46%	1	- 1	0% 100%	60 64	36 36	60% 56%	0	0	0%
Gender	Male	1	1	100%	69	33	48%	-	-	0%	95	61	64%	2	1	
	Female	2	2	100%	68	35	51%	2	1	50%	77	42		0	0	
	Ambiguous	-	-	0% 0%	-	-	0%	-	-	0%	0	0		0	0	
	Unknown Jan 2009	. 1	. 1	100%	- 4	- 2	50%		-	0%	6	2		0	0	
Month and Year of	Feb 2009	-	-	0%	3	1	33%	-	-	0%	2	1		0	0	
Episode Start Date	Mar 2009	-	-	0%	3	-	0%	-	-	0%	1	1	100%	0	0	0%
	Apr 2009	-	-	0%	2	1	50%	-	-	0%	1	1		0	0	
	May 2009 Jun 2009	-	-	0% 0%	3	3 2	100% 100%	-	-	0% 0%	6	4	67% 86%	0	0	
	Jul 2009	-	-	0%	2	2	100%	-	-	0%	3	5	33%	0	0	
	Aug 2009	-	-	0%	1	-	0%	-	-	0%	4	0		0	0	
	Sep 2009	-	-	0%	-	-	0%	-	-	0%	5	3	60%	0	0	
	Oct 2009	-	-	0%	1	-	0%	-	-	0%	4	2		0	0	
	Nov 2009 Dec 2009	-	-	0% 0%	2	1	50% 50%	-	-	0% 0%	7	5	71% 71%	0	0	
	Jan 2010		-	0%	7	2	29%	-	-	0%	5	3		0	0	
	Feb 2010	-	-	0%	6	1	17%	-	-	0%	5	3	60%	0	0	
	Mar 2010	-	-	0%	2	-	0%	-	-	0%	4	3		0	0	
	Apr 2010	-	-	0%	4	1	25%	-	-	0%	4	3		0	0	
	May 2010 Jun 2010	-	-	0% 0%	5	2	50% 40%	-	-	0% 0%	4	1	50% 50%	0	0	
	Jul 2010	-	-	0%	1	-	0%	-	-	0%	5	4	80%	0	0	
	Aug 2010	-	-	0%	2	1	50%	-	-	0%	2	0	0%	0	0	0%
	Sep 2010	-	-	0%	-	-	0%	-	-	0%	3	0		0	0	
	Oct 2010 Nov 2010	-	-	0% 0%	3	3 2	100% 100%	1	- 1	100% 0%	3	3	100% 50%	0	0	
	Dec 2010	-	-	0%	1	1	100%	-	-	0%	4	2		0	0	
	Jan 2011	-	-	0%	3	1	33%	-	-	0%	4	2	50%	1	0	0%
	Feb 2011	1	1	100%	3	-	0%	-	-	0%	3	1	33%	0	0	
	Mar 2011 Apr 2011	-	-	0% 0%	2	1	50% 33%	-	-	0% 0%	2	1	50% 100%	0	0	
	May 2011	-	-	0%	5	1	20%	-	-	0%	4	4	50%	0	0	
	Jun 2011	-	-	0%	2	1	50%	-	-	0%	0	0		0	0	
	Jul 2011	-	-	0%	2	-	0%	-	-	0%	4	4	100%	0	0	
	Aug 2011	-	-	0%	1	1	100%	-	-	0%	1	1	100%	0	0	
	Sep 2011 Oct 2011	-	-	0% 0%	4	2	50% 100%	1	-	0% 0%	3	3 0		1	1	
	Nov 2011	-	-	0%		-	0%	-	-	0%	1	1		0	0	
	Dec 2011	-	-	0%	3	2	67%	-	-	0%	1	1		0	0	
	Jan 2012	-	-	0%	2	1	50%	-	-	0%	2	2		0	0	
	Feb 2012	-	-	0%	2	1	50%	-	-	0%	5	4		0	0	
	Mar 2012	-	-	0%	3	3	100%	-	-	0%	2	1		0	0	
	Apr 2012 May 2012	1	1	100% 0%	5 4	- 5	100% 0%	-	-	0% 0%	3 0	2		0	0	
	Jun 2012	-	-	0%	- 4	-	0%	-	-	0%	2	1	50%	0	0	
	Jul 2012	-	-	0%	1	1	100%	-	-	0%	0	0	0%	0	0	
	Aug 2012	-	-	0%	4	3	75%	-	-	0%	1	1	100%	0	0	
	Sep 2012 Oct 2012	-	-	0% 0%	1	1	100% 100%	-	-	0% 0%	2	1		0	0	
	Nov 2012	-		0%	2	2	100%	-	-	0%	2	2		0	0	
	Dec 2012	-	-	0%	3	1	33%	-	-	0%	0	0		0	0	
	Jan 2013	-	-	0%	2	-	0%	-	-	0%	4	0		0	0	
	Feb 2013	-	-	0%	3	1	33%	-	-	0%	0	0		0	0	
	Mar 2013 Apr 2013	-	-	0% 0%	2	1	50% 0%	-	-	0% 0%	3	1	33% 67%	0	0	
	May 2013	-	-	0%	1	1	100%	-	-	0%	0	0		0	0	
	Jun 2013	-	-	0%	-	-	0%	-	-	0%	3	1	33%	0	0	
	Jul 2013	-	-	0%	3	3	100%	-	-	0%	2	2		0	0	
	Aug 2013 Sep 2013	-	-	0% 0%	2	2	100% 100%	-	-	0% 0%	3	1	33% 50%	0	0	
	Sep 2013 Oct 2013	-		0%	1	1	100% 25%	-	-	0%	2	1	50% 100%	0	0	
	Nov 2013	-	-	0%	1	1	100%	-	-	0%	3	2		0	0	
	Dec 2013	-	-	0%	1	-	0%	-	-	0%		1	50%		0	

Table 1a: Counts of Transdermal Fentanyl Episodes and Proportions of Transdermal Fentanyl Episodes with Prior Tolerance with a 183-day Washout Period



	Pri									
		Dos	e 175 mcg/	hr	Dos	e 200 mcg/	/hr	Dos	e 225 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerand
	Total	33	16	48%	4	3	75%	2	0	C
Age (years)	0 - 11 years	0	0	0%	0	0	0%	0	0	C
	12 - 17 years 18 - 24 years	1	1	100% 100%	0	0	0% 0%	0	0	(
	18 - 24 years 25 - 34 years	1	0	0%	0	0	0%	1	0	(
	35 - 44 years	4	3	75%	3	2		0	0	(
	45 - 54 years	9	4	44%	1	1	100%	0	0	(
	55 - 64 years	15	5	33%	0	0		1	0	(
Gender	Male Female	11 22	9 7	82% 32%	4	3 0	75% 0%	2	0	(
	Ambiguous	0	0	0%	0	0	0%	0	0	(
	Unknown	0	0	0%	0	0	0%	0	0	
	Jan 2009	1	0	0%	0	0	0%	0	0	
Month and Year of	Feb 2009	1	1	100%	0	0	0%	0	0	
Episode Start Date	Mar 2009	1	1	100%	0	0	0%	0	0	(
	Apr 2009 May 2009	3	3 0	100% 0%	1	1	100% 0%	0	0	(
	Jun 2009	0	0	0%	0	0	0%	0	0	
	Jul 2009	2	0	0%	0	0	0%	1	0	i
	Aug 2009	0	0	0%	0	0	0%	0	0	
	Sep 2009	1	1	100%	0	0	0%	0	0	
	Oct 2009	1	0	0%	0	0	0%	0	0	
	Nov 2009	0	0	0%	0	0	0%	0	0	
	Dec 2009 Jan 2010	1	0	0% 0%	0	0	0% 0%	0	0	
	Feb 2010	0	0	0%	0	0	0%	0	0	
	Mar 2010	1	1	100%	1	1	100%	0	0	
	Apr 2010	0	0	0%	0	0	0%	0	0	
	May 2010	0	0	0%	0	0	0%	0	0	
	Jun 2010	1	0	0%	0	0	0%	0	0	
	Jul 2010	0	0	0%	0	0	0%	0	0	
	Aug 2010 Sep 2010	1	1	100% 0%	0	0	0% 0%	0	0	
	Oct 2010	1	1	100%	0	0	0%	0	0	
	Nov 2010	0	0	0%	0	0	0%	0	0	
	Dec 2010	1	1	100%	0	0	0%	0	0	
	Jan 2011	0	0	0%	0	0	0%	0	0	
	Feb 2011	2	1	50%	0	0	0%	0	0	
	Mar 2011 Apr 2011	1	1	100%	0	0	0% 0%	0	0	
	Apr 2011 May 2011	0	0	0% 0%	0	0	0%	0	0	
	Jun 2011	2	1	50%	0	0	0%	0	0	
	Jul 2011	0	0	0%	0	0	0%	0	0	
	Aug 2011	1	0	0%	0	0	0%	0	0	
	Sep 2011	2	1	50%	0	0	0%	0	0	
	Oct 2011	2	0	0%	0	0	0%	0	0	
	Nov 2011	0	0	0%	0	0	0%	0	0	
	Dec 2011	0	0	0%	0	0		0		
	Jan 2012 Feb 2012	0	0	0% 0%	0	0		0		
	Feb 2012 Mar 2012	0	0	0% 0%	0	0		0		
	Apr 2012	1	0	0%	0	0		0		
	May 2012	0	0	0%	0	0		0		
	Jun 2012	0	0	0%	0	0		0		
	Jul 2012	0	0	0%	0	0		0		
	Aug 2012	0	0	0%	0	0		0		
	Sep 2012 Oct 2012	0	0	0% 0%	0	0		0		
	Nov 2012	0	0	0%	0	0		1		
	Dec 2012	0	0	0%	0	0		0		
	Jan 2013	0	0	0%	0	0		0		
	Feb 2013	1	0	0%	0	0		0		
	Mar 2013	0	0	0%	0	0		0		
	Apr 2013	0	0	0%	0	0		0		
	May 2013	0	0	0%	0	0		0		
	Jun 2013 Jul 2013	1	0	0% 0%	2	1		0		
	Aug 2013	0	0	0%	0	0		0		
	Sep 2013	1	1	100%	0	0		0		
	Oct 2013	0	0	0%	0	0		0		
	Nov 2013	0	0	0%	0	0	0%	0	0	
	Dec 2013	1	1	100%	0	0	0%	0	0	



		1			Secondary I	orerance Derinn	ion (≥30 mg per	aay ioi seven da	iya in the 50 day	3 1017						
		D	ose 12 mcg/h	r	C	Dose 24 mcg/h	r	ſ	ose 25 mcg/h	r	D	ose 36 mcg/H	nr	Dos	e 37 mcg/ł	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
• • • • • • • •	Total	16,379	7,855	48.0%	3			44,450	26,009	58.5%				298	210	
Age (years)	0 - 11 years 12 - 17 years	32 75	1	3.1% 21.3%		0	0%	23 79	4	17.4% 29.1%			0% 0%	1	0	
	18 - 24 years	375	151	40.3%	-	0	0%	827	440	53.2%	0			8	5	
	25 - 34 years 35 - 44 years	1,464 2,841	822 1,500	56.1% 52.8%	- 2	0	0% 50%	3,731 7,954	2,488 4,989	66.7% 62.7%		0	0% 0%	24 63	20 43	
	45 - 54 years	5,214	2,529	48.5%	-	0		14,785	8,764	59.3%			0%		64	
	55 - 64 years	6,378	2,836	44.5%	1	1	100%	17,051	9,301	54.5%					78	
Gender	Male Female	5,124 11,255	2,569 5,286	50.1% 47.0%	1	1		18,327 26,123	11,006 15,003	60.1% 57.4%				133 165	96 114	
	Ambiguous			0.0%		0	0%	-		0.0%				0	0	
	Unknown	0	0	0	0			-	0	0	0	0	0%	0	0	
Month and Year of	Jan 2009 Feb 2009	220 206	106 95	48.2% 46.1%		0	0%	953 890	539 519	56.6% 58.3%			0% 0%	4	4	
Episode Start Date	Mar 2009	267	121	45.3%		0	0%	982	547	55.7%			0%	5	5	
	Apr 2009	220	100	45.5%	-	0		969	526	54.3%				4	2	
	May 2009 Jun 2009	248 258	118 106	47.6% 41.1%		0	0%	875 909	510 521	58.3% 57.3%			0% 0%	6	5	
	Juli 2009 Juli 2009	258	105	41.1%		0		909 870	485	57.3%				5	4	
	Aug 2009	268	129	48.1%	-	0	0%	881	472	53.6%	0	0	0%	2	1	50
	Sep 2009	295	141	47.8%	-	0	0%	943	545	57.8%			0%	4	4	
	Oct 2009 Nov 2009	261 231	127 106	48.7% 45.9%		0	0%	857 818	494 441	57.6% 53.9%		0	0% 0%	1	1	
	Dec 2009	244	118	48.4%	-	0	0%	900	523	58.1%			0%	7	4	
	Jan 2010	226	94	41.6%		0		827	457	55.3%			0%	6	0	
	Feb 2010 Mar 2010	238 268	119 119	50.0% 44.4%	-	0	0%	753 791	432 445	57.4% 56.3%		0	0%	8	6	
	Apr 2010	208	119	44.4% 50.2%		0		833	443	56.1%			0% 0%	3	6	
	May 2010	227	122	53.7%		0	0%	738	467	63.3%		0	0%	5	1	
	Jun 2010	246	116	47.2%		0		746	434	58.2%				4	1	
	Jul 2010 Aug 2010	223 260	101 119	45.3% 45.8%		0	0%	764 810	468 459	61.3% 56.7%			0%	5	4	
	Sep 2010	301	153	50.8%		0	0%	833	506	60.7%				2	2	
	Oct 2010	288	122	42.4%	-	0		777	452	58.2%				5	5	
	Nov 2010 Dec 2010	290 291	147 143	50.7% 49.1%		0	0%	824 731	497 436	60.3% 59.6%		0	0% 0%	9	7	
	Jan 2011	252	145	45.1%		0		731	430	58.6%			0%	1	1	
	Feb 2011	264	114	43.2%	-	0	0%	639	376	58.8%	0	0	0%	3	3	100
	Mar 2011	279	122	43.7%	-	0	0%	802	485	60.5%				9	6	
	Apr 2011 May 2011	269 261	134 118	49.8% 45.2%		0	0%	710 700	422 388	59.4% 55.4%			0%	10 3	9	
	Jun 2011	276	137	49.6%		0	0%	678	398	58.7%				4	2	
	Jul 2011	282	134	47.5%	-	0		679	392	57.7%			0%	3	2	
	Aug 2011 Sep 2011	314 291	166 140	52.9% 48.1%		0	0%	758 730	411 446	54.2% 61.1%			0% 0%	4	3	
	Oct 2011	263	135	51.3%		0		711	432	60.8%		0	0%	3	2	
	Nov 2011	288	142	49.3%		0	0%	659	408	61.9%	0	0	0%	8	4	50
	Dec 2011	307	152	49.5%		0	0%	689	400	58.1%		0	0%	5	4	
	Jan 2012	279	125	44.8%		0	0%	720	426	59.2%			0%	2	2	
	Feb 2012 Mar 2012	255 294	124 138	48.6% 46.9%		0		638 683	356 409	55.8% 59.9%			0% 0%	7	5	
	Apr 2012	251	125	49.8%		0	0%	650	381	58.6%	0	0	0%		2	67
	May 2012	324	142	43.8%	-	0		631	384	60.9%			0%	8	6	
	Jun 2012 Jul 2012	242 295	114 159	47.1% 53.9%		0	0%	564 617	337 361	59.8% 58.5%			0% 0%	3	3	
	Aug 2012	304	155	53.0%		0		787	474	60.2%			0%	2	4	
	Sep 2012	279	138	49.5%	-	0	0%	645	389	60.3%			0%	5	5	
	Oct 2012	304	147	48.4%	-	0	0%	699	438	62.7%			0%	3	1	
	Nov 2012 Dec 2012	313 293	152 143	48.6% 48.8%		0	0%	712	398 373	55.9% 59.1%		0	0% 0%	6	3	
	Jan 2013	277	133	48.0%	-	0	0%	593	354	59.7%			0%	4	3	
	Feb 2013	254	126	49.6%	-	0		638	393	61.6%			0%	3	3	
	Mar 2013 Apr 2013	253 289	129 159	51.0% 55.0%		0	0%	585	358 375	61.2% 60.8%		0	0% 0%	4	4	
	Apr 2013 May 2013	289	159	45.6%		0		640	375	60.8%		0	0%	8	5	
	Jun 2013	271	121	44.6%	1	0	0%	602	375	62.3%		0	0%	4	3	5 75
	Jul 2013	331	164	49.5%		0	0%	663	407	61.4%			0%	8	7	
	Aug 2013 Sep 2013	341 302	157 142	46.0% 47.0%		0	0%	735 645	439 375	59.7% 58.1%		0	0% 0%	3	2	
	Oct 2013	331	165	49.8%	1	1	100%	714	437	61.2%			0%	3	2	
	Nov 2013	310	148	47.7%	1	1	100%	651 637	391 366	60.1% 57.5%	0	0	0%	5	1	20



		1			Secondary To	erance Den	intion (≥30 m	g per day for se	ven days in t	ine so days p	1101)					
		Dos	ie 50 mcg/l	ır	Dos	se 62 mcg/	hr	Do	se 75 mcg/ł	ır	Do	ose 87 mcg/	hr	Do	se 100 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	18,527	12,461	67%	22	7		5,118	3,578	70%	8				2,447	709
Age (years)	0 - 11 years 12 - 17 years	7 32	2 15	29% 47%	1	0		2 11	- 3	0% 27%	0				- 3	09 389
	12 - 17 years 18 - 24 years	32	228	60%	1	0		99	63	64%	0		0%		45	58%
	25 - 34 years	1,614	1,187	74%	2	0	0%	523	384	73%	1	1	100%	290	223	77%
	35 - 44 years	3,502	2,528	72%	4	1		1,011	719	71%		0			493	72%
	45 - 54 years 55 - 64 years	6,358	4,270	67%	11 3	4		1,785 1,687	1,265	71%	4		75% 50%		908	71% 66%
Gender	Male	6,634 8,727	4,231 6,009	64% 69%	11	6		2,510	1,144 1,812	68% 72%					775 1,331	72%
	Female	9,800	6,452	66%	11	1		2,608	1,766	68%	4				1,116	67%
	Ambiguous	-	-	0%	0	0	0%	-	-	0%	0	0	0%	-	-	0%
	Unknown	-	-	0%	0				-	0%					-	09
Month and Year of	Jan 2009	412 414	272 299	66% 72%	2	2		145 118	85 84	59% 71%	1				58 70	62% 71%
Episode Start Date		414	295	69%	0	0		118	69	62%					46	58%
	Apr 2009	423	288	68%	0	0		108	82	76%	0		0%		62	70%
	May 2009	368	226	61%	0	0		101	67	66%			0%		56	67%
	Jun 2009	409	259	63%	0	0		111	76	68%	0				56	75%
	Jul 2009 Aug 2009	376 348	245 233	65% 67%	2	0		89 97	59 70	66% 72%	0		0%		58 50	67% 69%
	Sep 2009	348	263	66%	0	0		95	74	72%	2		50%		47	65%
	Oct 2009	433	266	61%	0	0		100	72	72%	0		0%		61	68%
	Nov 2009	366	238	65%	1	1		94	70	74%	0				52	68%
	Dec 2009	379	247	65%	0	0		113	80	71%	0				50	68%
	Jan 2010 Feb 2010	359 325	228 206	64% 63%	0	0		101 84	65 52	64% 62%			0% 100%	89 60	65 39	73% 65%
	Mar 2010	331	215	65%	0	0	0%	113	77	68%	0				40	65%
	Apr 2010	307	201	65%	0	0	0%	100	77	77%	0	0	0%	67	50	75%
	May 2010	326	212	65%	0	0		84	52	62%	0				45	75%
	Jun 2010	340	229 235	67%	0	0	0% 0%	77 92	56 63	73%	0		0%		40 44	82%
	Jul 2010 Aug 2010	342 325	235	69% 67%	0	0		92	67	68% 68%	0				44 54	80% 76%
	Sep 2010	343	229	67%	1	1		93	72	77%	0		0%		49	70%
	Oct 2010	340	241	71%	0	0	0%	95	68	72%	0	0	0%	58	49	84%
	Nov 2010	326	228	70%	0	0		93	73	78%	0				47	75%
	Dec 2010 Jan 2011	356 306	229 198	64% 65%	0	0		78 112	58 71	74% 63%	0				36 62	56% 69%
	Feb 2011	277	198	69%	0	0		96	71	74%	0				47	71%
	Mar 2011	338	231	68%	1	0	0%	94	73	78%	0		0%		55	70%
	Apr 2011	322	205	64%	0	0	0%	86	58	67%	0	0	0%	52	33	63%
	May 2011	280	175	63%	0	0		86	59	69%	0				32	62%
	Jun 2011 Jul 2011	286 309	187 201	65% 65%	0	0	0% 0%	75 70	57 54	76% 77%	1	1	100%	41 48	29 36	71% 75%
	Aug 2011	322	201	67%	0	0		78	54	67%	0			45	38	84%
	Sep 2011	310	223	72%	0	0	0%	78	56	72%	0		0%	42	26	62%
	Oct 2011	269	179	67%	2	0	0%	77	58	75%	0	0	0%	56	39	70%
	Nov 2011	274	194	71%	0	0		77	55	71%	0		0%	47	32	68%
	Dec 2011	286	193	67%	0	0		72	47	65%					46	78%
	Jan 2012	273	198	73%	0	0		88	65	74%					34	64%
	Feb 2012 Mar 2012	266 282	197 201	74% 71%	1	0		75 76	54 58	72% 76%	0		0% 0%		43 39	81% 81%
	Apr 2012	202	199	72%	1	0		86	59	69%			0%		35	71%
	May 2012	287	185	64%	1	0		71	49	69%			0%		39	75%
	Jun 2012	234	157	67%	1	0		60	43	72%	0				37	769
	Jul 2012 Aug 2012	307 284	208 195	68% 69%	0	0	0% 100%	87 89	56 63	64% 71%	0		0% 0%		22 39	59% 76%
	Aug 2012 Sep 2012	284	195	72%	1	0		89 77	57	71%			100%		39	76%
	Oct 2012	251	157	63%	0	0		69	51	74%			0%		28	609
	Nov 2012	296	186	63%	0	0		90	52	58%			50%		40	659
	Dec 2012	261	185	71%	0	0		54	30	56%					27	599
	Jan 2013 Feb 2013	254 212	177 165	70% 78%	2	1	50% 0%	87 56	54 41	62% 73%			0%		30 35	719 809
	Feb 2013 Mar 2013	212	105	65%	2	0		72	41	64%					27	759
	Apr 2013	226	158	70%	0	0		68	47	69%			0%		29	789
	May 2013	250	173	69%	1	1	100%	65	53	82%			0%		26	629
	Jun 2013	244	172	70%	0	0		69	45	65%					23	689
	Jul 2013 Aug 2013	239 272	168 184	70% 68%	0	0	0% 0%	78 61	62 38	79% 62%			0% 0%		29 16	679 529
	Aug 2013 Sep 2013	272	184 174	68% 71%	0	0		61 66	38 47	62% 71%			0%		16	529
	Oct 2013	243	174	72%	0	0	0%	67	47	67%	0				35	749
	Nov 2013	241	153	63%	0	0	0%	58	43	74%	0	0	0%	47	30	649
	Dec 2013	247	167	68%	1	0	0%	57	41	72%	0	0	0%	42	28	675



		Do	se 112 mcg/	'nr	Do	se 125 mcg/l	hr	Do	se 137 mcg/	hr	Do	se 150 mcg/	hr	Do	se 162 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	3	3		137	83	61%	2	1	50%	172	119	69%	2	2	
Age (years)	0 - 11 years 12 - 17 years	0	0		- 1	-	0% 0%	-	-	0% 0%	- 1	-	0% 0%	-	-	0
	12 - 17 years 18 - 24 years	0	0		2	2	100%	-	-	0%	5	- 4	80%	1	1	100
	25 - 34 years	0	0	0%	9	7	78%	-	-	0%	12	8	67%	-	-	C
	35 - 44 years	0	0		20	13	65%	-	-	0%	30	24	80%	-	-	C
	45 - 54 years	1	1		57 48	34 27	60%	1	-	0%	60	41 42	68%	- 1	-	C 100
Gender	55 - 64 years Male	2	2		69	39	56% 57%	- 1	-	100%	64 95	74	66% 78%	2	2	
	Female	2	2		68	44	65%	2	1	50%	77	45	58%	-	-	C
	Ambiguous	0	0	0%	-	-	0%	-	-	0%	-	-	0%	-	-	C
	Unknown	0	0				0%	-	-	0%			0%	-	-	(
Month and Year of	Jan 2009	1	1		4	2	50% 67%	-	-	0% 0%	6 2	2	33% 100%	-	-	C
Episode Start Date		0	0		3	1	33%	-	-	0%	1	1	100%			C
	Apr 2009	0	0	0%	2	1	50%	-	-	0%	1	1	100%	-	-	C
	May 2009	0	0	0%	3	3	100%	-	-	0%	6	4	67%	-	-	C
	Jun 2009	0	0		2	2	100%	-	-	0%	7	6	86%	-	-	(
	Jul 2009	0	0		1	1	100%	-	-	0%	3	1	33%	-	-	
	Aug 2009 Sep 2009	0	0		1	1	100% 0%	-	-	0% 0%	4	1	25% 80%	-	-	
	Oct 2009	0	0		- 1	-	0%		-	0%	4	4	50%			
	Nov 2009	0	0	0%	2	1	50%	-	-	0%	7	5	71%	-	-	
	Dec 2009	0	0	0%	2	1	50%	-	-	0%	7	5	71%	-	-	
	Jan 2010	0	0	0%	7	3	43%		-	0%	5	3	60%		-	
	Feb 2010	0	0	0%	6	2	33%	-	-	0%	5	4	80%		-	
	Mar 2010	0	0		2	-	0%	-	-	0%	4	4	100%	-	-	
	Apr 2010	0	0		4	1	25%	-	-	0%	4	3	75%	-	-	
	May 2010 Jun 2010	0	0	0% 0%	2	1	50% 80%		-	0% 0%	4	3 2	75% 100%		-	
	Jul 2010	0	0		1	-	0%	-	-	0%	5	4	80%	-	-	
	Aug 2010	0	0		2	1	50%		-	0%	2	1	50%		-	
	Sep 2010	0	0	0%	-	-	0%	-	-	0%	3	1	33%	-	-	
	Oct 2010	0	0	0%	3	3	100%	1	1	100%	3	3	100%	-	-	
	Nov 2010	0	0	0%	2	2	100%	-	-	0%	2	1	50%	-	-	
	Dec 2010	0	0		1	1	100%	-	-	0%	4	2 3	50%	- 1	-	10
	Jan 2011 Feb 2011	1	0		3	1	33% 33%		-	0% 0%	4	1	75% 33%	-	1	10
	Mar 2011	0	0		2	2	100%		-	0%	2	1	50%		-	
	Apr 2011	0	0	0%	3	1	33%	-	-	0%	4	4	100%	-	-	
	May 2011	0	0	0%	5	3	60%		-	0%	2	2	100%		-	
	Jun 2011	0	0		2	1	50%	-	-	0%	-	-	0%		-	
	Jul 2011	0	0		2	-	0%	-	-	0%	4	4	100%	-	-	
	Aug 2011	0	0		1	1	100% 50%	- 1	-	0% 0%	1	1	100% 100%	- 1	- 1	10
	Sep 2011 Oct 2011	0	0		4	1	100%		-	0%	1	-	100%	-	-	10
	Nov 2011	0	0		-		0%		-	0%	1	1	100%			
	Dec 2011	0	0		3	2	67%		-	0%	1	1	100%			
	Jan 2012	0	0		2	1	50%		-	0%	2	2	100%			
	Feb 2012	0	0		2	2	100%	-	-	0%	5	4	80%	-	-	
	Mar 2012	0	0		3	3	100%	-	-	0%	2	2	100%	-	-	
	Apr 2012	1	1		5	5	100%	-	-	0%	3	3	100%	-	-	
	May 2012	0	0		4	1	25%	-	-	0%	-	-	0%	-	-	
	Jun 2012	0	0		-	-	0%	-	-	0%	2	1	50%	-	-	
	Jul 2012 Aug 2012	0	0		1 4	1	100% 100%	-	-	0% 0%	- 1	- 1	0% 100%	-	-	
	Aug 2012 Sep 2012	0	0		4	4	100%	-	-	0%	2	1	50%	-	-	
	Oct 2012	0	0		2	2	100%	-	-	0%	2	2	100%	-	-	
	Nov 2012	0	0	0%	2	2	100%	-	-	0%	5	3	60%	-	-	
	Dec 2012	0	0		3	1	33%	-	-	0%	-	-	0%	-	-	
	Jan 2013	0	0		2	-	0%	-	-	0%	4	1	25%	-	-	
	Feb 2013	0	0		3	2	67%	-	-	0%	-	-	0%	-	-	
	Mar 2013 Apr 2013	0	0		2	1	50% 0%	-	-	0% 0%	3	1	33% 100%	-	-	
	Apr 2013 May 2013	0	0		- 1	- 1	100%	-	-	0%	-	-	100%	-	-	
	Jun 2013	0	0		-	-	0%	-	-	0%	- 3	1	33%	-	-	
	Jul 2013	0	0		3	3	100%	-	-	0%	2	2	100%	-	-	
	Aug 2013	0	0	0%	2	2	100%	-	-	0%	3	1	33%	-	-	
	Sep 2013	0	0		1	1	100%	-	-	0%	2	1	50%	-	-	
	Oct 2013	0	0		4	1	25%	-	-	0%	1	1	100%	-	-	
	Nov 2013 Dec 2013	0	0		1	1	100% 0%	-	-	0% 0%	3 2	2 1	67% 50%	-	-	



		Do	se 175 mcg/	hr	Do	se 200 mcg/l	hr	Do	se 225 mcg/l	۱r
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Toleranc
	Total	33	18	55%	4	3	75%	2	1	5
Age (years)	0 - 11 years	-	-	0%	-	-	0%	-	-	
	12 - 17 years	1	1	100%	-	-	0%	-	-	
	18 - 24 years	3	3	100% 0%	-	-	0% 0%	- 1	- 1	10
	25 - 34 years 35 - 44 years	4	- 3	75%	- 3	2	67%	-		10
	45 - 54 years	9	6	67%	1	1	100%		_	
	55 - 64 years	15	5	33%	-	-	0%	1	_	
Gender	Male	11	9	82%	4	3	75%	2	1	
	Female	22	9	41%	-	-	0%	-	-	
	Ambiguous	-	-	0%	-	-	0%	-	-	
	Unknown	-		0%			0%			
	Jan 2009	1	-	0%	-	-	0%	-	-	
Month and Year of	Feb 2009	1	1	100%	-	-	0%	-	-	
pisode Start Date	Mar 2009	1	1	100%	-	-	0%	-	-	
	Apr 2009	3	3	100%	1	1	100%	-	-	
	May 2009	-	-	0%	-	-	0%	-	-	
	Jun 2009	-	-	0%	-	-	0%	-	-	
	Jul 2009	2	2	100%	-	-	0%	1	1	10
	Aug 2009	-	-	0%	-	-	0%	-	-	
	Sep 2009	1	1	100%	-	-	0%	-	-	
	Oct 2009 Nov 2009	1	-	0% 0%	-	-	0% 0%	-	-	
	Dec 2009	- 1	-	0%	-	-	0%	-	-	
	Jan 2010	-		0%			0%			
	Feb 2010	_	_	0%	_	_	0%		_	
	Mar 2010	1	1	100%	1	1	100%			
	Apr 2010	-		0%			0%	-	-	
	May 2010	-		0%	-		0%		-	
	Jun 2010	1	-	0%	-	-	0%	-	-	
	Jul 2010	-	-	0%	-	-	0%	-	-	
	Aug 2010	1	1	100%	-	-	0%	-	-	
	Sep 2010	-	-	0%	-	-	0%	-	-	
	Oct 2010	1	1	100%	-	-	0%	-		
	Nov 2010	-	-	0%	-	-	0%	-	-	
	Dec 2010	1	1	100%	-	-	0%	-	-	
	Jan 2011	-	-	0%	-	-	0%	-	-	
	Feb 2011	2	1	50%	-	-	0%	-		
	Mar 2011	1	1	100%	-	-	0%	-	-	
	Apr 2011	1	-	0%	-	-	0%	-	-	
	May 2011	-	-	0%	-	-	0%	-	-	
	Jun 2011	2	1	50%	-	-	0%	-	-	
	Jul 2011	-	-	0%	-	-	0%	-	-	
	Aug 2011	1	-	0%	-	-	0%	-	-	
	Sep 2011 Oct 2011	2	1	50% 0%	-	-	0% 0%	-	-	
		2	-		-	-		-	-	
	Nov 2011	-	-	0%	-	-	0%	-	-	
	Dec 2011	-	-	0%		-	0%	-	-	
	Jan 2012 Feb 2012	-	-	0%		-	0%	-	-	
		-	-	0%		-	0%	-	-	
	Mar 2012 Apr 2012	1	-	0% 0%	-	-	0% 0%	-	-	
	Apr 2012 May 2012	-	-	0%	-	-	0%	-	-	
	Jun 2012		-	0%		-	0%	-	-	
	Jul 2012	-	-	0%	-	-	0%	-	-	
	Aug 2012	-	-	0%	-	-	0%	-	-	
	Sep 2012	-	-	0%	-	-	0%	-	-	
	Oct 2012	-	-	0%	-	-	0%	-	-	
	Nov 2012		-	0%	-	-	0%	1	-	
	Dec 2012	-	-	0%	-	-	0%	-	-	
	Jan 2013	-	-	0%	-	-	0%	-	-	
	Feb 2013	1	-	0%	-	-	0%	-	-	
	Mar 2013	-	-	0%	-	-	0%	-	-	
	Apr 2013	-	-	0%	-	-	0%	-	-	
	May 2013	-	-	0%	-	-	0%	-	-	
	Jun 2013	1	-	0%	2	1	50%	-	-	
	Jul 2013	-	-	0%	-	-	0%	-	-	
	Aug 2013	-	-	0%	-	-	0%	-	-	
	Sep 2013	1	1	100%	-	-	0%	-	-	
	Oct 2013	-	-	0%	-	-	0%	-	-	
	Nov 2013 Dec 2013	-	-	0% 100%	-	-	0% 0%	-	-	



								,	7 consecutive d	4,5,	1			1		
		D	ose 12 mcg/hr	r	C	Dose 24 mcg/h	r	C	Oose 25 mcg/hr	r	D	ose 36 mcg/	hr	Dos	ie 37 mcg/l	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Toleranc
A == ()	Total	16,379	8,076	49.3%	3	2	67%	44,450	23,730	53.4%					181	
Age (years)	0 - 11 years 12 - 17 years	32 75	6 23	18.8% 30.7%		0	0%	23 79	6 28	26.1% 35.4%					0	
	18 - 24 years	375	167	44.5%	-	0	0%	827	427	51.6%	0	C	0%	8	3	
	25 - 34 years	1,464	870	59.4%	-	0	0%	3,731	2,285	61.2%		C			17	
	35 - 44 years 45 - 54 years	2,841 5,214	1,561 2,603	54.9% 49.9%	2	2	100% 0%	7,954 14,785	4,564 8,065	57.4% 54.5%					37 54	
	55 - 64 years	6,378	2,846	44.6%	1	0	0%	17,051	8,355	49.0%	0				70	
Gender	Male	5,124	2,585	50.4%	1	1	100%	18,327	9,822	53.6%					85	
	Female Ambiguous	11,255	5,491	48.8% 0.0%	2	1	50% 0%	26,123	13,908	53.2%					96 0	
	Unknown	0	0	0	0	0	0%	-	0	0					0	
	Jan 2009	220	117	53.2%	-	0	0%	953	470	49.3%					3	
Month and Year of Episode Start Date		206 267	97 118	47.1% 44.2%		0	0%	890 982	438 496	49.2% 50.5%					3	
Episode Start Date	Apr 2009	207	105	44.2%		0	0%	969	503	51.9%		C			2	
	May 2009	248	119	48.0%		0	0%	875	490	56.0%	0	C	0 0%	6	5	83
	Jun 2009	258	115	44.6%	-	0	0%	909	443	48.7%					5	
	Jul 2009 Aug 2009	249 268	124	49.8% 45.5%	-	0	0%	870 881	443 432	50.9% 49.0%					2	
	Sep 2009	295	145	49.2%		0	0%	943	481	51.0%					4	
	Oct 2009	261	114	43.7%		0	0%	857	423	49.4%					1	
	Nov 2009	231 244	109 115	47.2%		0	0%	818 900	412 497	50.4%					4	
	Dec 2009 Jan 2010	244 226	113	47.1% 48.2%		0	0%	827	437	55.2% 50.1%					0	
	Feb 2010	238	128	53.8%		0	0%	753	400	53.1%	0	C	0 0%	8	8	
	Mar 2010	268	126	47.0%		0	0%	791	411	52.0%					5	
	Apr 2010 May 2010	257 227	119 122	46.3% 53.7%		0	0%	833 738	418 407	50.2% 55.1%				3	2	
	Jun 2010	246	117	47.6%		0	0%	736	391	52.4%					1	
	Jul 2010	223	104	46.6%		0	0%	764	423	55.4%			0 0%		3	
	Aug 2010 Sep 2010	260 301	130 136	50.0% 45.2%		0	0%	810 833	420 463	51.9% 55.6%					2	
	Oct 2010	288	130	45.2%		0	0%	777	403	52.8%					3	
	Nov 2010	290	141	48.6%		0	0%	824	421	51.1%	0	C	0 0%	9	5	56
	Dec 2010	291	138	47.4%		0	0%	731	398	54.4%					1	
	Jan 2011 Feb 2011	252 264	116 121	46.0% 45.8%		0	0%	724 639	372 329	51.4% 51.5%					1	
	Mar 2011	279	144	51.6%		0	0%	802	433	54.0%					5	
	Apr 2011	269	135	50.2%		0	0%	710	381	53.7%					9	
	May 2011 Jun 2011	261 276	120 123	46.0% 44.6%		0	0%	700 678	371 377	53.0% 55.6%					3	
	Juli 2011 Juli 2011	270	125	44.0%		0	0%	679	377	52.3%					2	
	Aug 2011	314	162	51.6%		0	0%	758	389	51.3%	0	C	0 0%	4	2	50
	Sep 2011 Oct 2011	291 263	138 133	47.4% 50.6%		0	0%	730 711	392 404	53.7% 56.8%		C			4	
	Nov 2011	203	135	51.0%		0	0%	659	383	58.1%	0				2	
	Dec 2011	307	145	47.2%		0	0%	689	357	51.8%					3	
	Jan 2012	279	125	44.8%	-	0	0%	720	394	54.7%					2	
	Feb 2012	255	128	50.2%		0	0%	638	340	53.3%					5	
	Mar 2012 Apr 2012	294 251	145 126	49.3% 50.2%	-	0	0%	683 650	358 353	52.4% 54.3%					5	
	Apr 2012 May 2012	324	126	49.1%	-	0	0%	631	353	54.3%					6	
	Jun 2012	242	127	52.5%	-	0	0%	564	310	55.0%					2	
	Jul 2012	295	149	50.5%	-	0	0%	617	342	55.4%					2	
	Aug 2012 Sep 2012	304 279	169 131	55.6% 47.0%	-	0	0%	787 645	437 333	55.5% 51.6%					1	
	Oct 2012	304	160	52.6%		0	0%	699	426	60.9%					2	
	Nov 2012	313	161	51.4%	-	0	0%	712	373	52.4%					4	
	Dec 2012 Jan 2013	293 277	141 143	48.1% 51.6%	-	0	0%	631 593	347 320	55.0% 54.0%					3	
	Feb 2013	254	143	51.6%		0	0%	638	320	59.1%					3	
	Mar 2013	253	137	54.2%	-	0	0%	585	346	59.1%					3	
	Apr 2013	289	159	55.0%	-	0	0%	617	353	57.2%					5	
	May 2013 Jun 2013	261 271	135 146	51.7% 53.9%	-	0	0% 100%	640 602	362 339	56.6% 56.3%					5	
	Jul 2013	331	162	48.9%	-	0	0%	663	386	58.2%					7	
	Aug 2013	341	160	46.9%	-	0	0%	735	403	54.8%					1	
	Sep 2013 Oct 2013	302 331	149 173	49.3% 52.3%	-	0	0% 100%	645 714	348 397	54.0% 55.6%					2	
	Nov 2013	331 310	173	52.3%	1	1	100%	/14 651	397	55.6%					1	
	Dec 2013	298	161	54.0%	0				345	54.2%					4	



		Dos	se 50 mcg/h	ır	Dos	e 62 mcg/h	ır	Dos	se 75 mcg/h	ır	Do	se 87 mcg/l	ır	Dos	e 100 mcg/l	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerand
	Total	18,527	11,000	59%	22	6	27%	5,118	3,122	61%	8	2	25%	3,507	2,125	6
Age (years)	0 - 11 years	7	2	29%	1	0		2	-	0%	0			4	-	(
	12 - 17 years	32	10	31%	0	0	0%	11	3	27%	0			8	2	2
	18 - 24 years 25 - 34 years	380 1,614	205 1,055	54% 65%	1	0	0% 0%	99 523	55 337	56% 64%	0	0		77 290	39 191	5:
	35 - 44 years	3,502	2,240	64%	4	1	25%	1,011	613	61%	1	0		686	424	62
	45 - 54 years	6,358	3,779	59%	11	3	27%	1,785	1,110	62%	4	1		1,276	790	62
	55 - 64 years	6,634	3,709	56%	3	2	67%	1,687	1,004	60%	2	0	0%	1,166	679	58
Gender	Male	8,727	5,343	61%	11	5		2,510	1,590	63%	4			1,839	1,171	64
	Female	9,800	5,657	58%	11	1	9%	2,608	1,532	59%	4	1		1,668	954	57
	Ambiguous Unknown	-	-	0% 0%	0	0	0% 0%	-	-	0% 0%	0	0	0% 0%	-	-	(
	Jan 2009	412	223	54%	2	2		145	76	52%	1	0		94	46	49
Month and Year of		414	251	61%	0	0		118	68	58%	0			98	59	60
Episode Start Date	Mar 2009	424	263	62%	0	0	0%	112	67	60%	0	0	0%	79	40	51
	Apr 2009	423	262	62%	0	0	0%	108	68	63%	0			88	56	64
	May 2009	368	208	57%	0	0	0%	101	52	51%	0	0		84	46	55
	Jun 2009	409	227	56%	0	0		111	58	52%	0			75	56	75
	Jul 2009 Aug 2009	376 348	214 212	57% 61%	2	0	0% 0%	89 97	48 58	54% 60%	0	0		86 72	55 43	64 60
	Sep 2009	396	233	59%	0	0		95	69	73%	2	0		72	40	56
	Oct 2009	433	241	56%	0	0		100	59	59%	0			90	54	60
	Nov 2009	366	213	58%	1	1	100%	94	63	67%	0	0		77	48	62
	Dec 2009	379	216	57%	0	0		113	67	59%	0	0		74	44	59
	Jan 2010	359	200	56%	0	0	0%	101	59	58%	0	0		89	58	65
	Feb 2010 Mar 2010	325 331	176 195	54% 59%	1	0	0% 0%	84 113	44 71	52% 63%	1	0		60 62	35 37	58
	Apr 2010	307	193	56%	0	0	0%	113	67	67%	0	0		67	48	72
	May 2010	326	188	58%	0	0	0%	84	47	56%	0	0		60	41	68
	Jun 2010	340	206	61%	0	0	0%	77	42	55%	0	0	0%	49	39	80
	Jul 2010	342	216	63%	0	0	0%	92	51	55%	0	0		55	37	67
	Aug 2010	325	191	59%	0	0		98	58	59%	0			71	47	66
	Sep 2010 Oct 2010	343 340	206 215	60% 63%	1	1	100% 0%	93 95	61 64	66% 67%	0	0		70 58	41 43	59 74
	Nov 2010	326	207	63%	0	0	0%	93	62	67%	0	0		63	41	65
	Dec 2010	356	203	57%	0	0	0%	78	46	59%	0			64	30	47
	Jan 2011	306	165	54%	0	0	0%	112	60	54%	0	0	0%	90	55	61
	Feb 2011	277	171	62%	0	0	0%	96	64	67%	0	0		66	39	59
	Mar 2011	338	211	62%	1	0		94	64	68%	0	0		79	46	58
	Apr 2011 May 2011	322 280	173 156	54% 56%	0	0	0% 0%	86 86	56 54	65% 63%	0	0		52 52	30 31	58 60
	Jun 2011	280	150	55%	0	0		75	53	71%	1	0		41	27	66
	Jul 2011	309	185	60%	0	0	0%	70	52	74%	0	0		48	28	58
	Aug 2011	322	185	57%	0	0	0%	78	44	56%	0	0	0%	45	31	69
	Sep 2011	310	186	60%	0	0	0%	78	49	63%	0	0		42	25	60
	Oct 2011	269	156	58%	2	0	0%	77	56	73%	0	0		56	33	59
	Nov 2011	274	165	60%	0	0	0%	77	47	61%	0	0		47	28	60
	Dec 2011	286	167	58%	0	0	0%	72	41	57%	0			59	38	64
	Jan 2012 Feb 2012	273 266	167 168	61% 63%	0	0	0% 0%	88 75	60 49	68% 65%	0			53 53	27 36	5:
	Feb 2012 Mar 2012	266	168	63%	1	0		75	49	63%	0			48	30	63
	Apr 2012	282	175	63%	1	0		86	48 50	58%	0			48	29	60
	May 2012	287	181	63%	1	0		71	46	65%	0			52	37	7:
	Jun 2012	234	144	62%	1	0		60	38	63%	0			49	32	65
	Jul 2012	307	189	62%	0	0		87	48	55%	0			37	18	49
	Aug 2012	284 254	170 159	60% 63%	1	0	0% 0%	89 77	59 55	66% 71%	0	0		51 38	35 22	69 58
	Sep 2012 Oct 2012	254	159	58%	1	0		69	47	68%	0			38 47	22	4
	Nov 2012	296	145	56%	0	0	0%	90	47	51%	2	1		62	33	
	Dec 2012	261	171	66%	0	0		54	26	48%	0			46	20	4
	Jan 2013	254	156	61%	2	1	50%	87	45	52%	0			42	26	62
	Feb 2013	212	134	63%	2	0	0%	56	33	59%	0	0		44	29	66
	Mar 2013	236	148	63%	0	0		72	45	63%	0			36	19	53
	Apr 2013 May 2013	226 250	129 160	57% 64%	0	0	0% 100%	68 65	39 43	57% 66%	0	0		37 42	25 26	68 62
	Jun 2013	250	160	58%	1	0		65	43	64%	0			42	18	5
	Jul 2013	239	141	59%	0	0		78	49	63%	0	0		43	22	5:
	Aug 2013	272	169	62%	0	0	0%	61	29	48%	0	0		31	15	48
	Sep 2013	245	152	62%	0	0		66	41	62%	0			44	25	57
	Oct 2013	242	152	63%	0	0		67	43	64%	0			47	32	68
	Nov 2013	241	142	59%	0	0	0%	58	37	64%	0			47	26	55
	Dec 2013	247	148	60%	1	0	0%	57	37	65%	0	0	0%	42	27	6



		Do	se 112 mcg/	'hr	Do	se 125 mcg/ł	۱r	Do	se 137 mcg/	/hr	Do	se 150 mcg/	hr	Do	se 162 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Toleranc
	Total	3	3		137	73	53%	2	1		172	104	60%	2	1	50
ge (years)	0 - 11 years 12 - 17 years	0	0		- 1	-	0% 0%	-	-	0%	- 1	-	0% 0%	-	-	
	18 - 24 years	0	0		2	2	100%	-	-	0%	5	4	80%	1	-	
	25 - 34 years	0	0		9	7	78%	-	-	0%	12	6	50%	-	-	
	35 - 44 years 45 - 54 years	0	0		20 57	8 31	40% 54%	- 1	-	0%	30 60	21 37	70% 62%	-	-	
	55 - 64 years	2	2		48	25	52%	1	1	100%	64	36	56%	1	1	10
iender	Male	1	1		69	35	51%	-	-	0%		61	64%	2	1	5
	Female Ambiguous	2	2		68	38	56% 0%	2	1	50% 0%		43	56% 0%	-	-	
	Unknown	0	0				0%			0%			0%			
	Jan 2009	1	1	100%	4	2	50%	-	-	0%		2	33%	-	-	
Month and Year of		0	0		3	1	33%	-	-	0%		1	50%	-	-	
pisode Start Date	Mar 2009 Apr 2009	0	0		3	1	33% 50%	-	-	0% 0%	1	1	100% 100%	-	-	
	May 2009	0	0		3	3	100%	-	-	0%	6	4	67%	-	-	
	Jun 2009	0	0		2	2	100%	-	-	0%	7	6	86%	-	-	
	Jul 2009 Aug 2009	0	0		1	1	100% 100%	-	-	0%	3	1	33% 0%	-	-	
	Sep 2009	0	0		-	-	100%	-	-	0%	4	- 3	60%	-	-	
	Oct 2009	0	0		1	-	0%	-	-	0%	4	2	50%	-	-	
	Nov 2009	0	0		2	1	50%	-	-	0%	7	5	71%	-	-	
	Dec 2009 Jan 2010	0	0		2	1	50% 29%	-	-	0%	7 5	5 3	71% 60%	-	-	
	Feb 2010	0	0		6	1	17%	-	-	0%	5	3	60%	-	-	
	Mar 2010	0	0	0%	2	-	0%	-	-	0%	4	3	75%	-	-	
	Apr 2010	0	0		4	1	25%	-	-	0%	4	3	75%	-	-	
	May 2010 Jun 2010	0	0		2	1	50% 40%	-	-	0%	4	2 1	50% 50%	-	-	
	Jul 2010	0	0		1	-	40%	-	-	0%	5	4	80%	-	-	
	Aug 2010	0	0	0%	2	1	50%	-	-	0%	2	-	0%	-	-	
	Sep 2010	0	0		-	-	0%	-	-	0%	3	-	0%	-	-	
	Oct 2010 Nov 2010	0	0		3	3	100% 100%	1	1	100%	3	3 1	100% 50%	-	-	
	Dec 2010	0	0		1	1	100%	-	-	0%	4	2	50%	-	-	
	Jan 2011	0	0		3	1	33%	-	-	0%	4	2	50%	1	-	
	Feb 2011 Mar 2011	1	1		3	1	33% 50%	-	-	0%	3	1	33% 50%	-	-	
	Apr 2011	0	0		3	2	67%	-	-	0%	4	4	100%	-	-	
	May 2011	0	0	0%	5	1	20%	-	-	0%	2	1	50%	-	-	
	Jun 2011	0	0		2	1	50%	-	-	0%	-	-	0%	-	-	
	Jul 2011 Aug 2011	0	0		2	- 1	0% 100%	-	-	0% 0%	4	4	100% 100%	-	-	
	Sep 2011	0	0		4	3	75%	1	-	0%	3	3	100%	1	1	10
	Oct 2011	0	0	0%	1	1	100%	-	-	0%	1	-	0%	-	-	
	Nov 2011	0	0		-	-	0%	-	-	0%	1	1	100%	-	-	
	Dec 2011	0	0		3	2	67%	-	-	0%		1	100%	-	-	
	Jan 2012 Feb 2012	0	0		2	1	50% 50%	-	-	0%	2	2 4	100% 80%	-	-	
	Mar 2012	0	0		3	3	100%	-	-	0%		1	50%	-	-	
	Apr 2012	1	1		5	5	100%	-	-	0%		2	67%	-	-	
	May 2012 Jun 2012	0	0		4	-	0% 0%	-	-	0%	- 2	- 1	0% 50%	-	-	
	Juli 2012 Juli 2012	0	0		- 1	- 1	100%	-	-	0%		-	50%	-	-	
	Aug 2012	0	0		4	3	75%	-	-	0%		1	100%	-	-	
	Sep 2012	0	0		1	1	100%	-	-	0%		1	50%	-	-	
	Oct 2012 Nov 2012	0	0		2	2	100% 100%	-	-	0%	2	2 3	100% 60%	-	-	
	Dec 2012	0	0		3	1	33%	-	-	0%		-	0%	-	-	
	Jan 2013	0	0		2	-	0%	-	-	0%	4	-	0%	-	-	
	Feb 2013 Mar 2013	0	0		3	1	33% 50%	-	-	0% 0%		- 1	0% 33%	-	-	
	Mar 2013 Apr 2013	0	0		- 2	-	50%	-	-	0%	3	1	33% 67%	-	-	
	May 2013	0	0		1	1	100%	-	-	0%		-	0%	-	-	
	Jun 2013	0	0		-	-	0%	-	-	0%		1	33%	-	-	
	Jul 2013 Aug 2013	0	0		3	3	100% 100%	-	-	0%	2	2 1	100% 33%	-	-	
	Sep 2013	0	0		1	1	100%	-	-	0%		1	50%	-	-	
	Oct 2013	0	0		4	1	25%	-	-	0%		1	100%	-	-	
	Nov 2013	0	0	0%	1	1	100%	-	-	0%	3	2	67%	-	-	



		1								
			se 175 mcg/	hr		se 200 mcg/	hr		se 225 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerand
<i>,</i> ,	Total	33	16	48%	4	3	75%	2	-	
ge (years)	0 - 11 years	- 1	- 1	0% 100%	-	-	0% 0%	-	-	
	12 - 17 years 18 - 24 years	3	3	100%	-		0%		-	
	25 - 34 years	1	-	0%	-		0%	1	-	
	35 - 44 years	4	3	75%	3	2	67%	-	-	
	45 - 54 years	9	4	44%	1	1	100%	-	-	
	55 - 64 years	15	5	33%	-	-	0%	1	-	
ender	Male	11	9	82%	4	3	75%	2	-	
	Female	22	7	32%	-	-	0%	-	-	
	Ambiguous Unknown	-	-	0% 0%	-	-	0% 0%	-	-	
	Jan 2009	1	-	0%	-		0%			
Ionth and Year of	Feb 2009	1	1	100%	-		0%	-	-	
pisode Start Date	Mar 2009	1	1	100%	-	-	0%	-	-	
	Apr 2009	3	3	100%	1	1	100%	-	-	
	May 2009	-	-	0%	-	-	0%	-	-	
	Jun 2009	-	-	0%	-	-	0%	-	-	
	Jul 2009	2	-	0%	-	-	0%	1	-	
	Aug 2009	-	-	0%	-	-	0%	-	-	
	Sep 2009 Oct 2009	1	1	100% 0%	-	-	0% 0%	-	-	
	Nov 2009	-	-	0%	-		0%		_	
	Dec 2009	1	-	0%	-		0%		-	
	Jan 2010	-	-	0%	-	-	0%	-	-	
	Feb 2010	-	-	0%	-	-	0%	-	-	
	Mar 2010	1	1	100%	1	1	100%	-	-	
	Apr 2010	-	-	0%	-	-	0%	-	-	
I	May 2010	-	-	0%	-	-	0%	-	-	
	Jun 2010	1	-	0%	-	-	0%	-	-	
	Jul 2010	-	-	0%	-	-	0%	-	-	
	Aug 2010	1	1	100%	-	-	0%	-	-	
	Sep 2010 Oct 2010	- 1	- 1	0% 100%	-		0% 0%			
	Nov 2010	-		0%	-		0%	-	-	
	Dec 2010	1	1	100%	-	-	0%	-	-	
	Jan 2011	-	-	0%	-	-	0%	-	-	
	Feb 2011	2	1	50%	-	-	0%	-	-	
	Mar 2011	1	1	100%	-	-	0%	-	-	
	Apr 2011	1	-	0%	-	-	0%	-	-	
	May 2011	-	-	0%	-	-	0%	-	-	
	Jun 2011	2	1	50%	-	-	0%	-	-	
	Jul 2011 Aug 2011	-	-	0%	-	-	0% 0%	-	-	
	Sep 2011	1	1	50%	_		0%			
	Oct 2011	2	-	0%	-	-	0%	-	-	
	Nov 2011	-	-	0%	-	-	0%	-	-	
	Dec 2011	-	-	0%		-	0%	-	-	
	Jan 2012	-	-	0%		-	0%	-	-	
	Feb 2012	-	-	0%		-	0%	-	-	
	Mar 2012	1	-	0%		-	0%	-	-	
	Apr 2012	1	-	0%	-	-	0%	-	-	
	May 2012	-	-	0%		-	0%	-	-	
	Jun 2012	-	-	0%		-	0%	-	-	
	Jul 2012	-	-	0%	-	-	0%	-	-	
	Aug 2012 Sep 2012	-	-	0% 0%	-	-	0% 0%	-	-	
	Sep 2012 Oct 2012	-	-	0%		-	0%	-	-	
	Nov 2012	-	-	0%		-	0%	1	-	
	Dec 2012	-	-	0%		-	0%	-	-	
	Jan 2013	-	-	0%	-	-	0%	-	-	
	Feb 2013	1	-	0%	-	-	0%	-	-	
	Mar 2013	-	-	0%		-	0%	-	-	
	Apr 2013	-	-	0%		-	0%	-	-	
	May 2013	-	-	0%		-	0%	-	-	
	Jun 2013	1	-	0%		1	50%	-	-	
	Jul 2013	-	-	0% 0%		-	0%	-	-	
	Aug 2013 Sep 2013	-	-	0% 100%		-	0% 0%	-	-	
	Sep 2013 Oct 2013	1	1	100%		-	0%	-	-	
	Nov 2013	-	-	0%	-	-	0%	-	-	
	Dec 2013	- 1	- 1	100%	-	-	0%	-	-	



		1			1									1		
1		C	Oose 12 mcg/h	r	C	ose 24 mcg/h	r	C	ose 25 mcg/hr		D	ose 36 mcg/ł	ır	Dos	e 37 mcg/ł	nr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	16,379	11,725	71.6%	3	3		44,450	34,055	76.6%			0%		226	
Age (years)	0 - 11 years 12 - 17 years	32 75	13 34	40.6% 45.3%		0		23 79	9	39.1% 44.3%			0% 0%	1	0	
	18 - 24 years	375	244	45.3%		0		827	573	69.3%			0%	8	5	
	25 - 34 years	1,464	1,149	78.5%	-	0	0%	3,731	3,036	81.4%		0	0%	24	20	
	35 - 44 years	2,841	2,145	75.5%	2	2		7,954	6,322	79.5%			0%		45	
	45 - 54 years 55 - 64 years	5,214 6,378	3,758 4,382	72.1% 68.7%	-	0		14,785 17,051	11,417 12,663	77.2%	0		0% 0%		66 90	
Gender	Male	5,124	3,737	72.9%	1	1		18,327	12,005	74.3%			0%		105	
	Female	11,255	7,988	71.0%	2	2	100%	26,123	19,900	76.2%	1	0	0%	165	121	73
	Ambiguous	-	-	0.0%	-	0			-	0.0%					0	
	Unknown Jan 2009	0	0		0	0			0	72.9%	ő				0	
Month and Year of		220	165 140	75.0% 68.0%		0		953 890	672	73.8% 75.5%			0% 0%		4	
Episode Start Date		267	174	65.2%	-	0		982	739	75.3%			0%	5	5	
	Apr 2009	220	159	72.3%	-	0	0%	969	725	74.8%	1	0	0%	4	2	50
	May 2009	248	182	73.4%	-	0		875	689	78.7%			0%	6	6	
	Jun 2009 Jul 2009	258 249	172	66.7% 69.9%		0		909 870	689 643	75.8% 73.9%		0	0%	5	5	
	Aug 2009	245	174	71.3%		0		870	641	73.5%			0%	2	4	
	Sep 2009	295	219	74.2%	-	0		943	717	76.0%			0%	4	4	
	Oct 2009	261	172	65.9%	-	0		857	631	73.6%			0%	1	1	
	Nov 2009	231	157	68.0%		0		818	598	73.1%		0	0% 0%	8	5	
	Dec 2009 Jan 2010	244 226	167 156	68.4% 69.0%		0	0%	900 827	687 607	76.3% 73.4%		0	0%	6	5	
	Feb 2010	238	171	71.8%		0		753	562	74.6%			0%	8	8	
	Mar 2010	268	184	68.7%		0	0%	791	601	76.0%	0	0	0%	8	6	75
	Apr 2010	257	179	69.6%		0		833	621	74.5%			0%	3	2	
	May 2010 Jun 2010	227 246	179 171	78.9% 69.5%		0		738 746	595 557	80.6% 74.7%			0%	5	1	
	Jul 2010	240	171	69.5%		0		740	593	74.7%			0%	4 5	1	
	Aug 2010	260	186	71.5%	-	0	0%	810	623	76.9%		0	0%	3	2	
	Sep 2010	301	213	70.8%		0		833	643	77.2%			0%	2	2	
	Oct 2010	288	196	68.1%	-	0		777	586	75.4%			0%	5	5	
	Nov 2010 Dec 2010	290 291	210 209	72.4% 71.8%		0	0%	824 731	621 567	75.4%		0	0% 0%	3	7	
	Jan 2011	252	169	67.1%		0		724	547	75.6%		0	0%	1	1	
	Feb 2011	264	177	67.0%		0	0%	639	490	76.7%	0	0	0%	3	3	100
	Mar 2011	279	193	69.2%		0		802	622	77.6%			0%	9	6	
	Apr 2011 May 2011	269 261	199 184	74.0% 70.5%		0		710 700	553 527	77.9% 75.3%			0% 0%	10 3	10 3	
	Jun 2011	276	104	69.6%		0	0%	678	521	75.3%			0%	4	3	
	Jul 2011	282	193	68.4%		0	0%	679	515	75.8%	0	0	0%	3	2	
	Aug 2011	314	237	75.5%	-	0		758	559	73.7%		0	0%	4	3	
	Sep 2011 Oct 2011	291 263	208 194	71.5% 73.8%		0		730 711	565 555	77.4% 78.1%	0		0%	7	5	
	Nov 2011	263	204	73.8%		0		659	555	80.3%		0	0%		2	
	Dec 2011	307	215	70.0%		0		689	517	75.0%			0%		5	
	Jan 2012	279	190	68.1%		0		720	562	78.1%			0%	2	2	
	Feb 2012	255	189	74.1%		0		638	492	77.1%		0	0%		6	
	Mar 2012	294	218	74.1%	-	0		683	538	78.8%			0%		5	
	Apr 2012	251 324	180 225	71.7% 69.4%	-	0		650	494 486	76.0% 77.0%		0	0%		3	
	May 2012 Jun 2012	324 242	225	69.4% 74.0%		0		631 564	486	77.0%			0% 0%		7	
	Jul 2012	295	225	76.3%		0		617	464	75.2%		0	0%		4	
	Aug 2012	304	230	75.7%		0		787	625	79.4%			0%		2	
	Sep 2012	279	199	71.3%	-	0		645	496	76.9%		0	0%		5	
	Oct 2012 Nov 2012	304 313	223 227	73.4% 72.5%	-	0		699 712	565 553	80.8%			0% 0%		2	
	Dec 2012	293	214	72.3%		0		631	478	75.8%			0%	8	5	
	Jan 2013	277	200	72.2%	-	0		593	452	76.2%		0	0%		3	
	Feb 2013	254	182	71.7%	-	0		638	516	80.9%			0%		3	
	Mar 2013 Apr 2013	253 289	185 219	73.1% 75.8%	-	0		585	470 486	80.3% 78.8%		0	0% 0%	4	4	
	Apr 2013 May 2013	289 261	219	75.8%		0		617 640	486 500	78.8%			0%		6	
	Jun 2013	271	197	72.7%	1	1		602	482	80.1%		0	0%		3	
	Jul 2013	331	241	72.8%		0		663	530	79.9%			0%		7	
	Aug 2013	341	244	71.6%		0		735	582	79.2%			0%		2	
	Sep 2013 Oct 2013	302 331	221 248	73.2% 74.9%	-	0		645 714	489 550	75.8% 77.0%			0% 0%		2	
	Nov 2013	331	248	74.9%	1	1		651	550	77.0%			0%		2	
	Dec 2013	298	222	74.5%	0				491	77.1%					4	



		Dos	e 50 mcg/ł	nr	Dos	e 62 mcg/ł	nr	Dos	e 75 mcg/h	r	Do	se 87 mcg/l	hr	Do	se 100 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	18,527	14,686	79%	22	8		5,118	3,944	77%	8			3,507	2,603	74%
Age (years)	0 - 11 years	7	3	43%	1	0	0%	2	1	50%	0			4	-	0% 38%
	12 - 17 years 18 - 24 years	32 380	17 277	53% 73%	0	0	0% 0%	11 99	4 70	36% 71%	0	0		8 77	3 48	38%
	25 - 34 years	1,614	1,331	82%	2	0		523	409	78%	1	1		290	231	80%
	35 - 44 years	3,502	2,886	82%	4	2		1,011	771	76%	1	0		686	518	76%
	45 - 54 years	6,358	5,038	79%		4		1,785	1,396	78%	4	-		1,276	960	75%
Gender	55 - 64 years Male	6,634 8,727	5,134 7,004	77% 80%	3	6	67% 55%	1,687 2,510	1,293 1,966	77%	4	1		1,166 1,839	843 1,404	72%
	Female	9,800	7,682	78%	11	2		2,608	1,978	76%	4	2		1,668	1,199	72%
	Ambiguous	-	-	0%		0		-	-	0%	0			-	-	0%
	Unknown		-	0%	0	0				0%	0			-		0%
Month and Year of	Jan 2009 Feb 2009	412 414	313 346	76% 84%	2	2		145 118	98 90	68% 76%	1			94 98	65 75	69% 77%
Episode Start Date		424	348	82%	0	0	0%	110	80	71%	0	0		79	52	66%
	Apr 2009	423	337	80%	0	0		108	88	81%	0			88	68	77%
	May 2009	368	269	73%	0	0	0%	101	74	73%	0	0		84	62	74%
	Jun 2009	409	311	76%	0	0	0%	111	83	75%	0	0		75	66	88%
	Jul 2009 Aug 2009	376 348	294 285	78% 82%	2	0	0% 0%	89 97	62 75	70% 77%	0	0		86 72	63 52	73% 72%
	Sep 2009	396	312	79%	0	0	0%	95	81	85%	2	1		72	49	68%
	Oct 2009	433	322	74%	0	0		100	77	77%	0			90	64	71%
	Nov 2009	366	287	78%	1	1	100%	94	78	83%	0	0		77	57	74%
	Dec 2009	379	295	78%	0	0	0%	113	86	76%	0	0		74	55	74%
	Jan 2010 Feb 2010	359 325	269 241	75% 74%	0	0	0% 0%	101 84	70 60	69% 71%	0	0		89 60	67 43	75% 72%
	Mar 2010	331	260	79%	0	0	0%	113	86	76%	0			62	43	69%
	Apr 2010	307	240	78%	0	0	0%	100	84	84%	0	0	0%	67	53	79%
	May 2010	326	250	77%	0	0	0%	84	60	71%	0	0	0%	60	46	77%
	Jun 2010	340	272	80%	0	0	0%	77	61	79%	0	0		49	42	86%
	Jul 2010 Aug 2010	342 325	276 258	81% 79%	0	0	0% 0%	92 98	69 72	75% 73%	0	0		55 71	44 57	80% 80%
	Sep 2010	343	250	79%	1	1	100%	93	72	84%	0	0		70	51	73%
	Oct 2010	340	278	82%	0	0	0%	95	77	81%	0	0	0%	58	50	86%
	Nov 2010	326	269	83%	0	0	0%	93	77	83%	0	0		63	49	78%
	Dec 2010	356	281	79%	0	0	0%	78	61	78%	0			64	38	59%
	Jan 2011 Feb 2011	306 277	232 217	76% 78%	0	0	0% 0%	112 96	78 76	70% 79%	0	0		90 66	67 49	74% 74%
	Mar 2011	338	270	80%	1	0		94	78	83%	0			79	57	72%
	Apr 2011	322	244	76%	0	0	0%	86	67	78%	0	0	0%	52	38	73%
	May 2011	280	211	75%	0	0	0%	86	67	78%	0			52	34	65%
	Jun 2011	286 309	220 244	77% 79%	0	0	0% 0%	75 70	65 59	87% 84%	1	1		41 48	31 39	76%
	Jul 2011 Aug 2011	309	244	80%	0	0	0%	70	59	74%	0			48	39	81% 87%
	Sep 2011	310	253	82%	0	0	0%	78	63	81%	0	0		42	31	74%
	Oct 2011	269	210	78%	2	0	0%	77	64	83%	0	0	0%	56	41	73%
	Nov 2011	274	221	81%	0	0	0%	77	59	77%	0	0	0%	47	34	72%
	Dec 2011	286	236	83%	0	0	0%	72	52	72%	0	0	0%	59	48	81%
	Jan 2012	273	226	83%		0	0%	88	74	84%	0	0		53	35	66%
	Feb 2012 Mar 2012	266 282	219 237	82% 84%		0	0% 0%	75 76	56 64	75% 84%	0			53 48	45 40	85% 83%
	Mar 2012 Apr 2012	282	237	84% 80%	0	0		76 86	64 66	84%	0			48 48	40 37	83%
	May 2012	287	222	77%	1	0	0%	71	56	79%	0	0		52	39	75%
	Jun 2012	234	193	82%	1	0		60	49	82%	0			49	39	80%
	Jul 2012	307	245	80%	0	0		87	64	74%	0			37	22	59%
	Aug 2012 Sep 2012	284 254	225 213	79% 84%	1	1	100% 0%	89 77	68 64	76% 83%	0	0		51 38	39 31	76% 82%
	Sep 2012 Oct 2012	254 251	213	84% 80%		0	0%	69	64 57	83%	1			38 47	31	82%
	Nov 2012	296	211	71%		0		90	60	67%	2			62	43	69%
	Dec 2012	261	209	80%	0	0	0%	54	34	63%	0	0		46	31	67%
	Jan 2013	254	202	80%	2	1	50%	87	62	71%	0			42	31	74%
	Feb 2013 Mar 2013	212 236	180 187	85% 79%	2	0	0% 0%	56 72	46 52	82% 72%	0			44 36	36 27	82% 75%
	Apr 2013	236	187	79% 81%		0	0%	68	54	72%	0			30	27	737
	May 2013	250	205	82%		1	100%	65	56	86%	0			42	27	649
	Jun 2013	244	203	83%	0	0		69	51	74%	0			34	24	719
	Jul 2013	239	192	80%		0	0%	78	67	86%	0	0		43	30	709
	Aug 2013 Sep 2013	272 245	229 204	84% 83%	0	0	0% 0%	61 66	41 50	67% 76%	0	0		31 44	17 33	55% 75%
I	Oct 2013	245	204 197	81%		0	0%	67	50	76%	0			44	35	75%
	Nov 2013	241	189	78%	0	0	0%	58	47	81%	0			47	31	66%
	Dec 2013	247	194	79%		1	100%	57	43	75%	0				31	74%



		Do	se 112 mcg/	'hr	Dos	se 125 mcg/	hr	Do	se 137 mcg/	'nr	Do	se 150 mcg/	'nr	Do	se 162 mcg/	'nr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
• • • • • • •	Total	3	3		137	94	69%	2	1	50%	172	124	72%	2	2	
Age (years)	0 - 11 years 12 - 17 years	0	0		- 1	- 1	0% 100%	-	-	0% 0%	- 1	-	0% 0%	-	-	0%
	18 - 24 years	0	0		2	2	100%	-	-	0%	5	4	80%	1	1	1009
	25 - 34 years	0	0	0%	9	7	78%	-	-	0%	12	8	67%	-	-	09
	35 - 44 years	0	0		20	15	75%	-	-	0%	30	24	80%	-	-	0%
	45 - 54 years 55 - 64 years	1	1		57 48	38 31	67% 65%	1	- 1	0% 100%	60 64	44 44	73% 69%	- 1	- 1	0% 100%
Gender	Male	1	1		69	46	67%	-	-	0%	95	75	79%	2	2	
	Female	2	2	100%	68	48	71%	2	1	50%	77	49	64%	-	-	09
	Ambiguous	0	0		-	-	0%	-	-	0%	-	-	0%	-	-	09
	Unknown Jan 2009	0	0		- 4	- 3	0% 75%			0%	- 6	- 2	0% 33%			09
Month and Year of	Feb 2009	0	1		4	2	67%	-	-	0%	2	2	100%	-	-	09
Episode Start Date	Mar 2009	0	0		3	1	33%	-	-	0%	1	1	100%	-	-	09
	Apr 2009	0	0	0%	2	1	50%	-	-	0%	1	1	100%	-	-	0%
	May 2009	0	0		3	3	100%	-	-	0%	6	4	67%	-	-	09
	Jun 2009 Jul 2009	0	0		2	2 1	100% 100%	-	-	0% 0%	7	6 1	86% 33%	-	-	0% 0%
	Aug 2009	0	0		1	1	100%	-	-	0%	4	1	25%	-	-	09
	Sep 2009	0	0	0%	-	-	0%	-	-	0%	5	4	80%	-	-	0%
	Oct 2009	0	0	0%	1	-	0%	-	-	0%	4	2	50%	-	-	0%
	Nov 2009	0	0		2	1	50%	-	-	0%	7	5	71%	-	-	0%
	Dec 2009 Jan 2010	0	0		2	1	50% 57%		-	0% 0%	7	6 3	86% 60%		-	0% 0%
	Feb 2010	0	0		6	3	50%	-	-	0%	5	4	80%	-	-	0%
	Mar 2010	0	0	0%	2	-	0%	-	-	0%	4	4	100%	-	-	0%
	Apr 2010	0	0	0%	4	2	50%	-	-	0%	4	3	75%	-	-	0%
	May 2010	0	0		2	1	50%	-	-	0%	4	3	75%	-	-	0%
	Jun 2010 Jul 2010	0	0		5	4	80% 100%	-	-	0% 0%	2	2 4	100% 80%	-	-	0% 0%
	Aug 2010	0	0		2	1	50%	-	-	0%	2	1	50%		-	0%
	Sep 2010	0	0	0%	-	-	0%	-	-	0%	3	1	33%	-	-	0%
	Oct 2010	0	0		3	3	100%	1	1	100%	3	3	100%	-	-	0%
	Nov 2010 Dec 2010	0	0		2	2 1	100% 100%	-	-	0% 0%	2	1	50% 50%	-	-	0%
	Jan 2011	0	0		3	1	33%	-	-	0%	4	2	75%	- 1	- 1	100%
	Feb 2011	1	1		3	2	67%	-	-	0%	3	2	67%	-	-	0%
	Mar 2011	0	0	0%	2	2	100%	-	-	0%	2	1	50%	-	-	0%
	Apr 2011	0	0		3	2	67%	-	-	0%	4	4	100%	-	-	0%
	May 2011 Jun 2011	0	0		5	3 2	60% 100%		-	0% 0%	2	2	100% 0%		-	0%
	Jul 2011	0	0		2	-	0%	-	-	0%	4	4	100%	-	-	0%
	Aug 2011	0	0	0%	1	1	100%	-	-	0%	1	1	100%	-	-	0%
	Sep 2011	0	0		4	3	75%	1	-	0%	3	3	100%	1	1	
	Oct 2011	0	0		1	1	100%	-	-	0%	1	-	0%	-	-	0%
	Nov 2011	0	0		-	-	0%	-	-	0%	1	1	100%	-	-	0%
	Dec 2011 Jan 2012	0	0		3	2	67% 50%	-	-	0% 0%	1	1	100% 100%	-	-	0%
	Jan 2012 Feb 2012	0	0		2	1	100%	-	-	0%	2	4	80%	-	-	0%
	Mar 2012	0	0		3	3	100%	-	-	0%	2	2	100%	-	-	0%
	Apr 2012	1	1		5	5	100%	-	-	0%	3	3	100%	-	-	0%
	May 2012	0	0		4	2	50%	-	-	0%	-	-	0%	-	-	09
	Jun 2012 Jul 2012	0	0		- 1	- 1	0% 100%	-	-	0% 0%	2	1	50% 0%	-	-	09
	Aug 2012	0	0		4	4	100%	-	-	0%	1	1	100%	-	-	0%
	Sep 2012	0	0		1	1	100%	-	-	0%	2	1	50%	-	-	09
	Oct 2012	0	0		2	2	100%	-	-	0%	2	2	100%	-	-	09
	Nov 2012	0	0		2	2	100%	-	-	0%	5	4	80%	-	-	09
	Dec 2012 Jan 2013	0	0		3	1	33% 0%	-	-	0% 0%	- 4	- 1	0% 25%	-	-	0%
	Feb 2013	0	0		3	2	67%	-	-	0%	-	-	23%	-	-	09
	Mar 2013	0	0		2	2	100%	-	-	0%	3	1	33%	-	-	09
	Apr 2013	0	0		-	-	0%	-	-	0%	3	3	100%	-	-	09
	May 2013 Jun 2013	0	0		1	1	100% 0%	-	-	0% 0%	- 3	- 3	0% 100%	-	-	09
	Jun 2013 Jul 2013	0	0		- 3	- 3	100%	-	-	0%	3	3	100%	-	-	09
	Aug 2013	0	0		2	2	100%	-	-	0%	3	1	33%	-	-	09
	Sep 2013	0	0		1	1	100%	-	-	0%	2	1	50%	-	-	0%
	Oct 2013	0	0		4	1	25%	-	-	0%	1	1	100%	-	-	0%
	Nov 2013 Dec 2013	0	0		1	1	100% 0%	-	-	0% 0%	3 2	2 1	67% 50%	-	-	0%



			,		0 mg for seven		,,	1		
		Do	se 175 mcg/	hr	Do	se 200 mcg/	hr	Do	se 225 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	33	20	61%	4	3	75%	2	1	50
Age (years)	0 - 11 years	-	-	0%	-	-	0%	-	-	
	12 - 17 years	1	1	100%	-	-	0%	-	-	
	18 - 24 years 25 - 34 years	3	3	100% 0%	-	-	0% 0%	- 1	- 1	10
	25 - 34 years 35 - 44 years	4	- 4	100%	- 3	- 2	67%	-	-	10
	45 - 54 years	9	6	67%	1	1	100%	_		
	55 - 64 years	15	6	40%		-	0%	1	_	
Gender	Male	11	9	82%	4	3	75%	2	1	5
	Female	22	11	50%	-	-	0%	-	-	
	Ambiguous	-	-	0%	-	-	0%	-	-	
	Unknown			0%			0%	-		
	Jan 2009	1	-	0%	-	-	0%	-	-	
Month and Year of	Feb 2009	1	1	100%	-	-	0%	-	-	
Episode Start Date	Mar 2009	1	1	100%	-	-	0%	-	-	
	Apr 2009	3	3	100%	1	1	100%	-	-	
	May 2009	-	-	0%	-	-	0%	-	-	
	Jun 2009	-	-	0%	-	-	0%	-	-	
	Jul 2009	2	2	100%	-	-	0%	1	1	10
	Aug 2009	-	-	0%	-	-	0%	-	-	
	Sep 2009	1	1	100%	-	-	0%	-	-	
	Oct 2009 Nov 2009	1	-	0% 0%	-	-	0% 0%	-	-	
	Dec 2009	- 1	-	0%	-	-	0%	-	-	
	Jan 2010			0%			0%			
	Feb 2010	_	_	0%	_	_	0%	_		
	Mar 2010	1	1	100%	1	1	100%	-		
	Apr 2010			0%			0%	-	-	
	May 2010	-	-	0%	-		0%	-	-	
	Jun 2010	1	1	100%			0%	-		
	Jul 2010	-	-	0%	-	-	0%	-	-	
	Aug 2010	1	1	100%		-	0%	-		
	Sep 2010	-	-	0%		-	0%	-		
	Oct 2010	1	1	100%	-	-	0%	-	-	
	Nov 2010	-	-	0%	-	-	0%	-	-	
	Dec 2010	1	1	100%	-	-	0%	-	-	
	Jan 2011	-	-	0%	-	-	0%	-	-	
	Feb 2011	2	1	50%		-	0%	-		
	Mar 2011	1	1	100%	-	-	0%	-	-	
	Apr 2011	1	-	0%	-	-	0%	-	-	
	May 2011	-	-	0%	-	-	0%	-	-	
	Jun 2011	2	1	50%	-	-	0%	-	-	
	Jul 2011	-	-	0%	-	-	0%	-	-	
	Aug 2011	1	-	0%	-	-	0%	-	-	
	Sep 2011 Oct 2011	2	1	50% 0%	-	-	0% 0%	-	-	
		2	-		-	-		-	-	
	Nov 2011	-	-	0%	-	-	0%	-	-	
	Dec 2011	-	-	0%	-	-	0%	-	-	
	Jan 2012	-	-	0%	-	-	0%	-	-	
	Feb 2012	-	-	0%	-	-	0%	-	-	
	Mar 2012 Apr 2012	1	1	100%	-	-	0%	-	-	
	Apr 2012 May 2012	1	-	0%	-	-	0%	-	-	
	May 2012 Jun 2012	-	-	0% 0%	-	-	0% 0%	-	-	
	Jun 2012 Jul 2012	-	-	0%	-	-	0%	-	-	
	Aug 2012	-		0%	-	-	0%	-		
	Sep 2012	-	-	0%	-	-	0%	-	-	
	Oct 2012	-	-	0%	-	-	0%	-	-	
	Nov 2012	-	-	0%	-	-	0%	1	-	
	Dec 2012	-	-	0%	-	-	0%	-	-	
	Jan 2013	-	-	0%	-	-	0%	-	-	
	Feb 2013	1	-	0%	-	-	0%	-	-	
	Mar 2013	-	-	0%	-	-	0%	-	-	
	Apr 2013	-	-	0%	-	-	0%	-	-	
	May 2013	-	-	0%	-	-	0%	-	-	
	Jun 2013	1	-	0%	2	1	50%	-	-	
	Jul 2013	-	-	0%	-	-	0%	-	-	
	Aug 2013	-	-	0%	-	-	0%	-	-	
	Sep 2013	1	1	100%	-	-	0%	-	-	
		- 1	1	100% 0% 0%	-	-	0% 0% 0%	-	-	



		1		Primary Tole	rance Definition	i (250 mg per u	ay in the prior 7 o	consecutive days	>)		1		
		D	ose 12 mcg/h	r	ſ	Dose 24 mcg/ł	ır	C	ose 25 mcg/h	r	Do	ose 36 mcg/l	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	17,812	5,093	28.6%	3	1		49,148	18,322		1		
Age (years)	0 - 11 years	34	1	2.9%	-		- 0%	25	2		0		
	12 - 17 years 18 - 24 years	81 412	6 104	7.4%	-		· 0%		16 345		0	0	
	25 - 34 years	1,605	582	36.3%			. 0%		1,931			0	
	35 - 44 years	3,153	1,065	33.8%	2	1			3,696		0	0	
	45 - 54 years	5,672	1,650	29.1%			- 0%	16,409	6,277	38.3%	0	0	
	55 - 64 years	6,855	1,685	24.6%	1		- 0%	18,492	6,055	32.7%	0	0	09
Gender	Male	5,595	1,675	29.9%	1			20,233	7,836	38.7%	0		
	Female	12,217	3,418	28.0%	2		· 0%		10,486		1	0	
	Ambiguous Unknown	- 0	- 0	0.0%	-		· 0%		- 0	0.0%	0		
Month and Year	Jan 2009	238	72	30.3%					365		0		
of Episode Start	Feb 2009	227	53	23.3%			0%		346		0	0	
Date	Mar 2009	284	76	26.8%			- 0%	1,072	369	34.4%	0	0	09
	Apr 2009	251	57	22.7%			- 0%		388		1	0	
	May 2009	283	73	25.8%			- 0%		386		0	0	
	Jun 2009	300	72	24.0%			· 0%		368	34.1%	0	0	
	Jul 2009	267 284	73	27.3% 26.1%	-		· 0%	966 946	335 307	34.7% 32.5%	0	0	
	Aug 2009 Sep 2009	284	74 89	26.1%			· 0%		307	32.5%		0	
	Oct 2009	278	78	28.1%			· 0%		328		0	0	
	Nov 2009	244	71	29.1%			- 0%		294			0	
	Dec 2009	261	74	28.4%	-		- 0%	970	363	37.4%	0	0	09
	Jan 2010	245	59	24.1%			- 0%	881	292	33.1%	0	0	09
	Feb 2010	254	84	33.1%			- 0%		282		0	0	
	Mar 2010	283	79	27.9%	-		- 0%		317	37.2%		0	
	Apr 2010	289	78	27.0%	-		· 0%		331		0	0	
	May 2010 Jun 2010	261 285	84 81	32.2% 28.4%			· 0%		342 341		0	0	
	Jul 2010	239	68	28.5%			. 0%		333	39.8%	0	0	
	Aug 2010	270	77	28.5%			0%		310			0	
	Sep 2010	320	96	30.0%			- 0%	908	348	38.3%	0	0	09
	Oct 2010	313	74	23.6%			- 0%	843	312		0	0	
	Nov 2010	306	91	29.7%	-		- 0%		334			0	
	Dec 2010	307	90	29.3%			· 0%		321		0	0	
	Jan 2011 Feb 2011	264 279	69 66	26.1% 23.7%			· 0%	774 674	284 246	36.7% 36.5%	0	0	
	Mar 2011	292	82	28.1%			. 0%		331		0	0	
	Apr 2011	307	97	31.6%			- 0%		324		0	0	
	May 2011	299	84	28.1%	-		- 0%	795	286	36.0%	0	0	09
	Jun 2011	316	85	26.9%	-		- 0%	777	311	40.0%	0	0	09
	Jul 2011	294	82	27.9%			- 0%		263		0	0	
	Aug 2011	328	112	34.1%			• 0%		290			0	
	Sep 2011 Oct 2011	307 279	90 87	29.3% 31.2%			· 0%	795 768	300 308	37.7% 40.1%	0	0	
	Nov 2011	306	100	32.7%			. 0%		293				
	Dec 2011	306	96	29.7%			. 0%		293			0	
	Jan 2012	323 298	96	29.7%	-		. 0%		283			0	
	Feb 2012	298	68	29.2%			· 0%		236			0	
	Mar 2012	307	88	28.7%			. 0%		230			0	
	Apr 2012	316	96	30.4%			- 0%		302			0	
	May 2012	389	107	27.5%			- 0%	786	313	39.8%	0	0	
	Jun 2012	293	82	28.0%	-		- 0%		263				
	Jul 2012	315	96	30.5%	-		- 0%		264			0	
	Aug 2012	324	116	35.8%			· 0%		328				
	Sep 2012 Oct 2012	290 330	76 100	26.2% 30.3%	-		· 0%		264 325			0	
	Nov 2012	330	100	25.6%			· 0%		325			0	
	Dec 2012	316	83	25.6%			. 0%		261			0	
	Jan 2013	296	93	31.4%	-		0%		242			0	
	Feb 2013	275	81	29.5%			- 0%	675	281	41.6%	0	0	
	Mar 2013	274	95	34.7%	-		- 0%		256		0		
	Apr 2013	327	112	34.3%	-		• 0%		284			0	
	May 2013 Jun 2013	293 306	85 83	29.0% 27.1%	-		· 0%		303 278			0	
	Jun 2013 Jul 2013	306 345	83	27.1%	1		· 0% · 0%		278 282			0	
	Aug 2013	358	108	30.2%			. 0%		314			0	
	Sep 2013	323	85	26.3%	-		· 0%		269			0	
	Oct 2013	366	107	29.2%	1	1	100%	784	307	39.2%		0	
	Nov 2013	344	96	27.9%	1		- 0%	702	272	38.7%	0	0	09
	Dec 2013	325	91	28.0%	0		- 0%	686	252	36.7%	0	0	



		Dos	e 37 mcg/ł	nr	Dos	e 50 mcg/h	ır	Dos	e 62 mcg/h	nr	Dos	e 75 mcg/h	r	Dos	e 87 mcg/l	ır
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	339	174	51%	21,245	10,088	47%	26	7	27%	6,215	3,197	51%	14	4	29%
Age (years)	0 - 11 years 12 - 17 years	1	-	0% 0%	8 37	3 11	38% 30%	1	-	0% 0%	3 14	- 4	0% 29%	-	-	0% 0%
	18 - 24 years	9	3	33%	423	182	43%	2	-	0%	14	61	50%	-	-	0%
	25 - 34 years	27	16	59%	1,911	1,051	55%	2	-	0%	614	355	58%	2	2	100%
	35 - 44 years 45 - 54 years	71 99	35 51	49% 52%	4,031 7,320	2,108 3,506	52% 48%	6 11	2	33% 27%	1,229 2,201	649 1,141	53% 52%	1	- 2	0% 33%
	45 - 54 years 55 - 64 years	130	69	52%	7,520	3,227	48%	4	2	50%	2,201	987	49%	5	-	0%
Gender	Male	145	77	53%	9,916	4,945	50%	13	6	46%	2,974	1,629	55%	6	2	33%
	Female	194	97	50%	11,329	5,143	45%	13	1	8%	3,241	1,568	48%	8	2	25%
	Ambiguous Unknown			0% 0%		-	0% 0%	-	-	0% 0%	-	-	0% 0%	-	-	0%
	Jan 2009	6	3	50%	490	217	44%	2	2	100%	189	79	42%	1	-	0%
Month and Year of		9	4	44%	484	231	48%	-	-	0%	152	73	48%	-	-	0%
Episode Start Date	Mar 2009 Apr 2009	5	3 1	60% 25%	492 532	236 265	48% 50%	-	-	0% 0%	140 147	67 80	48% 54%	-	-	0% 0%
	May 2009	6	5	83%	470	205	45%	-	-	0%	147	69	54% 47%	-	-	0%
	Jun 2009	8	6	75%	496	215	43%	-	-	0%	138	64	46%	1	-	0%
	Jul 2009	8	2	25%	440	196	45%	2	-	0%	112	53	47%	1	1	100%
	Aug 2009 Sep 2009	3	1	33% 60%	398 457	182 210	46% 46%	-	-	0% 0%	129 108	66 69	51% 64%	- 2	-	0%
	Oct 2009	1	1	100%	486	215	44%	1	-	0%	123	60	49%	-	-	0%
	Nov 2009	8	4	50%	402	185	46%	1	1	100%	108	56	52%	-	-	0%
	Dec 2009 Jan 2010	8	4	50% 0%	429 406	191 177	45% 44%	-	-	0% 0%	135 120	67 54	50% 45%	1	-	0% 0%
	Feb 2010	9	- 7	78%	362	177	44%	- 1	-	0%	120	54 46	45%	- 1	-	0%
	Mar 2010	8	3	38%	354	153	43%	-	-	0%	132	67	51%	-	-	0%
	Apr 2010	4	2	50%	368	166	45%	-	-	0%	122	66	54%	-	-	0%
	May 2010 Jun 2010	6	2	33% 43%	388 402	172 195	44% 49%	- 1	-	0% 0%	109 103	49 55	45% 53%	1	-	0% 0%
	Jul 2010	5	3	60%	371	195	53%	-	-	0%	98	45	46%	-	-	0%
	Aug 2010	3	2	67%	363	170	47%	-	-	0%	116	58	50%	-	-	0%
	Sep 2010 Oct 2010	2	2 3	100% 60%	373 383	176 193	47% 50%	1	1	100% 0%	105 115	62 60	59% 52%	-	-	0% 0%
	Nov 2010	8	4	50%	353	175	50%	-	-	0%	102	61	60%	1	-	0%
	Dec 2010	3	1	33%	404	178	44%	-	-	0%	90	50	56%	-	-	0%
	Jan 2011	1	1	100%	346	148	43%	1	1	100%	138	63	46%	-	-	0%
	Feb 2011 Mar 2011	3	2 5	67% 56%	305 371	166 192	54% 52%	-	-	0% 0%	109 103	64 65	59% 63%	-	-	0% 0%
	Apr 2011	10	9	90%	386	175	45%	-	-	0%	124	67	54%	-	-	0%
	May 2011	4	2	50%	346	158	46%	-	-	0%	98	53	54%	-	-	0%
	Jun 2011 Jul 2011	4	2	50% 50%	344 350	144 170	42% 49%	1	-	0% 0%	96 80	54 51	56% 64%	1	-	0% 0%
	Aug 2011	5	2	40%	342	157	46%	-	-	0%	94	41	44%	-	-	0%
	Sep 2011	6	3	50%	337	161	48%	-	-	0%	87	47	54%	-	-	0%
	Oct 2011	3	2	67%	306	143	47%	2	-	0%	86	51	59%	-	-	0%
	Nov 2011 Dec 2011	7	2	29% 80%	300 312	155 146	52% 47%	-	-	0% 0%	85	46	54%	-	-	0%
	Jan 2012	3	4	80%	312	146	47%	-		0%	88 108	42 54	48% 50%	-	-	0%
	Feb 2012	7	3	43%	300	161	54%	1		0%	86	51	59%	-	-	0%
	Mar 2012	7	4	57%	314	157	50%	-	-	0%	84	47	56%	-	-	0%
	Apr 2012 May 2012	7	3 5	43% 63%	359 363	184 189	51% 52%	1	-	0% 0%	118 98	56 52	47% 53%	1	1	100% 0%
	Jun 2012	8	2	50%	299	189	52% 47%	1		0%	98	45	53%	-	-	0%
	Jul 2012	5	2	40%	331	170	51%	-	-	0%	103	52	50%	-	-	0%
	Aug 2012	2	1	50%	297	147	49%	1	-	0%	102	59	58%	-	-	0%
	Sep 2012 Oct 2012	5	4	80% 33%	283 285	135 127	48% 45%	-		0% 0%	89 83	47 45	53% 54%	- 1	- 1	100% 0%
	Nov 2012	6	3	50%	336	157	47%	-	-	0%	105	48	46%	2	1	50%
	Dec 2012	9	3	33%	286	156	55%	-	-	0%	64	26	41%	-	-	0%
	Jan 2013 Feb 2013	5	3 2	60% 67%	302 246	146 131	48% 53%	2	1	50% 0%	103 64	43 35	42% 55%	-	-	0% 0%
	Mar 2013	4	3	75%	248	123	50%	-	-	0%	80	40	50%	-	-	0%
	Apr 2013	11	4	36%	280	137	49%	-		0%	93	43	46%	-	-	0%
	May 2013	9	5	56%	307	152	50%	1	1	100%	83	46	55%	-	-	0%
	Jun 2013 Jul 2013	5	3 5	60% 56%	288 272	135 134	47% 49%	-	-	0% 0%	89 88	49 48	55% 55%	-	-	0%
	Aug 2013	7	2	29%	300	134	49%	-	-	0%	75	48	39%	-	-	0%
	Sep 2013	5	3	60%	276	131	47%	1	-	0%	75	38	51%	-	-	0%
	Oct 2013	4	1	25% 14%	274 265	145 125	53% 47%	-	-	0% 0%	78 71	45 42	58% 59%	-	-	0%
	Nov 2013 Dec 2013	6	1	14% 67%		125	47%	- 1	-	0%	71 67	42	59%	-	-	0% 0%



			e 100 mcg/ł	hr		se 112 mcg/	'nr		se 125 mcg/	hr		se 137 mcg/	'hr		se 150 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
Age (years)	Total 0 - 11 years	4,524 6	2,410	53% 0%	- 5	- 4	80% 0%	179	- 88	49% 0%	2	- 1	50% 0%	233 0	119 0	519
.ge (Jeans)	12 - 17 years	9	2	22%	-	-	0%	1	-	0%	-	-	0%	2	0	
	18 - 24 years	91	43	47%	-	-	0%	2	2	100%	-	-	0%	5	4	80
	25 - 34 years 35 - 44 years	375 870	226 492	60% 57%	- 1	- 1	0% 100%	10 30	8 15	80% 50%	-	-	0% 0%	13 37	6 22	46' 59'
	45 - 54 years	1,644	892	54%	1	1	100%	72	33	46%	1	-	0%		45	55
	55 - 64 years	1,529	755	49%	3	2	67%	64	30	47%	1	1	100%	88	42	48
Gender	Male	2,316 2,208	1,323 1,087	57% 49%	2	2	100% 67%	83 96	43 45	52% 47%	- 2	- 1	0% 50%		70 49	56 45
	Female Ambiguous	- 2,208	-	49%	-	-	0%	-	-	47%	-	-	0%		49	
	Unknown			0%			0%			0%			0%	0	0	0
	Jan 2009	131	56	43%	1	1	100%	5	3	60%	-	-	0%		3	
Month and Year o Episode Start Date		132 101	69 48	52% 48%	-	-	0% 0%	5	1	20% 25%	-	-	0% 0%	3	2	
	Apr 2009	101	66	55%	-	-	0%	5	3	60%	-	-	0%	7	3	
	May 2009	122	57	47%	-	-	0%	4	3	75%	-	-	0%	8	5	63
	Jun 2009	107	64	60%	-	-	0%	4	3	75%	-	-	0%	9	6	
	Jul 2009 Aug 2009	114 98	57 49	50% 50%	-	-	0% 0%	1	1	100% 33%	-	-	0% 0%	3	1	
	Sep 2009	89	43	47%	-	-	0%	1	-	0%	-	-	0%	5	3	
	Oct 2009	108	58	54%	-	-	0%	2	-	0%	-	-	0%	6	2	
	Nov 2009	93	50	54%	-	-	0%	3	2	67%	-	-	0%	7	5	
	Dec 2009 Jan 2010	96 115	52 63	54% 55%	-	-	0% 0%	5 10	2	40% 20%	-	-	0% 0%	7	5	71' 43'
	Feb 2010	74	35	47%	-	-	0%	6	1	17%	-	-	0%	5	3	60
	Mar 2010	71	38	54%	-	-	0%	3	-	0%	-	-	0%		3	
	Apr 2010	98	64	65%	-	-	0%	3	1	33%	-	-	0%	6	5	
	May 2010 Jun 2010	75 71	44 47	59% 66%	-	-	0% 0%	2	1	50% 50%	-	-	0% 0%	5	3	
	Jul 2010	66	41	62%	-	-	0%	4	3	75%	-	-	0%	6	4	67
	Aug 2010	86	52	60%	1	-	0%	3	1	33%	-	-	0%	3	0	0
	Sep 2010 Oct 2010	84 75	47 53	56% 71%	-	-	0% 0%	1	- 6	0% 86%	- 1	- 1	0% 100%	3	0	0 80
	Nov 2010	70	37	53%	-	-	0%	2	2	100%			0%	3	2	
	Dec 2010	77	35	45%	-	-	0%	1	1	100%	-	-	0%	4	2	50
	Jan 2011 Feb 2011	115 77	59 45	51%	-	-	0%	3	1	33% 0%	-	-	0% 0%	5	2	
	Mar 2011	101	45 56	58% 55%	-	- 1	100% 0%	2	- 1	33%	-	-	0%	3	1	
	Apr 2011	70	31	44%	-	-	0%	5	2	40%	-	-	0%	7	4	57
	May 2011	69	38	55%	-	-	0%	5	1	20%	-	-	0%	4	1	25
	Jun 2011 Jul 2011	59 53	31 28	53% 53%	-	-	0% 0%	2	1	50% 0%	-	-	0% 0%	0	0	0' 100'
	Aug 2011	52	34	65%	-	-	0%	1	1	100%	-	-	0%	1	1	100
	Sep 2011	55	31	56%	-	-	0%	4	2	50%	1	-	0%	5	4	80'
	Oct 2011	68	37	54%	-	-	0%	2	2	100%	-	-	0%		0	
	Nov 2011 Dec 2011	62 73	29 41	47% 56%	-	-	0% 0%	1	1	100% 50%	-	-	0% 0%		1	50'
	Jan 2012	73 69	41 35	56%	-	-	0%	4	2	67%	-	-	0%		2	
	Feb 2012	60	37	62%	-	-	0%	2	1	50%	-	-	0%		4	67
	Mar 2012	61	35	57%	-	-	0%	3	3	100%	-	-	0%		1	
	Apr 2012	74	37	50%	1	1	100%	5	5	100%	-	-	0%		3	50'
	May 2012 Jun 2012	77 64	43 37	56% 58%	-	-	0% 0%	4	- 2	0% 100%	-	-	0% 0%		0	0 17
	Jul 2012	52	22	42%	-	-	0%	1	1	100%	-	-	0%		0	0
	Aug 2012	61	39	64%	-	-	0%	4	3	75%	-	-	0%		1	
	Sep 2012 Oct 2012	48 60	26 23	54% 38%	-	-	0% 0%	2	2	100% 50%	-	-	0% 0%	2	1	
	Nov 2012	77	39	51%	-	-	0%	4	2	100%	-	-	0%		2	
	Dec 2012	54	23	43%	-	-	0%	3	1	33%	-	-	0%	1	0	0
	Jan 2013	64	30	47%	-	-	0%	4	-	0%	-	-	0%		0	0
	Feb 2013 Mar 2013	52 40	27 21	52% 53%	1	1	100% 0%	3	1	33% 50%	-	-	0% 0%		0	C 33
	Apr 2013	40 59	30	51%	-	-	0%	-	-	0%	-	-	0%		2	40
	May 2013	54	30	56%	-	-	0%	1	1	100%	-	-	0%	3	1	33
	Jun 2013	55	28	51%	-	-	0%	-	-	0%	-	-	0%		1	
	Jul 2013 Aug 2013	60 39	25 17	42% 44%	-	-	0% 0%	2	2	100% 100%	-	-	0% 0%	3	2	
	Sep 2013	52	25	48%	-	-	0%	1	-	0%	-	-	0%		1	
	Oct 2013	56	35	63%	-	-	0%	3	1	33%	-	-	0%		1	
	Nov 2013 Dec 2013	57 52	30 32	53% 62%	-	-	0% 0%	1 1	- 1	100% 0%	-	-	0% 0%		2	



		1		1	-	≥30 mg per da		1			[
		Do	se 162 mcg/	hr	Do	se 175 mcg/	hr	Do	se 200 mcg/l	hr	Do	se 225 mcg/l	ar
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	2	1	50%	52	25	48%	5		60%	4		09
Age (years)	0 - 11 years	0	0 0	0% 0%	0	0	0% 100%	0	0	0%	0	0 0	09
	12 - 17 years 18 - 24 years	1	0	0%	3	1	100%	0		0% 0%	0	0	09
	25 - 34 years	0	0	0%	3	2	67%	0	0	0%	1	0	09
	35 - 44 years	0	0	0%	7	4	57%	3	2	67%	1	0	0%
	45 - 54 years	0	0	0%	17	7	41%	2		50%	0		0%
Candar	55 - 64 years	1	1	100%	21	8	38%	0		0%	2	0	0%
Gender	Male Female	2	1	50% 0%	17 35	11 14	65% 40%	5		60% 0%	2		0%
	Ambiguous	0	0	0%	0	0	0%	0		0%	0		0%
	Unknown	0	0	0%	0	0	0%	0	0	0%	0	0	09
	Jan 2009	0	0	0%	2	0	0%	0		0%	0		0%
Month and Year of	Feb 2009	0	0	0%	2	1	50%	0		0%	0	0	0%
Episode Start Date	Mar 2009	0	0	0%	2	2	100%	1	0	0%	1	0	0%
	Apr 2009 May 2009	0	0	0% 0%	4	4	100% 100%	1	1	100% 0%	0	0	0%
	Jun 2009	0	0	0%	1	0	0%	0	0	0%	0	0	09
	Jul 2009	0	0	0%	2	0	0%	0	0	0%	1	0	0%
	Aug 2009	0	0	0%	0	0	0%	0		0%	0	0	0%
	Sep 2009	0	0	0%	2	1	50%	0		0%	0	0	0%
	Oct 2009 Nov 2009	0	0	0% 0%	0	0	0% 100%	0	0	0% 0%	0	0	0%
	Dec 2009	0	0	0%	0	0	0%	0		0%	0	0	0%
	Jan 2010	0	0	0%	0	0	0%	0	0	0%	0	0	0%
	Feb 2010	0	0	0%	0	0	0%	0	0	0%	0	0	0%
	Mar 2010	0	0	0%	1	1	100%	1	1	100%	0	0	0%
	Apr 2010	0	0	0%	0	0	0%	0		0%	0	0	0%
	May 2010	0	0	0%	1	0	0%	0		0%	0	0	0%
	Jun 2010 Jul 2010	0	0 0	0% 0%	1	0	0% 0%	0		0% 0%	0		0%
	Aug 2010	0	0	0%	2	2	100%	0	0	0%	1	0	0%
	Sep 2010	0	0	0%	0	0	0%	0	0	0%	0		0%
	Oct 2010	0	0	0%	1	1	100%	0		0%	0		0%
	Nov 2010	0	0	0%	0	0	0%	0	0	0%	0	0	0%
	Dec 2010 Jan 2011	0	0	0%	1	1	100%	0	0	0%	0	0	0%
	Feb 2011	1	0	0% 0%	1	1	0% 50%	0		0% 0%	0	0	0%
	Mar 2011	0	0	0%	2	1	50%	0		0%	0	0	0%
	Apr 2011	0	0	0%	2	0	0%	0	0	0%	0	0	0%
	May 2011	0	0	0%	0	0	0%	0	0	0%	0	0	0%
	Jun 2011	0	0	0%	2	1	50%	0		0%	0	0	0%
	Jul 2011	0	0	0% 0%	0	0	0% 0%	0	0	0% 0%	0	0	0%
	Aug 2011 Sep 2011	1	1	100%	3	1	33%	0		0%	0		0%
	Oct 2011	0	0	0%	2	0	0%	0	0	0%	0	0	0%
	Nov 2011	0	0	0%	0	0	0%	0	0	0%	0	0	0%
	Dec 2011	0	0	0%	0	0	0%	0	0	0%	0	0	0%
	Jan 2012	0	0	0%	0	0	0%			0%	0	0	0%
	Feb 2012	0	0	0%	0	0	0%			0%	0	0	0%
	Mar 2012	0	0	0%	1	0	0%			0%	0		0%
	Apr 2012	0	0	0%	2	1	50%	0		0%	0		0%
	May 2012 Jun 2012	0	0	0% 0%	1	1	100% 0%	0		0% 0%	0		0% 0%
	Juli 2012	0	0	0%	0	0	0%			0%	0		09
	Aug 2012	0	0	0%	0	0	0%	0		0%	0		09
	Sep 2012	0	0	0%	0	0	0%			0%	0		09
	Oct 2012	0	0	0%	0	0	0%			0%	0		09
	Nov 2012	0	0	0%	1	0	0%			0%	1	0	09
	Dec 2012 Jan 2013	0	0	0% 0%	0	0	0% 0%	0		0% 0%	0	0	09
Fe M A Ju Ju	Feb 2013	0	0	0%	1	0	0%	0		0%	0		09
	Mar 2013	0	0	0%	1	1	100%	0		0%	0		09
	Apr 2013	0	0	0%	0	0	0%	0		0%	0		09
	May 2013	0	0	0%	1	1	100%	0		0%	0		05
	Jun 2013 Jul 2013	0	0	0% 0%	1	0	0%			50%	0		0
	Jul 2013 Aug 2013	0	0	0%	0	0	0% 0%			0% 0%	0	0	0'
	Aug 2013 Sep 2013	0	0	0%	1	1	100%	0		0%	0		0
	Oct 2013	0	0	0%	1	0	0%	0		0%	0		0
	Nov 2013	0	0	0%	0	0	0%	0	0	0%	0	0	0
	Dec 2013	0	0	0%	1	1	100%	0	0	0%	0	0	C



Age (years)		D	ose 12 mcg/h	r	ſ	ose 24 mcg/h		г			D	ose 36 mcg/l	hr	Dos	e 37 mcg/i	
Age (years)								-	ose 25 mcg/h		D	JSE 30 meg/i		203	c 37 mcg/1	ır
Age (years)		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
Age (years)	Total	17,812	8,518	47.8%	3	2		49,148	28,665	58.3%	1	0		339	233	
	0 - 11 years 12 - 17 years	34 81	2	5.9% 22.2%	-	0		25 85	4 25	16.0% 29.4%	0	0	0% 0%	1	0	
	18 - 24 years	412	164	39.8%		0		925	494	53.4%	0	0	0%	9	6	
	25 - 34 years	1,605	898	56.0%	-	0		4,297	2,845	66.2%	1	0	0%	27	22	
	35 - 44 years 45 - 54 years	3,153 5,672	1,661 2,741	52.7% 48.3%	2	1		8,915 16,409	5,544 9,658	62.2% 58.9%	0	0		71 99	45 72	
	55 - 64 years	6,855	3,034	40.3%	1	1		18,492	10,095	54.6%	0	0		130	88	
Gender	Male	5,595	2,786	49.8%	1	1		20,233	12,138	60.0%		0		145	104	
	Female Ambiguous	12,217	5,732	46.9% 0.0%	2	1		28,915	16,527	57.2%	1	0	0% 0%	194 0	129 0	
	Unknown	0	0		0	0			0	0.0%		0		0	0	
	Jan 2009	238	115	48.3%		0	0%	1,070	609	56.9%	0	0		6	6	
	Feb 2009	227	107	47.1%	-	0		992	576	58.1%	0	0			5	
Month and Year of Episode Start Date	Mar 2009 Apr 2009	284 251	128 108	45.1% 43.0%		0		1,072 1,147	596 618	55.6% 53.9%	0	0	0% 0%	5	5	
	May 2009	283	136	48.1%		0		1,039	603	58.0%	0	0	0%	6	5	
	Jun 2009	300	120	40.0%	-	0		1,080	624	57.8%	0	0	0%	8	6	
	Jul 2009 Aug 2009	267 284	124 135	46.4% 47.5%	-	0		966 946	539 503	55.8% 53.2%	0	0	0% 0%	8	5	
	Sep 2009	318	135	46.9%	-	0		1,007	585	58.1%	0	0	0%	5	5	
	Oct 2009	278	136	48.9%	-	0		948	549	57.9%	0	0	0%	1	1	
	Nov 2009 Dec 2009	244 261	112 125	45.9% 47.9%	-	0		898 970	471 562	52.4% 57.9%	0	0	0% 0%	8	5	
	Jan 2010	201	125	47.5%		0		881	487	55.3%	0	0	0%	6	0	
	Feb 2010	254	125	49.2%		0	0%	790	458	58.0%	0	0	0%	9	7	78
	Mar 2010	283	123	43.5%		0		853	479	56.2%	0	0	0%	8	6	
	Apr 2010 May 2010	289 261	139 141	48.1% 54.0%		0		958 845	549 528	57.3% 62.5%	0	0	0% 0%	4	2	
	Jun 2010	285	136	47.7%		0		884	511	57.8%	0	0	0%	7	4	
	Jul 2010	239	110	46.0%	-	0		837	507	60.6%	0	0	0%	5	4	
	Aug 2010 Sep 2010	270 320	124 162	45.9% 50.6%	-	0		871 908	502 557	57.6% 61.3%	0	0	0% 0%	3	2	
	Oct 2010	313	130	41.5%		0		843	483	57.3%	0	0	0%	5	5	
	Nov 2010	306	154	50.3%	-	0		889	538	60.5%	0	0	0%	8	6	
	Dec 2010 Jan 2011	307 264	147 122	47.9% 46.2%	-	0		796 774	474 447	59.5% 57.8%	0	0	0% 0%	3	2	
	Feb 2011	204	122	40.2%		0		674	398	59.1%	0	0	0%	3	3	
	Mar 2011	292	132	45.2%	-	0	0%	845	516	61.1%	0	0	0%	9	6	
	Apr 2011	307	156	50.8%	-	0		812	473	58.3%	0	0	0%	10	9	
	May 2011 Jun 2011	299 316	140 154	46.8% 48.7%		0		795 777	438 458	55.1% 58.9%	0	0	0% 0%	4	3	
	Jul 2011	294	136	46.3%		0	0%	728	419	57.6%	0	0	0%	4	2	
	Aug 2011	328	176	53.7%	-	0		820	450	54.9%	0	0	0%	5	3	
	Sep 2011 Oct 2011	307 279	149 145	48.5% 52.0%		0		795 768	480 469	60.4% 61.1%	0	0	0% 0%	6	5	
	Nov 2011	306	147	48.0%		0		718	437	60.9%	0	0			4	
	Dec 2011	323	159	49.2%		0	0%	747	436	58.4%		0	0%		5	
	Jan 2012	298	136	45.6%		0	0%	776	464	59.8%	0	0	0%	3	2	67
	Feb 2012	269	127	47.2%	-	0		696	384	55.2%	0	0	0%	7	5	
	Mar 2012 Apr 2012	307 316	146 152	47.6% 48.1%	-	0		738 803	441 465	59.8% 57.9%	0	0	0% 0%	7	5	
	May 2012	389	174	44.7%	-	0		786	476	60.6%		0	0%	8	6	
	Jun 2012	293	140		-	0		683	404	59.2%		0			3	
	Jul 2012 Aug 2012	315 324	168 172	53.3% 53.1%	-	0		672 857	394 508	58.6% 59.3%	0	0	0% 0%	5	4	
	Sep 2012	290	1/2	49.7%	-	0		705	424	60.1%		0	0%	5	5	
	Oct 2012	330	161	48.8%	-	0		754	468	62.1%	0	0	0%	3	1	33
	Nov 2012 Dec 2012	332 316	160 156	48.2% 49.4%	-	0		775	435 394	56.1% 59.2%		0	0% 0%	6	3	
	Jan 2013	316	156	49.4%	-	0		650	394	59.2%		0	0%	5	3	
	Feb 2013	275	136	49.5%	-	0	0%	675	419	62.1%		0	0%	3	3	100
	Mar 2013	274	142	51.8%	-	0		632	382	60.4%	0	0	0%	4	4	
	Apr 2013 May 2013	327 293	179 131	54.7% 44.7%	-	0		724 754	440 448	60.8% 59.4%	0	0	0% 0%	11 9	7	
	Jun 2013	306	140	45.8%	1	0		701	428	61.1%		0	0%	5	4	
	Jul 2013	345	170		-	0		719	434	60.4%		0	0%	9	7	
	Aug 2013 Sep 2013	358 323	169 152	47.2% 47.1%		0		780 687	460 402	59.0% 58.5%	0	0	0% 0%	7	4	
	Sep 2013 Oct 2013	323	152	47.1%	- 1	1		784	402	58.5%	0	0	0%	5	3	
	Nov 2013	344	162	47.1%	1	1		702	418	59.5%	0	0		7	2	



		Dos	e 50 mcg/ł	nr	Dos	ie 62 mcg/ł	nr	Do	se 75 mcg/ł	ır	Do	se 87 mcg/h	r	Dos	se 100 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	21,245	14,126	66%	26	8		6,215	4,211	68%	14	7	50%	4,524	3,032	67
Age (years)	0 - 11 years	8 37	3	38%	1	0		3	-	0% 29%	0	0	0%	6 9	1	17
	12 - 17 years 18 - 24 years	423	17 254	46% 60%	0	0		14 121	4 76	29% 63%	0	0	0% 0%	9 91	52	33 57
	25 - 34 years	1,911	1,387	73%	2	0		614	443	72%	2	2	100%	375	284	76
	35 - 44 years	4,031	2,875	71%	6	2	33%	1,229	857	70%	1	0	0%	870	607	70
	45 - 54 years	7,320	4,882	67%	11	4	36%	2,201	1,507	68%	6		67%	1,644	1,121	6
	55 - 64 years	7,515	4,708	63%	4	2		2,033	1,324	65%	5	1	20%	1,529	964	6
ender	Male Female	9,916 11,329	6,779 7,347	68% 65%	13 13	7		2,974 3,241	2,091 2,120	70% 65%	6	4	67% 38%	2,316 2,208	1,621 1,411	7
	Ambiguous	-	-	0%	0	0		-	-	0%	0	0	0%	-	-	
	Unknown	-	-	0%	0	0	0%			0%	0	0	0%			
	Jan 2009	490	318	65%	2	2		189	112	59%	1	0	0%	131	79	6
	Feb 2009	484	338	70%	0	0		152	99	65%	0	0	0%	132	92	7
Nonth and Year of pisode Start Date	Mar 2009	492	332 355	67%	0	0		140 147	85 104	61% 71%	0	0	0% 0%	101 120	60 85	5
pisoue start Date	Apr 2009 May 2009	532 470	355 290	67% 62%	0	0		147 146	104	71% 62%	0	0	0%	120	85 76	6
	Jun 2009	470	317	64%	0	0		146	91	67%	1	0	0%	122	76	6
	Jul 2009	440	280	64%	2	0		112	75	67%	1	1	100%	107	70	e
	Aug 2009	398	259	65%	0	0	0%	129	89	69%	0	0	0%	98	61	e
	Sep 2009	457	302	66%	0	0		108	82	76%	2	1	50%	89	55	6
	Oct 2009	486	297	61%	1	0		123	83	67%	0	0	0%	108	73	e
	Nov 2009	402	257	64%	1	1		108	79	73%	0	0	0%	93	60 67	6
	Dec 2009 Jan 2010	429 406	278 255	65% 63%	0	0		135 120	90 72	67% 60%	1	0	0% 0%	96 115	67 76	:
	Feb 2010	362	235	62%	1	0		120	61	61%	1	1	100%	74	46	é
	Mar 2010	354	229	65%	0	0		132	87	66%	0	0	0%	71	44	6
	Apr 2010	368	244	66%	0	0		122	91	75%	0	0	0%	98	74	7
	May 2010	388	250	64%	0	0	0%	109	66	61%	1	0	0%	75	54	7
	Jun 2010	402	267	66%	1	0		103	77	75%	0	0	0%	71	53	7
	Jul 2010	371	255	69%	0			98	64	65%	0	0	0%	66	51	7
	Aug 2010	363	239	66%	0	0		116	76	66%	0	0	0%	86	62	7
	Sep 2010 Oct 2010	373 383	249 268	67% 70%	1	1		105 115	78 78	74% 68%	0	0	0% 0%	84 75	59 61	7
	Nov 2010	353	200	69%	0	0		102	79	77%	1	0	0%	70	50	7
	Dec 2010	404	256	63%	0	0		90	67	74%	0	0	0%	77	42	5
	Jan 2011	346	220	64%	1	1	100%	138	88	64%	0	0	0%	115	77	e
	Feb 2011	305	213	70%	0	0	0%	109	78	72%	0	0	0%	77	53	e
	Mar 2011	371	252	68%	0	0		103	79	77%	0	0	0%	101	70	e
	Apr 2011	386	245	63%	0	0		124	83	67%	0	0	0%	70	44	e
	May 2011 Jun 2011	346 344	215 224	62%	0	0		98 96	65 69	66% 72%	0	0	0% 100%	69 59	44 38	e
	Juli 2011	344	224	65% 65%	0	0		96 80	63	72%	1	0	100%	59	38	7
	Aug 2011	342	228	67%	0	0		94	59	63%	0	0	0%	52	44	8
	Sep 2011	337	237	70%	0	0		87	63	72%	0	0	0%	55	36	e
	Oct 2011	306	202	66%	2	0	0%	86	63	73%	0	0	0%	68	45	e
	Nov 2011	300	210	70%	0	0	0%	85	60	71%	0	0	0%	62	41	e
	Dec 2011	312	210	67%	0	0	0%	88	56	64%	0	0	0%	73	51	7
	Jan 2012	310	219	71%	0	0	0%	108	74	69%	0	0	0%	69	43	e
	Feb 2012	300	218	73%	1	0	0%	86	60	70%	0	0	0%	60	48	٤
	Mar 2012	314	222	71%	0	0	0%	84	62	74%	0	0	0%	61	48	7
	Apr 2012	359	251	70%	1	0	0%	118	79	67%	1	1	100%	74	48	(
	May 2012 Jun 2012	363 299	241 203	66% 68%	1	0	0% 0%	98 82	66 58	67% 71%	0	0	0% 0%	77 64	51 47	6
	Juli 2012 Juli 2012	331	203	68%	0	0	0%	103	68	66%	0	0	0%	52	30	
	Aug 2012	297	202	68%	1	1	100%	103	70	69%	0	0	0%	61	44	
	Sep 2012	283	195	69%	1	0		89	58	65%	1	1	100%	48	38	:
	Oct 2012	285	179	63%	0	0	0%	83	57	69%	0	0	0%	60	35	!
	Nov 2012	336	211	63%	0	0	0%	105	63	60%	2	1	50%	77	48	
	Dec 2012	286	200	70%	0	0	0%	64	37	58%	0	0	0%	54	33	
	Jan 2013 Feb 2013	302 246	198 185	66% 75%	2	1	50% 0%	103 64	62 46	60% 72%	0	0	0% 0%	64 52	37 39	
	Mar 2013	248	165	65%	2	0	0%	80	40 50	63%	0	0	0%	40	39	
	Apr 2013	248	101	70%	0	0		93	63	68%	0	0	0%	40 59	30	
	May 2013	307	203	66%	1	1	100%	83	60	72%	0	0	0%	54	33	
	Jun 2013	288	199	69%	0	0	0%	89	60	67%	0	0	0%	55	36	6
	Jul 2013	272	192	71%	0	0		88	66	75%	0	0	0%	60	36	6
	Aug 2013	300	204	68%	0	0	0%	75	44	59%	0	0	0%	39	21	5
	Sep 2013	276	190	69%	1	0	0%	75	50	67%	0	0	0%	52	32	e
	Oct 2013	274	193	70%	0	0		78	52	67%	0	0	0%	56	38	e
	Nov 2013 Dec 2013	265 276	166 182	63% 66%	0	0		71 67	52 50	73% 75%	0		0% 0%	57 52	37 38	



		Do	se 112 mcg	;/hr	Do	se 125 mcg/	hr	Do	se 137 mcg,	/hr	Do	se 150 mcg/	hr	Do	se 162 mcg/	'hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
• • • • • • • • •	Total	5	4		179	108	60%	2	1		233	143	61%	2	2	1009
Age (years)	0 - 11 years 12 - 17 years	0	C		- 1	-	0% 0%	-	-	0% 0%	- 2	-	0% 0%	-	-	09
	18 - 24 years	0	c		2	2	100%	-	-	0%	5	4	80%	1	1	1009
	25 - 34 years	0	C		10	8	80%	-	-	0%	13	9	69%	-	-	09
	35 - 44 years 45 - 54 years	1	1		30 72	22 38	73% 53%	- 1	-	0% 0%	37 88	26 54	70% 61%	-	-	0%
	43 - 54 years 55 - 64 years	3	2		64	38	59%	1	1		88	50	57%	1	1	100%
Gender	Male	2	2		83	50	60%	-	-	0%	125	85	68%	2	2	100%
	Female	3	2		96	58	60%	2	1		108	58	54%	-	-	0%
	Ambiguous Unknown	0	C		-		0% 0%	-	-	0%		-	0% 0%	-	-	0%
	Jan 2009	1	1		5	3	60%	-	-	0%	7	3	43%	-	-	0%
	Feb 2009	0	C	0 %	5	2	40%	-	-	0%	3	3	100%	-	-	0%
Month and Year of	Mar 2009	0	C		4	2	50%	-	-	0%	2	1	50%	-	-	0%
Episode Start Date	Apr 2009 May 2009	0	C		5	3	60% 75%	-	-	0% 0%	7	4	57% 63%	-	-	0%
	Jun 2009	0	0		4	3	75%	-	-	0%	8	5	63% 78%	-	-	0%
	Jul 2009	0	0		1	1	100%	-	-	0%	3	1	33%	-	-	09
	Aug 2009	0	C		3	2	67%	-	-	0%	5	1	20%	-	-	0%
	Sep 2009	0	C		1	-	0%	-	-	0%	5	4	80%	-	-	0%
	Oct 2009 Nov 2009	0	C		2	1	50% 67%	-	-	0% 0%	6 7	2	33% 71%	-	-	0%
	Dec 2009	0	C		5	4	80%	-	-	0%	7	5	71%	-	-	0%
	Jan 2010	0	C	0%	10	3	30%	-	-	0%	7	3	43%	-	-	0%
	Feb 2010	0	C		6	2	33%	-	-	0%	5	4	80%	-	-	0%
	Mar 2010	0	C		3	-	0%	-	-	0% 0%	5	4	80%	-	-	0%
	Apr 2010 May 2010	0	c		3	1	33% 50%	-	-	0%	6 5	5	83% 80%	-	-	0%
	Jun 2010	0	C		6	5	83%	-	-	0%	5	3	60%	-	-	09
	Jul 2010	0	C	0 %	4	3	75%	-	-	0%	6	4	67%	-	-	0%
	Aug 2010	1	C		3	1	33%	-	-	0%	3	1	33%	-	-	0%
	Sep 2010 Oct 2010	0	C		1 7	- 6	0% 86%	- 1	- 1	0% 100%	3	1	33% 100%	-	-	0%
	Nov 2010	0	C		2	2	100%	-	-	0%	3	2	67%	-	-	09
	Dec 2010	0	C	0%	1	1	100%	-	-	0%	4	2	50%	-	-	0%
	Jan 2011	0	C		3	1	33%	-	-	0%	5	3	60%	1	1	100%
	Feb 2011 Mar 2011	1	1		2	1	50% 67%	-	-	0% 0%	3	1	33% 25%	-	-	0%
	Apr 2011	0	C		5	3	60%	-	-	0%	4	5	71%	-	-	09
	May 2011	0	C	0%	5	3	60%	-	-	0%	4	2	50%	-	-	0%
	Jun 2011	0	C		2	1	50%	-	-	0%	-	-	0%	-	-	0%
	Jul 2011	0	0		2	-	0%	-	-	0%	4	4	100%	-	-	0%
	Aug 2011 Sep 2011	0	C		1 4	1	100% 50%	- 1	-	0% 0%	5	1	100% 80%	- 1	- 1	0% 100%
	Oct 2011	0	C		2	2	100%	-	-	0%	1	-	0%		-	0%
	Nov 2011	0	C	0%	1	1	100%	-	-	0%	2	1	50%	-	-	0%
	Dec 2011	0	C	0%	4	2	50%	-	-	0%	2	2	100%	-	-	09
	Jan 2012	0	C		3	2	67%	-	-	0%	3	2	67%	-	-	0%
	Feb 2012 Mar 2012	0	C		2	2	100% 100%	-	-	0% 0%	6 2	4	67% 100%	-	-	0%
	Mar 2012 Apr 2012	0	1		3	3	100%	-	-	0%	2	2 5	100%	-	-	0%
	May 2012	0	C			1	25%	-	-	0%	-	-	0%	-	-	09
	Jun 2012	0	C		2	2	100%	-	-	0%	6	1	17%	-	-	0%
	Jul 2012	0	C		1	1	100%	-	-	0%	-	-	0%	-	-	0%
	Aug 2012 Sep 2012	0	C		4	4	100% 100%	-	-	0% 0%	1	1	100% 50%	-	-	0%
	Oct 2012	0	c		4	3	75%	-	-	0%	2	2	100%	-	-	09
	Nov 2012	0	C			2	100%	-	-	0%	5	3	60%	-	-	09
	Dec 2012	0	C		3	1	33%	-	-	0%	1		0%	-	-	0%
	Jan 2013 Feb 2013	0	0		4	- 2	0% 67%	-	-	0% 0%	4	1	25% 0%	-	-	09
	Mar 2013	0	1		2	1	50%	-	-	0%	- 3	- 1	33%	-	-	09
	Apr 2013	0	C		-	-	0%	-	-	0%	5	3	60%	-	-	09
	May 2013	0	C			1	100%	-	-	0%	3	2	67%	-	-	09
	Jun 2013	0	C			-	0%	-	-	0%	5	2	40%	-	-	09
	Jul 2013 Aug 2013	0	C		2	2	100% 100%	-	-	0% 0%	3	3 1	100% 50%	-	-	09
	Sep 2013	0	c			-	0%	-	-	0%	3	1	33%	-	-	0%
	Oct 2013	0	C	0%	3	1	33%	-	-	0%	1	1	100%	-	-	0%
	Nov 2013	0	C	0%	1	1	100%	-	-	0%	3	2	67%	-	-	09



		Dos	se 175 mcg/	'nr	Do	se 200 mcg/	hr	Do	se 225 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerand
	Total	52	30	58%		3	60%	4	1	2
Age (years)	0 - 11 years	-	-	0%		-	0%	-	-	
	12 - 17 years 18 - 24 years	1	1	100% 100%		-	0% 0%	-	-	
	25 - 34 years	3	2	67%		-	0%	1	1	10
	35 - 44 years	7	4	57%		2	67%	1	-	
	45 - 54 years	17	10	59%		1	50%	-	-	
	55 - 64 years	21	10	48%	-	-	0%	2	-	
Gender	Male	17	12	71%		3	60%	2	1	5
	Female	35	18	51%		-	0%	2	-	
	Ambiguous	-	-	0%		-	0%	-	-	
	Unknown Jan 2009	2	- 1	0%			0%	-		
	Feb 2009	2	1	50%		-	0%			
Aonth and Year of	Mar 2009	2	2	100%		-	0%	1	-	
pisode Start Date	Apr 2009	4	4	100%		1	100%	-	-	
	May 2009	1	1	100%	-	-	0%	-	-	
	Jun 2009	1	-	0%		-	0%	-	-	
	Jul 2009	2	2	100%		-	0%	1	1	1
	Aug 2009	-	-	0%		-	0%	-	-	
	Sep 2009	2	2	100%		-	0%	-	-	
	Oct 2009	-	-	0%		-	0%	-	-	
	Nov 2009 Dec 2009	1	1	100%		-	0%	-	-	
	Jan 2010	-	-	0% 0%		-	0% 0%	-	-	
	Feb 2010			0%		-	0%			
	Mar 2010	1	1	100%		1	100%	_	-	
	Apr 2010			0%		-	0%			
	May 2010	1	-	0%		-	0%	-	-	
	Jun 2010	1	-	0%	-	-	0%	-	-	
	Jul 2010	-	-	0%	-	-	0%	-	-	
	Aug 2010	2	2	100%	-	-	0%	1		
	Sep 2010	-	-	0%		-	0%	-	-	
	Oct 2010	1	1	100%		-	0%	-	-	
	Nov 2010	-	-	0%		-	0%	-	-	
	Dec 2010 Jan 2011	1	1	100%		-	0%	-	-	
	Feb 2011	2	- 1	0% 50%		-	0%	-	-	
	Mar 2011	2	1	50%		-	0% 0%	-	-	
	Apr 2011	2		0%		-	0%	-	-	
	May 2011	-	-	0%		-	0%	-	-	
	Jun 2011	2	1	50%		-	0%	-	-	
	Jul 2011	-	-	0%	-	-	0%	-	-	
	Aug 2011	1	-	0%	-	-	0%	-	-	
	Sep 2011	3	2	67%	-	-	0%			
	Oct 2011	2	-	0%	-	-	0%	-	-	
	Nov 2011	-	-	0%	-	-	0%	-	-	
	Dec 2011	-	-	0%	-	-	0%	-	-	
	Jan 2012	-	-	0%	-	-	0%	-	-	
	Feb 2012	-	-	0%	-	-	0%	-	-	
	Mar 2012	1	-	0%		-	0%	-	-	
	Apr 2012	2	1	50%		-	0%	-	-	
	May 2012	1	1	100%		-	0%	-	-	
	Jun 2012	1	-	0%		-	0%	-	-	
	Jul 2012	-	-	0% 0%		-	0%	-	-	
	Aug 2012 Sep 2012	-	-	0%		-	0% 0%	-	-	
	Oct 2012	-	-	0%		-	0%	-	-	
	Nov 2012	1	-	0%		-	0%	1	-	
	Dec 2012	-	-	0%		-	0%		-	
	Jan 2013	-	-	0%		-	0%	-	-	
	Feb 2013	1	-	0%	-	-	0%	-	-	
	Mar 2013	1	1	100%	-	-	0%	-	-	
	Apr 2013	-	-	0%	-	-	0%	-	-	
	May 2013	1	1	100%		-	0%	-	-	
	Jun 2013	1	-	0%		1	50%	-	-	
	Jul 2013	-	-	0%		-	0%	-	-	
	Aug 2013	-	-	0%		-	0%	-	-	
	Sep 2013	1	1	100%		-	0%	-	-	
	Oct 2013	1	-	0%		-	0%	-	-	
	Nov 2013 Dec 2013	- 1	- 1	0% 100%		-	0% 0%	-	-	



					rereary	Tolerance Denni	intion (Formg per	ady in the prior	7 consecutive d	-1-/				1		
		0	ose 12 mcg/h	r	ſ	Dose 24 mcg/h	ır	0	ose 25 mcg/hr	r	Do	ose 36 mcg/	hr	Dos	e 37 mcg/	hr
	-	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	17,812	8,739	49.1%	3	2		49,148	26,155	53.2%	1	C		339	200	
Age (years)	0 - 11 years 12 - 17 years	34 81	7 25	20.6% 30.9%	-	0		25 85	6 31	24.0% 36.5%	0	C		1	0	
	12 - 17 years 18 - 24 years	412	181	43.9%		0		925	470	50.3%	0			9	4	
	25 - 34 years	1,605	945	58.9%		0	0%	4,297	2,619	60.9%	1	C	0%	27	18	
	35 - 44 years	3,153	1,732	54.9%	2	2		8,915	5,098	57.2%	0	C		71	39	
	45 - 54 years 55 - 64 years	5,672 6,855	2,807 3,042	49.5% 44.4%	- 1	0		16,409 18,492	8,870 9,061	54.1% 49.0%	0	0		99 130	60 79	
Gender	Male	5,595	2,805	50.1%	1	1	100%	20,233	10,836	53.6%	0	C) 0%	145	91	
	Female	12,217	5,934	48.6%	2	1		28,915	15,319	53.0%	1	C			109	
	Ambiguous Unknown	- 0	- 0	0.0%	- 0	0		-	- 0	0.0%	0	((0	0	
	Jan 2009	238	124	52.1%		0	0%	1,070	536	50.1%	0	C		6	3	
Month and Year of		227	102	44.9%	-	0		992	484	48.8%	0	C		9	4	
Episode Start Date	Mar 2009 Apr 2009	284 251	126 117	44.4% 46.6%		0		1,072 1,147	545 589	50.8% 51.4%	0	0		5	3	
	Apr 2009 May 2009	251 283	117	46.6%		0		1,147	566	51.4%	0			4	5	
	Jun 2009	300	130	43.3%	-	0		1,080	525	48.6%	0	C		8	7	88
	Jul 2009	267	133	49.8%	-	0		966	497	51.4%	0	0			4	
	Aug 2009 Sep 2009	284 318	128 153	45.1% 48.1%	-	0		946 1,007	458 516	48.4% 51.2%	0	((3	2	
	Oct 2009	278	125	45.0%	-	0		948	473	49.9%	0	0		1	1	
	Nov 2009	244	113	46.3%	-	0		898	444	49.4%	0	C		8	4	
	Dec 2009	261	120	46.0%	-	0		970	533	54.9%	0	C		8	4	
	Jan 2010 Feb 2010	245 254	114 135	46.5% 53.1%		0		881 790	444 414	50.4% 52.4%	0			9	9	
	Mar 2010	283	137	48.4%		0	0%	853	448	52.5%	0	C	0%	8	5	
	Apr 2010	289	130	45.0%	-	0		958	486	50.7%	0	C		4	2	
	May 2010 Jun 2010	261 285	137 139	52.5% 48.8%		0		845 884	463 470	54.8% 53.2%	0	((6	2	
	Jul 2010	239	115	48.1%		0		837	462	55.2%	0	0		5	3	
	Aug 2010	270	135	50.0%	-	0		871	457	52.5%	0	C		3	2	
	Sep 2010 Oct 2010	320 313	144 145	45.0% 46.3%	-	0		908 843	502 438	55.3% 52.0%	0	0		2	2	
	Nov 2010	306	143	40.3%		0		889	456	51.2%	0			8	5	
	Dec 2010	307	142	46.3%	-	0	0%	796	435	54.6%	0	C	0%	3	1	. 33
	Jan 2011	264 279	120 130	45.5%	-	0		774	397 344	51.3%	0	C		1	1	
	Feb 2011 Mar 2011	279	130	46.6% 52.7%		0		845	459	51.0% 54.3%	0	(3	2	
	Apr 2011	307	156	50.8%	-	0		812	439	54.1%	0	C		10	9	
	May 2011	299	135	45.2%	-	0		795	419	52.7%	0	C		4	3	
	Jun 2011 Jul 2011	316 294	145 148	45.9% 50.3%		0		777 728	433 375	55.7% 51.5%	0	0		4	2	
	Aug 2011	328	140	52.1%		0		820	418	51.0%	0	0		5	2	
	Sep 2011	307	144	46.9%		0		795	419	52.7%	0	C	0%	6	4	
	Oct 2011	279	143	51.3%	-	0		768	435	56.6%	0	C		3	2	
	Nov 2011	306	155	50.7%	-	0		718	409	57.0%	0	C			2	
	Dec 2011 Jan 2012	323 298	151 134	46.7% 45.0%	-	0		747	388 423	51.9% 54.5%	0	c			4	
	Feb 2012	269	134	48.7%	-	0		696	373	53.6%	0	0		7	5	
	Mar 2012	307	152	49.5%	-	0		738	383	51.9%	0	C			5	
	Apr 2012 May 2012	316 389	155 190	49.1% 48.8%	-	0		803 786	436 432	54.3% 55.0%	0	C		7	3	
	Jun 2012	293	190	48.8%	-	0		683	432 374	55.0%	0			8	2	
	Jul 2012	315	158	50.2%	-	0		672	373	55.5%	0	C	0%		2	40
	Aug 2012	324	176	54.3%	-	-		857	469	54.7%	0	0			1	
	Sep 2012 Oct 2012	290 330	135 173	46.6% 52.4%	-	0		705 754	370 453	52.5% 60.1%	0	0		5	4	
	Nov 2012	332	175	51.2%	-	0		775	397	51.2%		C			4	
	Dec 2012	316	154	48.7%	-	0		666	363	54.5%	0	C		9	3	
	Jan 2013 Feb 2013	296 275	151 139	51.0% 50.5%	-	0		650 675	354 394	54.5% 58.4%	0	0		5	3	
	Mar 2013	273	139	54.0%		0		632	354	58.2%	0	0		4	3	
	Apr 2013	327	180	55.0%	-	0		724	410	56.6%	0	C			5	
	May 2013	293	148	50.5%	-	0		754	436	57.8%	0	0		9	6 3	
	Jun 2013 Jul 2013	306 345	168 168	54.9% 48.7%	1	1		701 719	390 412	55.6% 57.3%	0	C		5	3	
	Aug 2013	358	100	47.8%	-	0		780	428	54.9%	0	C			2	
	Sep 2013	323	161	49.8%	-	0		687	373	54.3%	0	C		5	4	
	Oct 2013 Nov 2013	366 344	186 188	50.8% 54.7%	1	1		784	426 381	54.3% 54.3%	0	0			1	
	Dec 2013	344	188	54.7%				686	362	54.3%					4	



		Dos	se 50 mcg/H	ır	Dos	e 62 mcg/	hr	Do	se 75 mcg/ł	nr	Do	se 87 mcg/l	hr	Dos	se 100 mcg/	'hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	21,245	12,517	59%	26	7	27%	6,215	3,644	59%	14	4	29%	4,524	2,600	57
Age (years)	0 - 11 years	8	3	38%	1	0		3	-	0%	0	0	0%		-	0
	12 - 17 years	37 423	13 229	35% 54%	0	0		14 121	4 64	29% 53%	0	0	0% 0%		3 46	33
	18 - 24 years 25 - 34 years	425	1,240	54% 65%	2	0		614	392	53% 64%	2	2			239	51 64
	35 - 44 years	4,031	2,563	64%	6	2		1,229	728	59%	1	0			520	60
	45 - 54 years	7,320	4,328	59%	11	3		2,201	1,312	60%	6	2			956	58
	55 - 64 years	7,515	4,141	55%	4	2	50%	2,033	1,144	56%	5	0	0%	1,529	836	55
Gender	Male	9,916	6,031	61%	13	6	46%	2,974	1,824	61%	6	2	33%	2,316	1,413	61
	Female	11,329	6,486	57%	13	1		3,241	1,820	56%	8	2			1,187	54
	Ambiguous	-	-	0%	0	0		-	-	0%	0	0			-	0
	Unknown Jan 2009	- 490	- 264	0% 54%	2	2		- 189	- 97	0% 51%	0	0			- 62	47
Month and Year of	Feb 2009	490	288	54% 60%	2	2		189	79	52%	0	0		131	76	47
Episode Start Date	Mar 2009	492	298	61%	0	0		132	81	58%	0	0	0%		52	51
	Apr 2009	532	323	61%	0	0		147	89	61%	0	0			73	61
	May 2009	470	264	56%	0	0		146	73	50%	0	0	0%		63	52
	Jun 2009	496	278	56%	0	0	0%	138	69	50%	1	0	0%	107	73	68
	Jul 2009	440	248	56%	2	0		112	62	55%	1	1	100%		68	60
	Aug 2009	398	240	60%	0	0		129	74	57%	0	0			51	52
	Sep 2009	457	267	58%	0	0		108	75	69%	2	0			45	51
	Oct 2009	486	270	56%	1	0		123	72	59%	0	0	0%		62	57
	Nov 2009 Dec 2009	402 429	233 244	58% 57%	1	1		108 135	68 75	63% 56%	0	0	0% 0%		54 56	58 58
	Jan 2010	429	244	55%	0	0		135	65	54%	0	0			68	59
	Feb 2010	362	197	54%	1	0		120	52	52%	1	0	0%		40	54
	Mar 2010	354	208	59%	0	0		132	75	57%	0	0			40	56
	Apr 2010	368	210	57%	0	0	0%	122	77	63%	0	0	0%	98	68	69
	May 2010	388	218	56%	0	0	0%	109	60	55%	1	0	0%	75	46	61
	Jun 2010	402	240	60%	1	0	0%	103	58	56%	0	0	0%	71	49	69
	Jul 2010	371	237	64%	0	0	0%	98	52	53%	0	0	0%	66	43	65
	Aug 2010	363	210	58%	0	0		116	66	57%	0	0			55	64
	Sep 2010	373	219	59%	1	1		105	69	66%	0	0	0%		47	56
	Oct 2010	383 353	243 223	63% 63%	0	0		115 102	72 69	63% 68%	0	0	0% 0%		55 42	73 60
	Nov 2010 Dec 2010	404	223	56%	0	0		90	54	60%	0	0	0%		42	47
	Jan 2011	346	186	54%	1	1		138	72	52%	0	0		115	61	53
	Feb 2011	305	191	63%	0	0		109	69	63%	0	0	0%		48	62
	Mar 2011	371	230	62%	0	0	0%	103	69	67%	0	0	0%	101	59	58
	Apr 2011	386	211	55%	0	0	0%	124	81	65%	0	0	0%	70	36	51
	May 2011	346	195	56%	0	0	0%	98	60	61%	0	0	0%	69	41	59
	Jun 2011	344	187	54%	1	0		96	64	67%	1	0			35	59
	Jul 2011	350	216	62%	0	0		80	55	69%	0	0	0%		30	57
	Aug 2011 Sep 2011	342 337	195 199	57% 59%	0	0		94 87	49 53	52% 61%	0	0	0% 0%		36 34	69
	Sep 2011 Oct 2011	337	199	59%	2	0		87	61	71%	0	0			34 38	56
	Nov 2011	300	181	60%	0	0		85	50	59%	0	0			31	50
	Dec 2011	312	181	58%	0	0		88	48	55%	0	0			43	59
	Jan 2012	312	181	58%	0	0		88 108	48 66	61%	0	0	0%		43 36	52
	Feb 2012	300	182	63%	1	0		86	56	65%	0	0			39	65
	Mar 2012	314	190	63%	0	0		84	52	62%	0	0	0%		41	67
	Apr 2012	359	226	63%	1	0		118	67	57%	1	1	100%		41	5
	May 2012	363	232	64%	1	0	0%	98	61	62%	0	0			50	6
	Jun 2012	299	180	60%	1	0	0%	82	51	62%	0	0	0%	64	40	6
	Jul 2012	331	207	63%	0	0		103	57	55%	0	0			23	4
	Aug 2012	297	176	59%	1	0		102	64	63%	0	0			40	6
	Sep 2012	283	169	60%	1	0		89	54	61%	1	1			28	5
	Oct 2012	285 336	166 188	58% 56%	0	0		83 105	53 57	64% 54%	0	0	0% 50%		25 40	4
	Nov 2012 Dec 2012	336 286	188	56% 65%	0	0		105	30	54% 47%	2	1			40 24	4
	Jan 2013	302	187	59%	2	1		103	51	47% 50%	0	0			32	4
	Feb 2013	246	149	61%	2	0		64	38	59%	0	0	0%		30	5
	Mar 2013	248	153	62%	0	0		80	47	59%	0	0	0%		21	5
	Apr 2013	280	162	58%	0	0		93	51	55%	0	0			34	5
	May 2013	307	188	61%	1	1	100%	83	51	61%	0	0	0%	54	34	6
	Jun 2013	288	162	56%	0	0	0%	89	57	64%	0	0	0%	55	30	5
	Jul 2013	272	161	59%	0	0		88	53	60%	0	0			27	4
	Aug 2013	300	186	62%	0	0		75	33	44%	0	0			19	49
	Sep 2013	276	168	61%	1	0		75	42	56%	0	0	0%		28	54
	Oct 2013	274	169	62%	0	0		78	48	62%	0	0			35	6
	Nov 2013 Dec 2013	265 276	156 163	59% 59%	0	0		71 67	46 45	65% 67%	0	0			33 34	5



		Do	se 112 mcg/	'nr	Dos	e 125 mcg/ł	ır	Do	se 137 mcg/	ĥr	Do	se 150 mcg/	hr	Dos	se 162 mcg/	ĥr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	5 0	4		179	93	52% 0%	2	1	50% 0%	233	121	52% 0%	2	1	50
Age (years)	0 - 11 years 12 - 17 years	0			- 1	-	0%	-	-	0%	- 2	-	0%	-	-	(
	18 - 24 years	0			2	2	100%	-	-	0%	5	4	80%	1	-	
	25 - 34 years 35 - 44 years	0	0		10 30	8 15	80% 50%	-	-	0% 0%	13 37	6 22	46% 59%	-	-	
	45 - 54 years	1			72	35	49%	1	-	0%	88	46	52%	-	-	
	55 - 64 years	3	2		64	33	52%	1	1	100%	88	43	49%	1	1	10
iender	Male Female	2	2		83 96	45 48	54% 50%	- 2	- 1	0% 50%	125 108	71 50	57% 46%	2	1	5
	Ambiguous	0			-	-	0%	-	-	0%		-	0%	-	-	
	Unknown	0					0%	-		0%			0%	-	-	
Aonth and Year of	Jan 2009 Feb 2009	1			5	3 1	60% 20%	-	-	0% 0%	7	3	43% 67%	-	-	
pisode Start Date		0			4	2	50%	-	-	0%	2	1	50%	-	-	
	Apr 2009	0			5	3	60%	-	-	0%	7	3	43%	-	-	
	May 2009 Jun 2009	0				3	75% 75%	-	-	0% 0%	8 9	5 6	63% 67%	-	-	
	Juli 2009 Juli 2009	0			4	3	100%	-	-	0%	3	6	33%	-	-	
	Aug 2009	0			3	2	67%	-	-	0%	5	-	0%	-	-	
	Sep 2009 Oct 2009	0	0		1	-	0% 0%	-	-	0% 0%	5	3	60% 33%	-	-	
	Nov 2009	0	0		2	- 2	67%	-	-	0%	7	2	53%	-	-	
	Dec 2009	0	0	0%	5	2	40%	-	-	0%	7	5	71%	-	-	
	Jan 2010	0	0		10	2	20%	-	-	0%	7	3	43%	-	-	
	Feb 2010 Mar 2010	0			6 3	1	17% 0%	-	-	0% 0%	5	3	60% 60%	-	-	
	Apr 2010	0	0		3	1	33%	-	-	0%	6	5	83%	-	-	
	May 2010	0			2	1	50%	-	-	0%	5	3	60%	-	-	
	Jun 2010 Jul 2010	0	0		6 4	3	50% 75%	-	-	0% 0%	5	2	40% 67%	-	-	
	Aug 2010	1	0		3	1	33%	-	-	0%	3	1	33%	-	-	
	Sep 2010	0			1	-	0%	-	-	0%	3	-	0%	-	-	
	Oct 2010 Nov 2010	0			7	6 2	86% 100%	1	1	100% 0%	5	4	80% 67%	-	-	
	Dec 2010	0			1	1	100%	-	-	0%	4	2	50%	-	-	
	Jan 2011	0	0		3	1	33%	-	-	0%	5	2	40%	1	-	
	Feb 2011	1	1		2	1	50%	-	-	0%	3	1	33%	-	-	
	Mar 2011 Apr 2011	0	0		5	3	33% 60%	-	-	0% 0%	4	1	25% 57%	-	-	
	May 2011	0	0	0%	5	1	20%	-	-	0%	4	1	25%	-	-	
	Jun 2011	0	0		2	1	50%	-	-	0%	-		0%	-	-	
	Jul 2011 Aug 2011	0	0		2	- 1	0% 100%	-	-	0% 0%	4	4	100% 100%	-	-	
	Sep 2011	0				3	75%	1	-	0%	5	4	80%	1	1	10
	Oct 2011	0			2	2	100%	-	-	0%	1	-	0%	-	-	
	Nov 2011	0	0			1	100%	-	-	0%	2	1	50%	-	-	
	Dec 2011 Jan 2012	0	0			2	50% 67%	-	-	0% 0%	2 3	2	100% 67%	-	-	
	Feb 2012	0				1	50%	-	-	0%	6	4	67%	-	-	
	Mar 2012	0				3	100%	-	-	0%	2	1	50%	-	-	
	Apr 2012 May 2012	1	1		5	5	100% 0%	-	-	0% 0%	6	3	50% 0%	-	-	
	May 2012 Jun 2012	0				2	0% 100%	-	-	0%	- 6	- 1	0% 17%	-	-	
	Jul 2012	0	0	0%	1	1	100%	-	-	0%	-	-	0%	-	-	
	Aug 2012	0				3	75%	-	-	0%	1	1	100%	-	-	
	Sep 2012 Oct 2012	0	0			2	100% 50%	-	-	0% 0%	2	1	50% 100%	-	-	
	Nov 2012	0				2	100%	-	-	0%	5	3	60%	-	-	
	Dec 2012	0				1	33%	-	-	0%	1	-	0%	-	-	
	Jan 2013 Feb 2013	0				- 1	0% 33%	-	-	0% 0%	4	-	0% 0%	-	-	
	Mar 2013	0				1	50%	-	-	0%	3	1	33%	-	-	
	Apr 2013	0				-	0%	-	-	0%	5	2	40%	-	-	
	May 2013 Jun 2013	0				1	100% 0%	-	-	0% 0%	3 5	1 1	33% 20%	-	-	
	Juli 2013 Juli 2013	0				- 2	100%	-	-	0%	3	2	67%	-	-	
	Aug 2013	0			2	2	100%	-	-	0%	2	1	50%	-	-	
	Sep 2013	0 0				-	0% 33%	-	-	0% 0%	3 1	1 1	33% 100%	-	-	
	Oct 2013 Nov 2013	0				1	33% 100%	-	-	0%	1	1	100%	-	-	
	Dec 2013	0				-	0%	-	-	0%	3	2	67%	-		



			se 175 mcg/	hr		se 200 mcg/	hr		se 225 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Toleranc
A == ()	Total	52	26	50%	5	3	60%	4	-	(
Age (years)	0 - 11 years 12 - 17 years	- 1	- 1	0% 100%		-	0% 0%	-	-	(
	18 - 24 years	3	3	100%	-	-	0%	-	-	
	25 - 34 years	3	2	67%	-	-	0%	1	-	
	35 - 44 years	7	5	71%	3	2	67%	1	-	
	45 - 54 years	17	7	41%	2	1	50%	-	-	
	55 - 64 years	21	8	38%	-	-	0%	2	-	
Gender	Male	17	11	65%	5	3	60%	2	-	
	Female	35	15	43% 0%	-	-	0% 0%	2	-	
	Ambiguous Unknown			0%			0%	-	-	
	Jan 2009	2	-	0%	-	-	0%	-	-	
Month and Year of	Feb 2009	2	1	50%	-	-	0%	-	-	
Episode Start Date	Mar 2009	2	2	100%	1	-	0%	1	-	
	Apr 2009	4	4	100%	1	1	100%	-	-	
	May 2009	1	1	100%	-	-	0%	-	-	
	Jun 2009	1	1	100%	-	-	0%	-	-	
	Jul 2009	2	-	0%	-	-	0%	1	-	
	Aug 2009	-	-	0%	-	-	0%	-	-	
	Sep 2009 Oct 2009	2	1	50%	-	-	0% 0%	-	-	
	Nov 2009	- 1	- 1	0% 100%			0%		-	
	Dec 2009		-	0%			0%			
	Jan 2010	_	_	0%	-	-	0%	-	_	
	Feb 2010	-		0%			0%			
	Mar 2010	1	1	100%	1	1	100%	-	-	
	Apr 2010	-	-	0%	-	-	0%	-	-	
	May 2010	1	-	0%	-	-	0%	-	-	
	Jun 2010	1	-	0%	-	-	0%	-	-	
	Jul 2010	-	-	0%	-	-	0%	-	-	
	Aug 2010	2	2	100%	-	-	0%	1	-	
	Sep 2010	-	-	0%	-	-	0%	-	-	
	Oct 2010	1	1	100%	-	-	0%	-	-	
	Nov 2010	-	-	0%	-	-	0%	-	-	
	Dec 2010	1	1	100%	-	-	0%	-	-	
	Jan 2011 Feb 2011	1	- 1	0% 50%	-	-	0% 0%	-	-	
	Mar 2011	2	1	50%	-	-	0%	-	-	
	Apr 2011	2		0%			0%			
	May 2011	-	-	0%	-	-	0%	-	-	
	Jun 2011	2	1	50%	-	-	0%	-	-	
	Jul 2011	-	-	0%	-	-	0%	-	-	
	Aug 2011	1	-	0%	-	-	0%	-	-	
	Sep 2011	3	1	33%	-	-	0%	-	-	
	Oct 2011	2	-	0%	-	-	0%	-	-	
	Nov 2011	-	-	0%	-	-	0%	-	-	
	Dec 2011	-	-	0%	-	-	0%	-	-	
	Jan 2012	-	-	0%	-	-	0%	-	-	
	Feb 2012	-	-	0%	-	-	0%	-	-	
	Mar 2012	1	-	0%	-	-	0%	-	-	
	Apr 2012	2	1	50%	-	-	0%	-	-	
	May 2012	1	1	100%	-	-	0%	-	-	
	Jun 2012	1	-	0%		-	0%	-	-	
	Jul 2012	-	-	0%		-	0%	-	-	
	Aug 2012	-	-	0%		-	0%	-	-	
	Sep 2012	-	-	0%		-	0%	-	-	
	Oct 2012	- 1	-	0% 0%		-	0% 0%	-	-	
	Nov 2012 Dec 2012	-	-	0%		-	0%	1	-	
	Jan 2013	-	-	0%		-	0%	-	-	
	Feb 2013	1	-	0%	-	-	0%	-	-	
	Mar 2013	1	1	100%	-	-	0%	-	-	
	Apr 2013	-	-	0%		-	0%	-	-	
	May 2013	1	1	100%		-	0%	-	-	
	Jun 2013	1	-	0%		1	50%	-	-	
	Jul 2013	-	-	0%	-	-	0%	-	-	
	Aug 2013	-	-	0%	-	-	0%	-	-	
	Sep 2013	1	1	100%	-	-	0%	-	-	
	Oct 2013	1	-	0%	-	-	0%	-	-	
	Nov 2013	-		0%	-	-	0%	-	-	



Transdermal Prior Prior Formal Prior			1	(Quaternary Tole	rance Definitior	n (>0 mg per da	y for seven days	in the 30 days pr	ior)		1		
Interner Partner			C	Dose 12 mcg/h	r	C	Oose 24 mcg/h	ır	D	ose 25 mcg/h	r	Do	ose 36 mcg/l	۱r
Ap- No No <			Transdermal Fentanyl	Prior	Prior	Transdermal Fentanyl	Prior	Prior	Transdermal Fentanyl	Prior	Prior	Transdermal Fentanyl	Prior	% with Prior Tolerance
1.1 prove 1.1 prove 1.1 prove 1.2 prove 1		Total	17,812	12,713	71.4%	3	3	100%	49,148	37,514	76.3%	1	0	0
ii A yang 1.41 <td>Age (years)</td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Age (years)					-								
8-1 Mayer 1.00 1.07 0.70 <td></td>														
1.4.4.9.1 1.5.1 1.5.2 1.6.2 1.6 1.6.4														
No. No. </td <td></td> <td></td> <td></td> <td></td> <td></td> <td>2</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						2								
Gender Mate														
Feeds 12.2 13.4 7.4 1 1 1.4 <th1.4< th=""> 1.4 <th1.4< th=""></th1.4<></th1.4<>		55 - 64 years	6,855	4,687	68.4%	1	1	100%	18,492	13,736	74.3%	0	0	09
Murboni n N <	Gender													
biolog			12,217	8,646		2				21,941				
pr:00 78 77 77.8 . 0 0.0 1.07 78.4 7.4.6 0 0 Mooth and 200 1.44 78.4 0.1 0.0 1.07 60.0 77.45 0 0 Mooth and 200 2.1.2 1.7 73.55 . 0 0.0 1.1.27 60.0 77.65 0 0 May 202 2.1.2 2.7 73.55 . 0 0.05 1.107 74.8 0 0 May 202 2.1.2 0.2.0 0.0 0.05 1.007 74.7 0 0 0.0			- 0	- 0		-				- 0				
nnn <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>														
prineprineprin <th< td=""><td></td><td></td><td></td><td>154</td><td>67.8%</td><td></td><td>C</td><td>0%</td><td></td><td>740</td><td></td><td></td><td></td><td></td></th<>				154	67.8%		C	0%		740				
My 200P1P3P	Month and Year of	Mar 2009	284	186	65.5%		C	0%	1,072	803	74.9%	0	0	05
AnX00NO	Episode Start Date													
Arboy <th< td=""><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>						-								
MethodMeth														
SequenceSequen														
C-12007.28.48.78.79.7 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>														
be-200Ad.B.M.A.M.B.B.M.B.						-								
an2002416300330006880673400Mar2010281640350006653073073500Mar2010281640350006653073073500Mar201028164073073500065073073500Mar201029173073500065073073500Mar201029173073500065073073073500Mar201029173073500065073073073500Mar2010291237235000650740537375000Mar20102912372350000550740537375000Mar20112912372350000550740537375000Mar201129<		Nov 2009	244	163	66.8%	-	C	0%	898	642	71.5%	0	0	05
rh2002.41.60.7 <th< td=""><td></td><td>Dec 2009</td><td>261</td><td>179</td><td>68.6%</td><td>-</td><td>C</td><td>0%</td><td>970</td><td>737</td><td>76.0%</td><td></td><td></td><td></td></th<>		Dec 2009	261	179	68.6%	-	C	0%	970	737	76.0%			
Mar 2010281960.780.70.70.780.						-								
Ar 2012012048.0%-00%9.0%9.1%9.7%9.7%00May2012512867.5%-00%8.46.47.7%000Ar 2010251297.1%-00%6.76.7%7.7%000Se 20102011297.1%-00%6.8%6.7%7.7%000Se 20102012127.7%-00%6.8%6.6%7.1%000Na 20202037.7%-00%7.4%6.6%7.4%00														
Mwy20125.26.27.77.00%87.07.78.0012002817071.5%100%1716377.5%00142002817.9%17.5%100%18107.5%07.5%00142002812972.5%100%18107.5%07.5%0004201021021021727.7%000%77.6%0.5777.5%0004201021721770.7%100%0.6%77.6%0.7%0.7%0.7%0016201021721770.7%100.6%77.6%0.7%0.7%00016201121621770.7%100.6%77.7%0.7%0.7%000016201121721770.7%100.6%77.7%0.7%0.7%0.7%000 <td></td>														
handline1000<														
Aug.2012.03.47.9.%00.69.7.17.3.%000Sey 20102.32.36.3.500.6.66.432.5.57.1.5.000.6Nov 20102.0.12.2.17.2.%00.6.66.677.7.5.0.60.6Nov 20102.0.12.0.17.7.66.6.7%00.6.66.7.75.7.6.600.6.7Nov 20112.0.27.0.7.66.7.7%.00.6.67.7.65.7.6.600.6.7Nov 20112.0.27.0.7.600.6.67.7.60.6.77.7.6.67.7.6.600.6.7Nov 20112.0.27.0.7.600.6.67.7.60.6.77.7.6.600.7.60.6.70.7.6.700.7.6.700.7.6.700.7.6.700.7.6.700.7.6.700.7.6.700.7.6.700.7.6.700.7.6.700.7.6.700.7.6.70.7.6.700.7.6.700.7.6.7<				198			C	0%	884	654			0	09
Sep 201010022370.3K00%9%70.72.K00Nov 201013022162.K00%48062577.5K00Der 201010712170.7K00%76666777.5K00Der 201022472.K00%76665876.5K00Feb 201122912767.0K00%72867.6K00Mar201123022077.5K00%72859977.5K00May201123022167.5K00%72859977.5K000May201123023167.5K00%7286377.5K000May201123023277.5K00%7356176.5K000May201123023567.5K00%7366075.5K000May201123023567.5K00%7365975.5K000May201123023567.5K00%7365975.5K000May201123023573.5K00%7365975.5K0		Jul 2010	239	170	71.1%		C	0%	837	645	77.1%	0	0	09
Dr. 2000132.30.5%0.00%8.86.257.3%00De: 20102072.7%200%0%7.85.857.3%00De: 20102072.7%000%7.7%5.87.5%000Her 20112.722.30.5%-00%4.855.9%7.5%000Her 20112.922.00.5%-00%7.7%5.9%7.5%000Har 20112.922.00.7%-00%7.7%5.9%7.5%000Har 20112.922.00.7%-00%7.7%5.9%7.5%000Har 20112.42.4%7.5%00007.7%5.9%7.5%0000Har 20112.4%7.5%0.7%00007.8%000 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>														
Nov.20096217.2%00%886697.5%00De callo2477.7%00%7.7%.5%.000Inabiti240170.7%00%.6%.5%.000Inabiti242170.7%00%.6%.5%.0.00Arazoti292107.5%00%.7%.0						-								
De 201030721770.%-00%766.777.%00ian 201120416766.7%-00%48569.978.0%00Mar 201120220279.5%-00%84569.978.3%000Mar 201120320279.5%-00%79.559.973.3%000Mar 201120421079.5%-00%72.863.873.8%000Ara201123424975.6%-00%72.863.873.8%000Ara201123021273.8%-00%78.860.973.8%000Ara201123021273.8%-00%78.860.973.8%000De 201123021273.8%-00%78.860.978.8%000Ara20122829.573.8%-00%76.863.978.8%0000Ara20122829.777.8%-00%63.977.6%00000000000000000000000000000														
an 201241767%767%74587.6%00reb20129167%-00%6745187.6%00Ar2012007.8%-00%8126.4%7.6%00Ar201120207.2%-00%8126.4%7.8%00Jac20121007.2%-00%7.2%5687.3%00Jac20121007.6%-00%7.2%5687.3%00Jac2012302107.5%-00%7.2%6.17.3%00Jac2012302107.5%-00%7.2%6.17.3%000Jac2012302107.5%-00%7.8%7.5%0000Jac2012302107.5%-00%7.8%7.5%0000Jac2012302307.5%-00%7.8%7.5%0000Jac2012302307.2%-00%7.8%7.5%0000Jac2012302307.2%-00%7.8%7.5%000000000000000 <td></td>														
Mar 201120220369.5%.00%64.565.978.0%00Arg 201120773.9%.00%67.9556.8%.000Ang 201121607.0%.00%77.260077.2%00Ang 201121821875.6%.00%72.866.873.9%00Ang 201121821875.6%.00%75.861.175.9%00Seg 201120720.573.8%.00%77.856.975.9%00No 201121573.8%.00%77.856.975.9%000No 201121621573.7%.00%77.856.975.9%000No 201121621573.7%.00%77.856.975.9%000No 201121721872.7%.00%78.956.977.9%000No 201121721872.7%.00%78.956.977.9%000No 201121872.7%100%78.956.977.9%0000075.9%0000121.900000000<		Jan 2011	264	176			C	0%	774	585			0	
Ar 20112072.277.3.%00%0.126.247.6.%00May 20112.940.7.0%00.6%7.7.80.00.7.2.%0.0Jal 20112.941.976.7.0%00.6%7.8.85.8.87.3.3%0.00.0Aug 20112.941.976.7.0%00.6%7.8.85.8.80.00.00.0Sep 20112.922.067.3.8%00.6%7.8.80.0<		Feb 2011	279	187	67.0%		C	0%	674	518	76.9%	0	0	05
Mw 201129921070.2%00%79559975.3%00Mu 20113642110.9%00%77260077.2%00Aug 201132824875.6%00%28066673.9%00Sep 201130721971.3%00%78860078.1%00Ot 201130721570.3%00%78859973.5%00Nov 201130822569.7%00%78859973.5%00Be 201132322569.7%00%78857900Har 201228873.6%00%66653877.5%00Har 201230722874.3%00%68356775.6%00Har 201230722874.3%00%68357377.5%000Har 201232922670.7%00%68577.5%000Har 201232922670.7%00%65756775.3%000Har 201232023072.7%00%65651776.5%000Har 20123														
JAN201131622169.9%00%777600772%00JAL20112419767.0%00%72854875.3%00Sep 201130721971.3%00%76861175.9%00Oc 201127920673.9%00%76860975.9%00Dec 201132322569.7%00%77660975.9%00Dec 201132322569.7%00%77663975.9%00Han201229820568.8%00%77663977.9%00Mar201230722871.2%00%78863777.9%00Mar201231622571.2%00%78863777.9%00Mar201231622871.4%00%63863577.9%00Jan201231621871.4%00%63763677.9%00Jan201231621871.4%00%63763677.9%00Jan201231621871.4%00%63763777.9%00Jan2012316 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>														
Jal201129419767.0%-00%7285487.3%00Aug 20112822487.5%-00%8206667.3%00Sep 20112792067.3%-00%7.8%6007.1%00Oct 20112792067.3%-00%7.4%5697.2%00De col13232250.7%-00%7.4%5697.5%00In 20122891987.5%-00%7.4%5697.5%00In 20123072287.4%-00%7.8%7.5%000Mar 20123072287.4%-00%7.8%7.5%000Mar 20123072287.4%-00%7.8%7.7%000Mar 20123192757.7%-00%68357.5%000Mar 20122392487.5%-00%68357.5%000Mar 20122392447.5%-00%67557.4%000Mar 20122362387.5%-00%7.5%57.4%000Mar 20122362387.5%-0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>														
Aug 201128287.5%-00%82066073.9%00Sep 201130721971.3%-00%75861176.9%00Or 20112790670.3%-00%7856972.3%00De 20112322567.7%-00%7766978.5%00Ain 20122820568.8%-00%7853377.3%00Ain 20122820568.8%-00%7853377.3%00Ain 20122821371.2%-00%66353377.3%00Ain 201231622571.2%-00%66365577.3%00Ain 201231622571.2%-00%67653377.3%00Ain 201231622571.2%-00%67653377.3%00Ain 201231622571.2%-00%67653377.3%00Ain 201231672.6%75.3%000%67653377.3%00Ain 201231672.6%75.3%000%67557.3%00Ain 201431572.6%77.5%-														
Oct 201127926073.8%-00%76860078.1%00Nov 201130521570.3%-00%71856073.2%00Ic 201123322569.7%-00%77656073.5%00Ia 201228929569.7%-00%76653377.3%00If eb 201229029873.6%-00%78357577.9%00Mar 201231722871.2%-00%78357577.9%00Mar 201231622571.2%-00%68363373.3%00Mar 201231524076.2%-00%68333573.3%00Jun 201231524077.5%-00%68757577.5%00Jun 201231524071.6%-00%75554477.2%00Jun 201231024072.7%-00%75554477.2%00Jun 201231024077.7%-00%65650177.2%00Jun 201331024077.5%-00%65650175.2%00Jun 201325671.5% <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>C</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							C							
Nov 201130621570.3%-00%71856979.2%00Dec 201122322569.7%-00%77660975.5%00Jan 201228820568.8%-00%77660975.5%00Feb 201226919873.6%-00%78357577.9%00Mar 201231622571.2%-00%80360775.6%00May 201238927570.7%-00%78660577.0%00Jul 201229321874.4%-00%67256675.3%00Jul 201223424475.3%-00%67256675.3%00Aug 201223424475.3%-00%75557270.5%00Nov 201233623373.7%-00%66550175.2%00Nov 201231623373.7%-00%66550175.2%00Mar 201327420070.9%-00%66550175.2%00Mar 201327420073.5%-00%66550175.2%00Mar 2013274200		Sep 2011	307	219	71.3%		C	0%	795	611	76.9%	0	0	09
Dec 2011 323 225 69.7% - 0 0% 747 560 75.0% 0 Jan 2012 298 205 68.8% - 0 0% 776 609 78.5% 0 0 Feb 2012 269 198 73.6% - 0 0% 696 538 77.3% 0 0 Mar 2012 307 228 74.3% - 0 0% 638 675 77.9% 0 0 Mar 2012 397 218 74.4% - 0 0% 683 535 77.9% 0 0 Jul 2012 315 240 75.3% - 0 0% 672 568 77.9% 0 0 Aug 2012 324 244 75.3% - 0 0% 754 633 80.0% 0 0 Sep 2012 300 240 72.7% - 0 0%		Oct 2011	279	206	73.8%	-	C	0%	768	600	78.1%	0	0	09
Jan 201229820568.8%-00%77660978.5%00Feb 201226919873.6%-00%66653877.3%00Mar 201230722874.3%-00%78857577.9%00Ap 201231622571.2%-00%80360775.6%00May 201229321874.4%-00%68353578.3%00Jul 201229321874.4%-00%68355577.9%00Jul 201229324075.2%-00%68354477.2%00Ag 201232024075.7%-00%67554477.2%00Oc 201233024072.7%-00%65045376.2%00Nov 201232324473.5%-00%65051777.6%00Ja 201325271.6%-00%65051776.2%00May 201425373.9%-00%65051776.2%00May 201325473.9%-00%65051776.2%00May 201325473.9%-00%650 <td></td> <td>Nov 2011</td> <td>306</td> <td>215</td> <td>70.3%</td> <td>-</td> <td>C</td> <td>0%</td> <td>718</td> <td>569</td> <td>79.2%</td> <td>0</td> <td>0</td> <td>09</td>		Nov 2011	306	215	70.3%	-	C	0%	718	569	79.2%	0	0	09
Feb 2012 269 198 73.6% - 0 0% 666 538 77.3% 0 0 Mar 2012 307 228 74.3% - 0 0% 738 575 77.9% 0 0 Apr 2012 316 225 71.2% - 0 0% 803 607 75.6% 0 0 May 2012 389 275 70.7% - 0 0% 683 635 77.3% 0 0 Jul 2012 315 240 76.2% - 0 0% 683 535 78.3% 0 0 Aug 2012 315 240 76.2% - 0 0% 675 544 77.3% 0 0 Sep 2012 30 240 75.3% - 0 0% 755 547 77.4% 0 0 Nox012 316 233 73.7% - 0 0% 650 551 75.4% 0 0 0 0 0 0			323	225		-	C	0%	747	560			0	
Mar 2012 307 228 74.3% - 0 0% 738 575 77.9% 0 0 Apr 2012 316 225 71.2% - 0 0% 803 607 75.6% 0 0 May 2012 398 275 70.7% - 0 0% 786 605 77.0% 0 0 Jui 2012 315 240 76.2% - 0 0% 672 506 75.3% 0 0 Aug 2012 324 244 75.3% - 0 0% 672 564 77.2% 0 0 Sep 2012 290 266 71.0% - 0 0% 705 544 77.2% 0 0 Ot 2012 330 240 72.7% - 0 0% 755 543 76.2% 0 0 In 2013 352 73.7% - 0 0% 656 501 75.2% 0 0 In 2013 275 155 <td< td=""><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>						-								
Apr 2012 316 225 71.2% - 0 0% 803 607 75.6% 0 0 May 2012 389 275 70.7% - 0 0% 786 605 77.0% 0 0 Jun 2012 293 218 74.4% - 0 0% 683 535 78.3% 0 0 Jul 2012 315 240 75.3% - 0 0% 687 672 506 75.3% 0 0 Aug 2012 240 75.3% - 0 0% 755 547 78.4% 0 0 Sep 2012 300 240 72.7% - 0 0% 755 597 77.0% 0 0 0 Nov 2012 316 233 73.7% - 0 0% 666 501 75.2% 0 0 0 Jan 2013 266 212 71.6% - 0 0% 650 495 76.2% 0 0 0 0						-								
May 2012 389 275 70.7% - 0 0% 786 605 77.0% 0 0 Jun 2012 293 218 74.4% - 0 0% 683 535 78.3% 0 0 Jul 2012 315 240 76.2% - 0 0% 683 535 78.3% 0 0 Aug 2012 315 240 76.2% - 0 0% 672 506 75.3% 0 0 Aug 2012 320 240 75.3% - 0 0% 755 603 80.0% 0 0 OC 1012 330 240 73.5% - 0 0% 755 597 77.0% 0 0 Nov 2012 316 233 73.7% - 0 0% 666 501 75.2% 0 0 0 Jan 2013 296 212 71.6% - 0 0% 650 495 76.2% 0 0 0 0 0						-								
In 2012 293 218 74.4% - 0 0% 683 535 78.3% 0 0 Jul 2012 315 240 76.2% - 0 0% 672 506 75.3% 0 0 Aug 2012 324 244 75.3% - 0 0% 857 672 78.4% 0 0 Sep 2012 290 260 71.0% - 0 0% 705 544 77.2% 0 0 Oc 2012 330 240 73.5% - 0 0% 755 597 77.0% 0 0 Nov 2012 316 233 73.7% - 0 0% 665 501 75.2% 0 0 Jan 2013 296 212 71.6% - 0 0% 650 495 76.2% 0 0 Mar 2013 296 71.2% 71.0% 0 0%														
Idi 201231524076.2%-00%67250675.3%00Aug 201232424475.3%-00%85767278.4%00Sep 201229020671.0%-00%70554477.2%00Oct 201233024473.5%-00%75759777.0%00Nov 201233224473.5%-00%66650175.2%00Dec 201231623373.7%-00%66650175.2%00Jan 201329621271.6%-00%65049576.2%00Mar 201327619570.9%-00%67554781.0%00Mar 201327724875.3%-00%75459078.2%00Mar 201329320670.3%11100%70155378.9%00Jun 201330622673.9%11100%70155378.9%00Jun 201336525072.5%-00%74155678.7%00Jun 201336525072.5%-00%75151878.9%00Jun 2013365250														
Sep 2012 290 206 71.0% - 0 0% 705 544 77.2% 0 0 Oct 2012 330 240 72.7% - 0 0% 754 603 80.0% 0 0 Nov 2012 332 244 73.5% - 0 0% 757 597 77.0% 0 0 0 Dec 2012 316 233 73.7% - 0 0% 666 501 75.2% 0 0 0 Jan 2013 275 155 70.9% - 0 0% 650 495 75.2% 0 0 0 Mar 2013 275 155 70.9% - 0 0% 652 506 80.1% 0		Jul 2012		240		-	C	0%	672	506	75.3%	0	0	0
Oct 2012 330 240 7.2.% - 0 0% 754 603 80.0% 0 0 Nov 2012 332 244 73.5% - 0 0% 775 597 77.0% 0 0 Dec 2012 316 233 73.7% - 0 0% 666 501 75.2% 0 0 Jan 2013 296 212 71.6% - 0 0% 650 495 76.2% 0 0 Heb 2013 275 292 71.6% - 0 0% 650 495 76.2% 0 0 Mar 2013 275 292 71.6% - 0 0% 623 566 81.5% 0 0 0 Mar 2013 277 248 75.8% - 0 0% 724 568 78.5% 0 0 Jun 2013 366 226 73.9% 1 <						-								
Nov 2012 332 244 73.5% - 0 0% 775 597 77.0% 0 0 Dec 2012 316 233 73.7% - 0 0% 666 501 75.2% 0 0 Jan 2013 296 212 71.6% - 0 0% 666 501 75.2% 0 0 Feb 2013 296 212 71.6% - 0 0% 650 495 75.2% 0 0 Ma2013 296 212 71.6% - 0 0% 657 547 81.0% 0 0 May 2013 274 200 73.6% - 0 0% 754 590 78.2% 0 0 Jun 2013 306 226 73.5% 1 1 100% 701 553 78.9% 0 0 Jul 2013 368 250 72.5% - 0 <						-								
Dec 2012 316 233 73.7% - 0 0% 666 501 75.2% 0 0 Jan 2013 296 212 71.6% - 0 0% 650 495 76.2% 0 0 Feb 2013 275 195 70.9% - 0 0% 675 547 81.0% 0 0 Mar 2013 275 248 75.8% - 0 0% 675 547 81.0% 0 0 Mar 2013 272 248 75.8% - 0 0% 724 568 78.5% 0 0 May 2013 293 206 70.3% - 0 0% 754 590 78.2% 0 0 Jun 2013 306 226 73.9% 1 1 100% 701 553 78.9% 0 0 Jul 2013 365 250 72.5% - 0						-								
Jan 2013 296 212 71.6% - 0 0% 650 495 76.2% 0 0 Feb 2013 275 195 70.9% - 0 0% 675 547 81.0% 0 0 Mar 2013 274 200 73.0% - 0 0% 632 506 80.1% 0 0 Apr 2013 327 248 75.8% - 0 0% 754 568 78.5% 0 0 May 2013 293 206 70.3% - 0 0% 754 590 78.2% 0 0 Jun 2013 366 226 73.9% 1 1 100% 701 553 78.9% 0 0 Jun 2013 345 256 71.5% - 0 0% 719 566 78.7% 0 0 Aug 2013 358 255 71.5% - 0														
Feb 2013 275 195 70.9% - 0 0% 675 547 81.0% 0 0 Mar 2013 274 200 73.0% - 0 0% 632 506 80.1% 0 0 Apr 2013 327 248 75.8% - 0 0% 724 568 78.5% 0 0 May 2013 293 206 70.3% - 0 0% 734 590 78.2% 0 0 Jun 2013 366 226 73.9% 1 1 100% 701 553 78.9% 0 0 Jun 2013 365 226 71.5% - 0 0% 719 566 78.7% 0 0 Agg 2013 358 256 71.5% - 0 0% 687 521 75.8% 0 0 Sep 2013 323 237 73.4% - 0														
Apr 2013 327 248 75.8% - 0 0% 724 568 78.5% 0 0 May 2013 293 206 70.3% - 0 0% 754 590 78.2% 0 0 Jun 2013 306 226 73.9% 1 1 100% 701 553 78.9% 0 0 Jul 2013 306 226 73.9% 1 1 100% 701 553 78.9% 0 0 Jul 2013 366 226 73.9% 1 1 100% 701 553 78.9% 0 0 Aug 2013 358 256 71.5% - 0 0% 76.0% 79.2% 0 0 Sep 2013 323 237 73.4% - 0 0% 687 521 75.9% 0 0 Oct 2013 366 270 73.8% 1 1 100%							C							
May 2013 293 206 70.3% - 0 0% 754 590 78.2% 0 0 Jun 2013 306 226 73.9% 1 1 100% 701 553 78.9% 0 0 Jul 2013 365 226 72.5% - 0 0% 719 566 78.7% 0 0 Aug 2013 358 256 71.5% - 0 0% 780 618 79.2% 0 0 Aug 2013 323 237 73.4% - 0 0% 686 512 75.8% 0 0 Sep 2013 323 237 73.8% 1 1 100% 78.4 604 7.0% 0 0		Mar 2013	274	200	73.0%		C	0%	632	506	80.1%	0	0	
Jun 2013 306 226 73.9% 1 1 100% 701 553 78.9% 0 0 Jul 2013 345 250 72.5% - 0 0% 719 566 78.7% 0 0 Aug 2013 358 256 71.5% - 0 0% 780 618 79.2% 0 0 Sep 2013 323 237 73.4% - 0 0% 687 521 75.8% 0 0 Oct 2013 366 270 73.8% 1 1 100% 784 604 77.0% 0 0						-								
Jul 2013 345 250 72.5% - 0 0% 719 566 78.7% 0 0 Aug 2013 358 256 71.5% - 0 0% 780 618 79.2% 0 0 Sep 2013 323 237 73.4% - 0 0% 687 521 75.8% 0 0 Oct 2013 366 270 73.8% 1 1 100% 784 604 77.0% 0 0						-								
Aug 2013 358 256 71.5% - 0 0% 780 618 79.2% 0 0 Sep 2013 323 237 73.4% - 0 0% 687 521 75.8% 0 0 Oct 2013 366 270 73.8% 1 1 100% 784 604 77.0% 0 0						1								
Sep 2013 323 237 73.4% - 0 0% 687 521 75.8% 0 0 Oct 2013 366 270 73.8% 1 1 100% 784 604 77.0% 0 0														
Oct 2013 366 270 73.8% 1 1 100% 784 604 77.0% 0 0														
Nov 2013 344 262 76.2% 1 1 100% 702 541 77.1% 0 0						1								
		Nov 2013	344	262	76.2%	1	1	100%	702	541	77.1%	0	0	0



	1			1	Quaternary To	bieraniee be		ig per uay for 3	even days n	i tile so uujs				1		
		Dos	e 37 mcg/h	r	Dos	e 50 mcg/ł	nr	Dos	e 62 mcg/	hr	Dos	e 75 mcg/h	ır	Do	se 87 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	339	253	75%	21,245	16,661	78%	26	9	35%	6,215	4,682	75%	14	7	509
Age (years)	0 - 11 years	1	0	0%	8	4	50%	1	0		3	1	33%	0	C	
	12 - 17 years 18 - 24 years	2	0 6	0% 67%	37 423	20 306	54% 72%	0	0		14 121	5 83	36% 69%	0	C	
	25 - 34 years	27	22	81%	1,911	1,557	81%	2	0		614	480	78%	2	2	
	35 - 44 years	71	47	66%	4,031	3,293	82%	6	3		1,229	928	76%	1	C	
	45 - 54 years	99	76	77%	7,320	5,753	79%	11	4	36%	2,201	1,668	76%	6	4	679
	55 - 64 years	130	102	78%	7,515	5,728	76%	4	2		2,033	1,517	75%	5	1	209
Gender	Male	145	114	79%	9,916	7,893	80%	13	7		2,974	2,284	77%	6		
	Female	194 0	139 0	72% 0%	11,329	8,768	77% 0%	13 0	2		3,241	2,398	74% 0%	8	3 0	
	Ambiguous Unknown	0	0	0%	-	-	0%	0	0			-	0%	0		
	Jan 2009	6	6	100%	490	364	74%	2	2		189	128	68%	1	C	
	Feb 2009	9	5	56%	484	394	81%	0	0	0%	152	108	71%	0	C	09
Month and Year of	Mar 2009	5	5	100%	492	396	80%	0	0	0%	140	98	70%	0	C	0 09
Episode Start Date	Apr 2009	4	2	50%	532	413	78%	0	0		147	116	79%	0	C	
	May 2009	6	6	100%	470	342	73%	0	0		146	102	70%	0	C	
	Jun 2009	8	7	88% 75%	496 440	377 342	76% 78%	0	0		138 112	101 80	73% 71%	1	0	
	Jul 2009 Aug 2009	8	6	75% 67%	440 398	342 321	78% 81%	2	0		112	80 99	71%	1	1	
	Sep 2009	5	5	100%	457	359	79%	0	0		129	90	83%	2	1	
	Oct 2009	1	1	100%	486	359	74%	1	0		123	95	77%	0	C	
	Nov 2009	8	5	63%	402	312	78%	1	1	100%	108	89	82%	0	C	0 09
	Dec 2009	8	6	75%	429	334	78%	0	0	0%	135	97	72%	1	C	09
	Jan 2010	6	0	0%	406	300	74%	0	0		120	80	67%	0	C	
	Feb 2010	9	9	100%	362	268	74%	1	0		100	71	71%	1	1	
	Mar 2010	8	6 2	75% 50%	354 368	278 288	79% 78%	0	0		132 122	99 99	75% 81%	0	C	
	Apr 2010 May 2010	4	2	33%	368	288	78%	0	0		122	99 78	81%	1	0	
	Jun 2010	7	4	57%	402	318	79%	1	0		103	83	81%	0		
	Jul 2010	5	4	80%	371	300	81%	0	0		98	71	72%	0	0	
	Aug 2010	3	2	67%	363	287	79%	0	0	0%	116	81	70%	0	C	09
	Sep 2010	2	2	100%	373	291	78%	1	1		105	88	84%	0	C	
	Oct 2010	5	5	100%	383	313	82%	0	0		115	88	77%	0		
	Nov 2010	8	6	75%	353	287	81%	0	0		102	85	83%	1	0	
	Dec 2010 Jan 2011	3	2	67% 100%	404 346	315 260	78% 75%	0	0		90 138	71 97	79% 70%	0	C	
	Feb 2011	3	3	100%	305	200	79%	0	0		109	83	76%	0	C	
	Mar 2011	9	6	67%	371	294	79%	0	0		103	85	83%	0	C	
	Apr 2011	10	10	100%	386	292	76%	0	0	0%	124	94	76%	0	C	0 09
	May 2011	4	3	75%	346	261	75%	0	0	0%	98	73	74%	0	C	0 09
	Jun 2011	4	3	75%	344	263	76%	1	0		96	79	82%	1	1	
	Jul 2011	4	2	50%	350	279	80%	0	0		80	69	86%	0	C	
	Aug 2011	5	3	60% 83%	342 337	270 271	79% 80%	0	0		94 87	67 70	71% 80%	0	C	
	Sep 2011 Oct 2011	6	5	67%	306	271	78%	2	0		87	70	80%	0	0	
	Nov 2011	7	4	57%	300	238	79%	0	0		85	64	75%	0		
	Dec 2011	5	4	100%	312	255	82%	0	0		88	61	69%	0	0	
	Jan 2012	3	2	67%	312	235	79%	0	0		108	85	79%	0	c	
	Feb 2012	7	6	86%	300	245	82%	1	0		86	65	76%	0	c	
	Mar 2012	7	6	86%	314	260	83%	0	0		84	68	81%	0		
	Apr 2012	7	5	71%	359	284	79%	1	0	0%	118	87	74%	1	1	1009
	May 2012	8	7	88%	363	284	78%	1	0		98	77	79%	0		
	Jun 2012	4	3	75%	299	243	81%	1	0		82	65	79%	0		
	Jul 2012	5	4	80%	331	266	80%	0	0		103	76	74%	0	0	
	Aug 2012 Sep 2012	2	2	100% 100%	297 283	233 229	78% 81%	1	1		102 89	77 67	75% 75%	0	0	
	Oct 2012	3	2	67%	285	229	80%	0	0		83	65	73%	0	0	
	Nov 2012	6	4	67%	336	241	72%	0	0		105	72	69%	2	1	
	Dec 2012	9	5	56%	286	226	79%	0	0	0%	64	41	64%	0	C	0 09
	Jan 2013	5	3	60%	302	235	78%	2	1		103	72	70%	0	C	
	Feb 2013	3	3	100%	246	201	82%	2	0		64	52	81%	0	C	
	Mar 2013	4	4	100%	248	194	78%	0	0		80	57	71%	0	0	
	Apr 2013 May 2013	11 9	8 7	73%	280 307	225	80% 79%	0	0		93	71 67	76% 81%	0	0	
	May 2013 Jun 2013	9	4	78% 80%	307	241 232	79% 81%	1	1		83 89	67 67	81% 75%	0	C	
	Jul 2013	9	7	78%	200	219	81%	0	0		88	73	83%	0	c	
	Aug 2013	7	5	71%	300	249	83%	0	0		75	48	64%	0	c	
Se	Sep 2013	5	4	80%	276	225	82%	1	0	0%	75	54	72%	0	C	0 09
	Oct 2013 Nov 2013	4	2	50% 43%	274 265	218 207	80% 78%	0	0		78 71	58 56	74% 79%	0		



	1			1		-			seven days ir		-			1		
		Dose	e 100 mcg/	′hr	Do	se 112 mcg/	'hr	Dos	se 125 mcg/	hr	Do	se 137 mcg/	hr	Dos	se 150 mcg/l	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Toleranc
	Total	4,524	3,253	72%	5	4		179	121	68%	2	1	50%	233	152	6
Age (years)	0 - 11 years 12 - 17 years	6 9	1	17% 44%	0	0	0% 0%	- 1	- 1	0% 100%	-	-	0% 0%	- 2	-	(
	18 - 24 years	91	56	62%	0	0		2	2	100%	-	-	0%	5	4	80
	25 - 34 years	375	297	79%	0	0		10	8	80%	-	-	0%	13	9	69
	35 - 44 years 45 - 54 years	870 1,644	640 1,189	74% 72%	1	1		30 72	24 43	80% 60%	-	-	0% 0%	37 88	27 57	7: 6!
	55 - 64 years	1,529	1,066	70%	3	2	67%	64	43	67%	1	1	100%	88	55	6
Gender	Male	2,316	1,730	75%	2	2		83	57	69%	-	-	0%	125	90	7.
	Female	2,208	1,523	69% 0%	3	2		96	- 64	67% 0%	2	1	50% 0%	108	62	5
	Ambiguous Unknown			0%	0	0				0%			0%			
	Jan 2009	131	88	67%	1	1	100%	5	4	80%	-	-	0%	7	3	4
	Feb 2009	132	100	76%	0	0		5	2	40%	-	-	0%	3	3	10
Nonth and Year of pisode Start Date		101 120	68 92	67% 77%	0	0		4	2	50% 60%	-	-	0% 0%	2	1 5	5
pisoue start pute	May 2009	120	83	68%	0	0	0%	4	3	75%	-	-	0%	8	5	6
	Jun 2009	107	84	79%	0	0	0%	4	3	75%	-	-	0%	9	7	7
	Jul 2009	114	80	70%	0	0	0%	1	1	100%	-	-	0%	3	1	1
	Aug 2009 Sep 2009	98 89	64 58	65% 65%	0	0	0% 0%	3	2	67% 0%	-	-	0% 0%	5	1	2
	Oct 2009	108	77	71%	0	0	0%	2	1	50%	-	-	0%	6	2	3
	Nov 2009	93	67	72%	0	0	0%	3	2	67%	-	-	0%	7	5	7
	Dec 2009	96	72	75%	0	0	0%	5	4	80%	-	-	0%	7	6	1
	Jan 2010 Feb 2010	115 74	80 50	70% 68%	0	0	0% 0%	10 6	4	40% 50%	-	-	0% 0%	7	4	5
	Mar 2010	71	48	68%	0	0	0%	3	-	0%	-	-	0%	5	4	1
	Apr 2010	98	78	80%	0	0	0%	3	2	67%	-	-	0%	6	5	1
	May 2010	75	56	75%	0	0	0%	2	1	50%	-	-	0%	5	4	
	Jun 2010 Jul 2010	71 66	56 53	79% 80%	0	0	0% 0%	6 4	5 4	83% 100%	-	-	0% 0%	5	3	6
	Aug 2010	86	65	76%	1	0	0%	3	2	67%	-	-	0%	3	2	
	Sep 2010	84	63	75%	0	0		1	-	0%	-	-	0%	3	1	1
	Oct 2010 Nov 2010	75 70	63 53	84% 76%	0	0	0% 0%	7	6 2	86% 100%	1	1	100% 0%	5	5 2	10
	Dec 2010	70	45	58%	0	0		1	1	100%	-	-	0%	4	2	
	Jan 2011	115	82	71%	0	0	0%	3	1	33%	-	-	0%	5	3	6
	Feb 2011	77	57	74%	1	1	100%	2	2	100%	-	-	0%	3	2	6
	Mar 2011 Apr 2011	101 70	73 49	72% 70%	0	0	0% 0%	3	2	67% 80%	-	-	0% 0%	4	2 5	5
	May 2011	69	46	67%	0	0	0%	5	3	60%	-	-	0%	4	2	5
	Jun 2011	59	44	75%	0	0	0%	2	2	100%	-	-	0%	-	-	
	Jul 2011 Aug 2011	53 52	41 45	77% 87%	0	0	0% 0%	2	- 1	0% 100%	-	-	0% 0%	4	4	10
	Sep 2011	55	45	75%	0	0	0%	4	3	75%	1	-	0%	5	4	1
	Oct 2011	68	47	69%	0	0	0%	2	2	100%	-	-	0%	1	-	
	Nov 2011	62	43	69%	0	0	0%	1	1	100%	-	-	0%	2	1	5
	Dec 2011	73	54	74%	0	0	0%	4	2	50%	-	-	0%	2	2	10
	Jan 2012 Feb 2012	69 60	45 50	65% 83%	0	0	0% 0%	3	2	67% 100%	-	-	0% 0%	3	2 4	
	Feb 2012 Mar 2012	61	50	83%	0	0		2	2	100%	-	-	0%	2	4	1
	Apr 2012	74	52	70%	1	1		5	5	100%	-	-	0%	6	5	:
	May 2012	77	57	74%		0	0%	4	2	50%	-	-	0%	-	-	
	Jun 2012 Jul 2012	64 52	49 31	77% 60%	0	0	0% 0%	2	2	100% 100%	-	-	0% 0%	6	1	
	Aug 2012	61	46	75%	0	0	0%	4	4	100%	-	-	0%	1	1	1
	Sep 2012	48	39	81%	0	0	0%	2	2	100%	-	-	0%	2	1	
	Oct 2012	60 77	40 51	67% 66%	0	0	0%	4	3	75% 100%	-	-	0% 0%	2	2	1
	Nov 2012 Dec 2012	54	51 37	66% 69%	0	0	0% 0%	2	2	33%	-	-	0%	5	- 4	
	Jan 2013	64	39	61%	0	0		4	-	0%	-	-	0%	4	1	
	Feb 2013	52	40	77%		1	100%	3	2	67%	-	-	0%	-	-	
	Mar 2013 Apr 2013	40 59	30 41	75% 69%	0	0	0% 0%	2	2	100% 0%	-	-	0% 0%	3	1	
	Apr 2013 May 2013	59	41 35	69%	0	0		- 1	- 1	0% 100%	-	-	0%	3	3	
	Jun 2013	55	38	69%	0	0	0%	-	-	0%	-	-	0%	5	4	
	Jul 2013	60	39	65%	0	0	0%	2	2	100%	-	-	0%	3	3	1
	Aug 2013 Sep 2013	39 52	23 37	59% 71%	0	0	0% 0%	2	2	100% 100%	-	-	0% 0%	2	1	:
	Sep 2013 Oct 2013	52	37	71% 68%	0	0	0%	1	1	33%	-	-	0%	3	1	: 10
	Nov 2013	57	39	68%	0	0		1	1	100%			0%	3	2	



0%

0%

		1					1	[
		Do	se 162 mcg/	hr	Do	se 175 mcg/l	hr	Do	se 200 mcg/	hr	Do	se 225 mcg/	hr
		Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance	Total N of Transdermal Fentanyl Episodes	N with Prior Tolerance	% with Prior Tolerance
	Total	2	2	100%	52	33	63%	5	3	60%		1	25
ge (years)	0 - 11 years 12 - 17 years	-	-	0% 0%	- 1	- 1	0% 100%	-	-	0% 0%	-	-	(
	18 - 24 years	1	1	100%	3	3	100%	-	-	0%	-	-	(
	25 - 34 years	-	-	0%	3	2	67%	-	-	0%		1	100
	35 - 44 years	-	-	0%	7	6	86%	3	2	67%	1	-	(
	45 - 54 years	-	-	0%	17	10	59%	2	1	50%		-	(
andar	55 - 64 years	2	2	100%	21	11	52%	- 5	-	0%	2	- 1	(
ender	Male Female	- 2	- 2	100% 0%	17 35	12 21	71% 60%	-	3	60% 0%		1	50
	Ambiguous		-	0%	-	-	0%	-	-	0%		-	
	Unknown			0%	-	-	0%			0%		-	
	Jan 2009	-	-	0%	2	1	50%	-	-	0%	-	-	(
	Feb 2009	-	-	0%	2	1	50%	-	-	0%		-	(
Nonth and Year of		-	-	0%	2	2	100%	1	-	0%		-	(
pisode Start Date		-	-	0%	4	4	100%	1	1	100%		-	(
	May 2009 Jun 2009	-	-	0% 0%	1	1	100% 100%	-	-	0%	-	-	
	Jul 2009	-	-	0%	2	2	100%	-	-	0%	- 1	- 1	100
	Aug 2009	-	-	0%	-	-	0%	-	-	0%		-	
	Sep 2009	-	-	0%	2	2	100%	-	-	0%	-	-	
	Oct 2009	-	-	0%	-	-	0%	-	-	0%	-	-	
	Nov 2009	-	-	0%	1	1	100%	-	-	0%	-	-	
	Dec 2009	-	-	0%	-	-	0%	-	-	0%	-	-	
	Jan 2010	-	-	0%	-	-	0%	-	-	0%	-	-	(
	Feb 2010 Mar 2010	-	-	0% 0%	- 1	- 1	0% 100%	- 1	- 1	0% 100%		-	
	Apr 2010	-	-	0%	-	-	0%		-	0%	-	-	
	May 2010	-	-	0%	1	-	0%	-	-	0%	-	-	
	Jun 2010	-	-	0%	1	1	100%	-	-	0%	-	-	(
	Jul 2010	-	-	0%	-	-	0%	-	-	0%	-	-	(
	Aug 2010	-	-	0%	2	2	100%	-	-	0%	1	-	
	Sep 2010	-	-	0%	- 1	- 1	0%	-	-	0%	-	-	(
	Oct 2010 Nov 2010	-	-	0% 0%	1	1	100% 0%	-	-	0% 0%	-	-	
	Dec 2010	-	-	0%	1	1	100%	-	-	0%	-	-	
	Jan 2011	1	1	100%	1	-	0%	-	-	0%	-	-	
	Feb 2011	-	-	0%	2	1	50%	-	-	0%	-	-	
	Mar 2011	-	-	0%	2	1	50%	-	-	0%	-	-	
	Apr 2011	-	-	0%	2	-	0%	-	-	0%		-	
	May 2011	-	-	0%	-	-	0%	-	-	0%	-	-	
	Jun 2011 Jul 2011	-	-	0% 0%	2	1	50% 0%		-	0% 0%	-	-	
	Aug 2011	-	-	0%	1	-	0%		-	0%	-	-	
	Sep 2011	1	1	100%	3	2	67%		-	0%	-	-	
	Oct 2011	-	-	0%	2	-	0%		-	0%	-	-	
	Nov 2011	-	-	0%	-	-	0%	-	-	0%	-	-	
	Dec 2011	-	-	0%	-	-	0%	-	-	0%	-	-	
	Jan 2012	-	-	0%	-	-	0%		-	0%	-	-	
	Feb 2012	-	-	0%	-	-	0%	-	-	0%	-	-	
	Mar 2012	-	-	0%	1	1	100%	-	-	0%		-	
	Apr 2012	-	-	0%	2	1	50%	-	-	0%		-	
	May 2012 Jun 2012	-	-	0%	1	1	100%	-	-	0%		-	
	Jun 2012 Jul 2012	-	-	0% 0%	1	-	0% 0%		-	0% 0%		-	
	Aug 2012	_	_	0%	-	-	0%	-	_	0%		-	
	Sep 2012	-	-	0%	-	-	0%	-	-	0%		-	
	Oct 2012	-	-	0%	-	-	0%	-	-	0%	-	-	
	Nov 2012	-	-	0%	1	-	0%	-	-	0%		-	
	Dec 2012	-	-	0%	-	-	0%	-	-	0%	-	-	
	Jan 2013	-	-	0% 0%	-	-	0%	-	-	0% 0%	-	-	
	Feb 2013 Mar 2013	-	-	0%	1	- 1	0% 100%	-	-	0%		-	
	Mar 2013 Apr 2013	-	-	0%	-	-	100%	-	-	0%	-	-	
	May 2013	-	-	0%	1	1	100%	-	-	0%	-	-	
	Jun 2013	-	-	0%	1	-	0%	2	1	50%		-	
	Jul 2013	-	-	0%	-	-	0%	-	-	0%	-	-	
	Aug 2013	-	-	0%	-	-	0%	-	-	0%		-	
	Sep 2013	-	-	0%	1	1	100%	-	-	0%		-	
	Oct 2013	-	-	0%	1	-	0%	-	-	0%	-	-	
	Nov 2013			0%			0%			0%			

Dec 2013

0%

1

1

100%



Appendix A: Latest Date of Available Data for Each Data Partner up to Request Send Date (April 20, 2016)

DP ID	Start Date	End Date
DP0001	1/1/2009	12/31/2013
DP0002	1/1/2009	12/31/2013
DP0003	1/1/2009	12/31/2013
DP0004	1/1/2009	12/31/2013
DP0005	1/1/2009	12/31/2013
DP0006	1/1/2009	6/30/2012
DP0007	1/1/2009	12/31/2013
DP0008	1/1/2009	12/31/2013
DP0009	1/1/2009	12/31/2013
DP0010	1/1/2009	12/31/2013
DP0011	1/1/2009	12/31/2013
DP0012	1/1/2009	12/31/2013
DP0013	1/1/2009	12/31/2013
DP0014	1/1/2009	12/31/2013
DP0015	1/1/2009	12/31/2013



Appendix B: List of Drugs Used to Define Exposures in this Request

Generic Name	Form	Route	Strength	Unit
Fentanyl Patch				
FENTANYL	PATCH 72 HOUR	TRANSDERMAL	25	MCG/HR
FENTANYL	PATCH 72 HOUR	TRANSDERMAL	50	MCG/HR
FENTANYL	PATCH 72 HOUR	TRANSDERMAL	75	MCG/HR
FENTANYL	PATCH 72 HOUR	TRANSDERMAL	100	MCG/HR
FENTANYL	PATCH 72 HOUR	TRANSDERMAL	12	MCG/HR



Appendix C: List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) Codes Used to Define Exclusion Criteria in this Request

Opioid Poisoning	Description	Code Type
965.0	Poisoning by opiates and related narcotics	ICD-9-CM Diagnosis Code
965.00	Poisoning by opium (alkaloids), unspecified	ICD-9-CM Diagnosis Code
965.01	Poisoning by heroin	ICD-9-CM Diagnosis Code
965.02	Poisoning by methadone	ICD-9-CM Diagnosis Code
965.09	Poisoning by other opiates and related narcotics	ICD-9-CM Diagnosis Code